Document_and_Entity_Informatio
Document and Entity Information (USD $) | 12 Months Ended | ||
Sep. 30, 2013 | Nov. 05, 2013 | Mar. 28, 2013 | |
Document and Entity Information [Abstract] | ' | ' | ' |
Trading Symbol | 'BRKS | ' | ' |
Entity Registrant Name | 'BROOKS AUTOMATION INC | ' | ' |
Entity Central Index Key | '0000933974 | ' | ' |
Current Fiscal Year End Date | '--09-30 | ' | ' |
Entity Filer Category | 'Large Accelerated Filer | ' | ' |
Document Type | '10-K | ' | ' |
Document Period End Date | 30-Sep-13 | ' | ' |
Document Fiscal Year Focus | '2013 | ' | ' |
Document Fiscal Period Focus | 'FY | ' | ' |
Amendment Flag | 'false | ' | ' |
Entity Well-known Seasoned Issuer | 'No | ' | ' |
Entity Current Reporting Status | 'Yes | ' | ' |
Entity Voluntary Filers | 'No | ' | ' |
Entity Common Stock, Shares Outstanding | ' | 66,577,235 | ' |
Entity Public Float | ' | ' | $662,787,700 |
CONSOLIDATED_BALANCE_SHEETS
CONSOLIDATED BALANCE SHEETS (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||
Current assets | ' | ' |
Cash and cash equivalents | $82,971 | $54,639 |
Restricted cash | 177 | 763 |
Marketable securities | 45,900 | 85,646 |
Accounts receivable, net | 77,483 | 78,855 |
Inventories | 97,719 | 102,985 |
Deferred tax assets | 16,839 | 15,531 |
Prepaid expenses and other current assets | 9,030 | 9,070 |
Total current assets | 330,119 | 347,489 |
Property, plant and equipment, net | 47,870 | 64,478 |
Long-term marketable securities | 44,491 | 59,946 |
Long-term deferred tax assets | 99,146 | 104,626 |
Goodwill | 122,030 | 88,440 |
Intangible assets, net | 60,088 | 39,400 |
Equity investment in joint ventures | 25,687 | 31,428 |
Other assets | 7,332 | 6,153 |
Total assets | 736,763 | 741,960 |
Current liabilities | ' | ' |
Accounts payable | 35,392 | 28,988 |
Deferred revenue | 19,653 | 9,986 |
Accrued warranty and retrofit costs | 7,349 | 7,329 |
Accrued compensation and benefits | 14,225 | 14,118 |
Accrued restructuring costs | 1,412 | 2,098 |
Accrued income taxes payable | 1,077 | 1,699 |
Accrued expenses and other current liabilities | 13,453 | 16,973 |
Total current liabilities | 92,561 | 81,191 |
Long-term tax liabilities | 7,036 | 6,356 |
Long-term pension liability | 815 | 1,688 |
Other long-term liabilities | 3,695 | 3,424 |
Total liabilities | 104,107 | 92,659 |
Commitments and contingencies (Note 21) | ' | ' |
Equity | ' | ' |
Preferred stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding | 0 | 0 |
Common stock, $0.01 par value, 125,000,000 shares authorized, 79,926,322 shares issued and 66,464,453 shares outstanding at June 30, 2013, 79,790,557 shares issued and 66,328,688 shares outstanding at September 30, 2012 | 800 | 798 |
Additional paid-in capital | 1,825,499 | 1,817,706 |
Accumulated other comprehensive income | 22,604 | 23,642 |
Treasury stock at cost, 13,461,869 shares | -200,956 | -200,956 |
Total Brooks Automation, Inc. stockholders’ equity | -1,015,991 | -992,524 |
Total Brooks Automation, Inc. stockholders’ equity | 631,956 | 648,666 |
Noncontrolling interest in subsidiaries | 700 | 635 |
Total equity | 632,656 | 649,301 |
Total liabilities and equity | $736,763 | $741,960 |
CONSOLIDATED_BALANCE_SHEETS_Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
Statement of Financial Position [Abstract] | ' | ' |
Preferred stock, par value (USD per share) | $0.01 | $0.01 |
Preferred stock, shares authorized | 1,000,000 | 1,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value (USD per share) | $0.01 | $0.01 |
Common stock, shares authorized | 125,000,000 | 125,000,000 |
Common stock, shares issued | 80,039,104 | 79,790,557 |
Common stock, shares outstanding | 66,577,235 | 66,328,688 |
Treasury stock, shares | 13,461,869 | 13,461,869 |
CONSOLIDATED_STATEMENTS_OF_OPE
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) | 12 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Revenue | ' | ' | ' |
Product | $362,404 | $431,961 | $611,117 |
Services | 88,548 | 87,490 | 76,988 |
Total revenue | 450,952 | 519,451 | 688,105 |
Cost of revenue | ' | ' | ' |
Product | 243,709 | 283,377 | 411,610 |
Services | 61,261 | 62,588 | 53,474 |
Total cost of revenue | 304,970 | 345,965 | 465,084 |
Gross profit | 145,982 | 173,486 | 223,021 |
Operating expenses | ' | ' | ' |
Research and development | 48,991 | 47,464 | 39,846 |
Selling, general and administrative | 99,545 | 101,223 | 102,542 |
Restructuring and other charges | 6,465 | 3,275 | 1,036 |
Pension settlement | 0 | 8,937 | 0 |
In-process research and development | 0 | 3,026 | 0 |
Total operating expenses | 155,001 | 163,925 | 143,424 |
Operating income (loss) | -9,019 | 9,561 | 79,597 |
Interest income | 1,032 | 1,213 | 1,153 |
Interest expense | -2 | -14 | -65 |
Gain on sale of contract manufacturing business | 0 | 0 | 45,009 |
Other income, net | 1,227 | 660 | 1,882 |
Income (loss) before income taxes and equity in earnings of joint ventures | -6,762 | 11,420 | 127,576 |
Income tax provision (benefit) | -2,170 | -123,282 | 1,954 |
Income (loss) before equity in earnings of joint ventures | -4,592 | 134,702 | 125,622 |
Equity in earnings of joint ventures | 2,442 | 2,133 | 4,815 |
Net income (loss) | -2,150 | 136,835 | 130,437 |
Net income attributable to noncontrolling interests | -65 | -46 | -52 |
Net income (loss) attributable to Brooks Automation, Inc. | ($2,215) | $136,789 | $130,385 |
Basic net income (loss) per share attributable to Brooks Automation, Inc. common stockholders | ($0.03) | $2.10 | $2.02 |
Diluted net income (loss) per share attributable to Brooks Automation, Inc. common stockholders | ($0.03) | $2.08 | $2.01 |
Dividend declared per share | $0.32 | $0.32 | $0.08 |
Weighted-average shares used in computing earnings (loss) per share | ' | ' | ' |
Basic (shares) | 65,912 | 65,128 | 64,549 |
Diluted (shares) | 65,912 | 65,722 | 65,003 |
CONSOLIDATED_STATEMENTS_OF_COM
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Statement of Other Comprehensive Income [Abstract] | ' | ' | ' |
Net income (loss) | ($2,150) | $136,835 | $130,437 |
Cumulative translation adjustment | -2,113 | -2,406 | 947 |
Unrealized gain (loss) on marketable securities | -135 | 393 | -445 |
Unrealized gain on cash flow hedge | 14 | 0 | 0 |
Actuarial gain (loss) | 1,109 | -606 | -1,044 |
Pension settlement | 87 | 8,937 | 0 |
Comprehensive income (loss), net of tax | -3,188 | 143,153 | 129,895 |
Comprehensive income attributable to noncontrolling interests | -65 | -46 | -52 |
Comprehensive income (loss) attributable to Brooks Automation, Inc., net of tax | ($3,253) | $143,107 | $129,843 |
CONSOLIDATED_STATEMENTS_OF_CAS
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Cash flows from operating activities | ' | ' | ' |
Net income (loss) | ($2,150) | $136,835 | $130,437 |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ' | ' | ' |
Depreciation and amortization | 24,155 | 21,620 | 17,249 |
Impairment of assets | 1,960 | 0 | 0 |
Stock-based compensation | 7,757 | 8,647 | 6,752 |
Amortization of premium on marketable securities | 1,274 | 2,401 | 2,283 |
Undistributed earnings of joint ventures | -2,442 | -2,133 | -4,815 |
Deferred income tax benefit | -2,936 | -122,136 | -276 |
Pension settlement | 87 | 8,937 | 0 |
Gain on sale of contract manufacturing business | 0 | 0 | -45,009 |
Loss (gain) on disposal of long-lived assets | -1,394 | -63 | 10 |
Changes in operating assets and liabilities, net of acquisitions and disposals: | ' | ' | ' |
Accounts receivable | 6,422 | -784 | 9,916 |
Inventories | 15,490 | 5,874 | -19,131 |
Prepaid expenses and other current assets | 4,359 | 5,801 | 4,205 |
Accounts payable | 3,123 | -11,182 | -15,099 |
Deferred revenue | 8,971 | -4,684 | 1,841 |
Accrued warranty and retrofit costs | -1,806 | -123 | -1,420 |
Accrued compensation and benefits | -2,625 | -4,878 | 1,717 |
Accrued restructuring costs | -972 | 1,930 | -3,212 |
Accrued pension | -950 | -5,772 | 2,014 |
Net cash provided by operating activities | -3,934 | -4,252 | 188 |
Net cash provided by operating activities | 54,389 | 36,038 | 87,650 |
Cash flows from investing activities | ' | ' | ' |
Purchases of property, plant and equipment | -3,635 | -8,653 | -6,455 |
Purchases of marketable securities | -91,740 | -132,015 | -186,718 |
Sale/maturity of marketable securities | 145,023 | 131,317 | 120,095 |
Acquisitions, net of cash acquired | -68,331 | -9,216 | -88,309 |
Decrease (increase) in restricted cash | 586 | 530 | -1,293 |
Proceeds from the sale of the contract manufacturing business | 0 | 0 | 78,249 |
Other investment | 0 | -3,000 | 0 |
Proceeds from the sale of property, plant and equipment | 14,082 | 0 | 0 |
Payment of deferred leasing cost | -3,134 | 0 | 0 |
Other | 0 | 0 | 181 |
Net cash used in investing activities | -7,149 | -21,037 | -84,250 |
Cash flows from financing activities | ' | ' | ' |
Proceeds from issuance of common stock, net of issuance costs | 1,851 | 1,705 | 1,358 |
Common stock dividend paid | -21,328 | -20,953 | -5,180 |
Net cash used in financing activities | -19,477 | -19,248 | -3,822 |
Effects of exchange rate changes on cash and cash equivalents | 569 | 53 | -568 |
Net increase (decrease) in cash and cash equivalents | 28,332 | -4,194 | -990 |
Cash and cash equivalents, beginning of year | 54,639 | 58,833 | 59,823 |
Cash and cash equivalents, end of year | 82,971 | 54,639 | 58,833 |
Supplemental disclosures: | ' | ' | ' |
Cash paid during the year for interest | 2 | 14 | 65 |
Cash paid (refunded) during the year for income taxes, net | ($762) | $4,282 | $1,042 |
CONSOLIDATED_STATEMENTS_OF_CHA
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (USD $) | Total | Common Stock | Additional Paid-In Capital | Accumulated Other Comprehensive Income (Loss) | Accumulated Deficit | Treasury Stock | Total Brooks Automation, Inc. Stockholders' Equity | Noncontrolling Interests in Subsidiaries |
In Thousands, unless otherwise specified | ||||||||
Beginning Balance at Sep. 30, 2010 | $388,169 | $789 | $1,803,121 | $17,866 | ($1,233,188) | ($200,956) | $387,632 | $537 |
Beginning Balance (in shares) at Sep. 30, 2010 | ' | 78,869,331 | ' | ' | ' | ' | ' | ' |
Shares issued under stock option, restricted stock and purchase plans, net (in shares) | ' | 867,858 | ' | ' | ' | ' | ' | ' |
Shares issued under stock option, restricted stock and purchase plans, net | -578 | 8 | -586 | ' | ' | ' | -578 | ' |
Stock-based compensation | 6,752 | ' | 6,752 | ' | ' | ' | 6,752 | ' |
Common stock dividend declared | -5,302 | ' | ' | ' | -5,302 | ' | -5,302 | ' |
Comprehensive income (loss): | ' | ' | ' | ' | ' | ' | ' | ' |
Net income (loss) | 130,437 | ' | ' | ' | 130,385 | ' | 130,385 | 52 |
Currency translation adjustments | 947 | ' | ' | 947 | ' | ' | 947 | ' |
Changes in unrealized loss on marketable securities | -445 | ' | ' | -445 | ' | ' | -445 | ' |
Actuarial gain (loss) arising in the year | -1,044 | ' | ' | -1,044 | ' | ' | -1,044 | ' |
Ending Balance at Sep. 30, 2011 | 518,936 | 797 | 1,809,287 | 17,324 | -1,108,105 | -200,956 | 518,347 | 589 |
Ending Balance (in shares) at Sep. 30, 2011 | ' | 79,737,189 | ' | ' | ' | ' | ' | ' |
Shares issued under stock option, restricted stock and purchase plans, net (in shares) | ' | 53,368 | ' | ' | ' | ' | ' | ' |
Shares issued under stock option, restricted stock and purchase plans, net | -227 | 1 | -228 | ' | ' | ' | -227 | ' |
Stock-based compensation | 8,647 | ' | 8,647 | ' | ' | ' | 8,647 | ' |
Common stock dividend declared | -21,208 | ' | ' | ' | -21,208 | ' | -21,208 | ' |
Comprehensive income (loss): | ' | ' | ' | ' | ' | ' | ' | ' |
Net income (loss) | 136,835 | ' | ' | ' | 136,789 | ' | 136,789 | 46 |
Currency translation adjustments | -2,406 | ' | ' | -2,406 | ' | ' | -2,406 | ' |
Changes in unrealized gain on marketable securities | 393 | ' | ' | 393 | ' | ' | 393 | ' |
Actuarial gain (loss) arising in the year | -606 | ' | ' | -606 | ' | ' | -606 | ' |
Recognition of pension settlement in earnings | 8,937 | ' | ' | 8,937 | ' | ' | 8,937 | ' |
Ending Balance at Sep. 30, 2012 | 649,301 | 798 | 1,817,706 | 23,642 | -992,524 | -200,956 | 648,666 | 635 |
Ending Balance (in shares) at Sep. 30, 2012 | ' | 79,790,557 | ' | ' | ' | ' | ' | ' |
Shares issued under stock option, restricted stock and purchase plans, net (in shares) | ' | 248,547 | ' | ' | ' | ' | ' | ' |
Shares issued under stock option, restricted stock and purchase plans, net | 188 | 2 | 186 | ' | ' | ' | 188 | ' |
Stock-based compensation | 7,607 | ' | 7,607 | ' | ' | ' | 7,607 | ' |
Common stock dividend declared | -21,252 | ' | ' | ' | -21,252 | ' | -21,252 | ' |
Comprehensive income (loss): | ' | ' | ' | ' | ' | ' | ' | ' |
Net income (loss) | -2,150 | ' | ' | ' | -2,215 | ' | -2,215 | 65 |
Currency translation adjustments | -2,113 | ' | ' | -2,113 | ' | ' | -2,113 | ' |
Changes in unrealized loss on marketable securities | -135 | ' | ' | -135 | ' | ' | -135 | ' |
Changes in unrealized gain on marketable securities | 14 | ' | ' | 14 | ' | ' | 14 | ' |
Actuarial gain (loss) arising in the year | 1,109 | ' | ' | 1,109 | ' | ' | 1,109 | ' |
Recognition of pension settlement in earnings | 87 | ' | ' | 87 | ' | ' | 87 | ' |
Ending Balance at Sep. 30, 2013 | $632,656 | $800 | $1,825,499 | $22,604 | ($1,015,991) | ($200,956) | $631,956 | $700 |
Ending Balance (in shares) at Sep. 30, 2013 | ' | 80,039,104 | ' | ' | ' | ' | ' | ' |
Nature_of_the_Business
Nature of the Business | 12 Months Ended |
Sep. 30, 2013 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' |
Nature of the Business | ' |
Nature of the Business | |
Brooks Automation, Inc. (“Brooks” or the “Company”) is a leading worldwide provider of automation, vacuum and instrumentation solutions for multiple markets including semiconductor manufacturing, technology device manufacturing and life sciences. The Company's technologies, engineering competencies and global service capabilities provide customers speed to market and ensure high uptime and rapid response, which equate to superior value in their mission-critical controlled environments. Since 1978, the Company has been a leading partner to the global semiconductor manufacturing markets and through product development initiatives and strategic business acquisitions Brooks has expanded its reach to meet the needs of customers in technology markets adjacent to semiconductor and life sciences. |
Summary_of_Significant_Account
Summary of Significant Accounting Policies | 12 Months Ended | |||||||||||
Sep. 30, 2013 | ||||||||||||
Accounting Policies [Abstract] | ' | |||||||||||
Summary of Significant Accounting Policies | ' | |||||||||||
Summary of Significant Accounting Policies | ||||||||||||
Principles of Consolidation and Basis of Presentation | ||||||||||||
The consolidated financial statements include the accounts of the Company and all majority-owned subsidiaries. All intercompany accounts and transactions are eliminated. Equity investments in which the Company exercises significant influence but does not control and is not the primary beneficiary are accounted for using the equity method. | ||||||||||||
Use of Estimates | ||||||||||||
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates are associated with accounts receivable, inventories, intangible assets, goodwill, deferred income taxes, warranty obligations, revenue recognized using the percentage of completion method and stock-based compensation expense on performance-based awards. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. | ||||||||||||
Foreign Currency Translation | ||||||||||||
Some transactions of the Company and its subsidiaries are made in currencies different from their functional currency. Foreign currency gains (losses) on these transactions or balances are recorded in “Other (income) expense, net” when incurred. Net foreign currency transaction losses included in income (loss) before income taxes and equity in earnings of joint ventures totaled $0.9 million, $0.4 million and $0.1 million for the years ended September 30, 2013, 2012 and 2011, respectively. For non-U.S. subsidiaries, assets and liabilities are translated at period-end exchange rates, and statements of operations items are translated at the average exchange rates for the period. The local currency is considered to be the functional currency for all of our foreign subsidiaries and, accordingly, translation adjustments are reported in “Accumulated other comprehensive income.” Foreign currency translation adjustments are one of the components of comprehensive net income (loss). | ||||||||||||
Derivative Financial Instruments | ||||||||||||
All derivatives, whether designated in a hedging relationship or not, are recorded on the consolidated balance sheets at fair value. The accounting for changes in fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must designate the hedging instrument, based on the exposure being hedged, as a fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation. Certain derivatives held by the Company are not designated as hedges but are used in managing exposure to changes in foreign exchange rates. | ||||||||||||
A fair value hedge is a derivative instrument designated for the purpose of hedging the exposure of changes in fair value of an asset or a liability resulting from a particular risk. If the derivative is designated as a fair value hedge, the changes in the fair value of the derivative and of the hedged item attributable to the hedged risk are both recognized in the same caption in the consolidated statements of operations and comprehensive income. | ||||||||||||
A cash flow hedge is a derivative instrument designated for the purpose of hedging the exposure to variability in future cash flows resulting from a particular risk. If the derivative is designated as a cash flow hedge, the effective portions of changes in the fair value of the derivative are recorded in accumulated other comprehensive income and are recognized in the results of operations when the hedged item affects earnings. Ineffective portions of changes in the fair value of cash flow hedges are recognized in the results of operations. | ||||||||||||
A hedge of a net investment in a foreign operation is achieved through a derivative instrument designated for the purpose of hedging the exposure of changes in value of investments in foreign subsidiaries. If the derivative is designated as a hedge of a net investment in a foreign operation, the effective portions of changes in the fair value of the derivative are recorded in other comprehensive income as a part of the currency translation adjustment. Ineffective portions of net investment hedges are recognized in the results of operations. | ||||||||||||
For derivative instruments not designated as hedging instruments, changes in fair value are recognized in the Consolidated Statements of Operations as gains and losses consistent with the classification of the underlying risk. | ||||||||||||
Cash and Cash Equivalents | ||||||||||||
Cash and cash equivalents include cash and highly liquid investments with original maturities of three months or less. At September 30, 2013 and 2012, cash equivalents were $7.8 million and $17.5 million, respectively. Cash equivalents are held at cost which approximates fair value due to their short-term maturities and varying interest rates. | ||||||||||||
Concentration of Credit Risk | ||||||||||||
Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of trade receivables and temporary and long-term cash investments in treasury bills and commercial paper. The Company restricts its investments to U.S. government and its agencies, municipalities, corporate securities and mutual funds that invest in U.S. government securities. The Company's customers are concentrated in the semiconductor industry, and relatively few customers account for a significant portion of the Company's revenue. The Company's top ten largest customers account for approximately 39% of revenue for the year ended September 30, 2013. One of the Company's customers accounted for 11% of revenue for the year ended September 30, 2013. The Company regularly monitors the creditworthiness of its customers and believes that it has adequately provided for exposure to potential credit losses. | ||||||||||||
Accounts Receivable and Allowance for Doubtful Accounts and Sales Returns | ||||||||||||
Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in its existing accounts receivable. The Company determines the allowance based on a number of factors, including an evaluation of customer credit worthiness, the age of the outstanding receivable, economic trends and historical experience. The Company reviews its allowance for doubtful accounts on a quarterly basis and changes in estimates are reflected in the period in which they become known. Accounts receivable balances are written-off against the allowance for doubtful accounts when the Company determines that the receivable is not recoverable. Provisions for doubtful accounts are recorded in "General and Administrative Expenses" in the Consolidated Statements of Operations. The allowance for sales returns is the Company's best estimate of probable returns from one of its semiconductor customers. Provisions for sales returns are recorded in "Revenue" in the Consolidated Statements of Operations. The Company does not have any off-balance-sheet credit exposure related to its customers. | ||||||||||||
Inventories | ||||||||||||
Inventories are stated at the lower of cost or market, cost being determined using a standard costing system which approximates cost based on a first-in, first-out method. The Company provides inventory reserves for excess, obsolete or damaged inventory based on changes in customer demand, technology and other economic factors. | ||||||||||||
Fixed Assets, Intangible Assets and Impairment of Long-lived Assets | ||||||||||||
Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method. Depreciable lives are summarized below: | ||||||||||||
Buildings | 20 - 40 years | |||||||||||
Computer equipment and software | 2 - 7 years | |||||||||||
Machinery and equipment | 2 - 10 years | |||||||||||
Furniture and fixtures | 3 - 10 years | |||||||||||
Leasehold improvements are amortized over the shorter of their estimated useful lives or the term of the respective leases. Equipment used for demonstrations to customers is included in machinery and equipment and is depreciated over its estimated useful life. Repair and maintenance costs are expensed as incurred. | ||||||||||||
The Company has developed software for internal use. Internal and external labor costs incurred during the application development stage of a project are capitalized. Costs incurred prior to application development and post implementation are expensed as incurred. Training and data conversion costs are expensed as incurred. | ||||||||||||
When an asset is retired, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts, and any resulting gain or loss is included in the determination of operating profit (loss). | ||||||||||||
As a result of the Company's acquisitions, the Company has identified finite-lived intangible assets other than goodwill. Finite-lived intangible assets are valued based on estimates of future cash flows and amortized over their estimated useful life using methods that approximate the pattern in which the economic benefits are expected to be realized. | ||||||||||||
Finite-lived intangibles assets and fixed assets are tested for impairment when indicators of impairment are present. For purposes of this test, long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. When the Company determines that indicators of potential impairment exist, the next step of the impairment test requires that the potentially impaired long-lived asset group is tested for recoverability. The test for recoverability compares the undiscounted future cash flows of the long-lived asset group to its carrying value. The future cash flow period is based on the future service life of the primary asset within the long-lived asset group. If the carrying values of the long-lived asset group exceed the future cash flows, the assets are considered to be potentially impaired. The next step in the impairment process is to determine the fair value of the individual net assets within the long-lived asset group. If the aggregate fair values of the individual net assets of the group are less than their carrying values, an impairment is recorded equal to the excess of the aggregate carrying value of the group over the aggregate fair value. The loss is allocated to each asset within the group based on their relative carrying values, with no asset reduced below its fair value. | ||||||||||||
The amortizable lives of intangible assets, including those identified as a result of purchase accounting, are summarized as follows: | ||||||||||||
Patents | 7 - 15 years | |||||||||||
Completed technology | 2 - 10 years | |||||||||||
License agreements | 5 years | |||||||||||
Trademarks and trade names | 2 - 6 years | |||||||||||
Non-competition agreements | 3 - 5 years | |||||||||||
Customer relationships | 4 - 13 years | |||||||||||
Goodwill | ||||||||||||
Goodwill represents the excess of purchase price over the fair value of net tangible and identifiable intangible assets of the businesses the Company acquired. The Company performs an annual impairment test of its goodwill on September 30 of each fiscal year unless interim indicators of impairment exist. | ||||||||||||
The testing of goodwill for impairment is performed at a level referred to as a reporting unit. A reporting unit is either the “operating segment level” or one level below, which is referred to as a “component.” The level at which the impairment test is performed requires an assessment as to whether the operations below the operating segment constitute a self-sustaining business, testing is generally required to be performed at this level. The Company currently has five reporting units that have goodwill, including three components that are part of the Brooks Product Solutions operating segment, one reporting unit that is the Brooks Global Services operating segment and one reporting unit that is the Brooks Life Science Systems operating segment. | ||||||||||||
The Company determines the fair value of its reporting units using an Income Approach, specifically the Discounted Cash Flow Method (“DCF Method”). The DCF Method includes future cash flow projections, which are discounted to present value, and an estimate of terminal values, which are also discounted to present value. Terminal values represent the present value an investor would pay today for the rights to the cash flows of the business for the years subsequent to the discrete cash flow projection period. The Company considers the DCF Method to be the most appropriate valuation indicator as the DCF analyses are based on management's long-term financial projections. Given the dynamic nature of the cyclical semiconductor equipment market, management's projections as of the valuation date are considered more objective since other market metrics for peer companies fluctuate over the cycle. However, the Company also uses market-based valuation techniques to test the reasonableness of the reporting unit fair values determined by the DCF Method and compares the aggregate fair value of its reporting units plus its net corporate assets to its overall market capitalization. | ||||||||||||
Goodwill impairment testing is a two-step process. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of each reporting unit to its respective carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered impaired. If the reporting unit's carrying amount exceeds the fair value, the second step of the goodwill impairment test must be completed to measure the amount of the impairment loss, if any. The second step compares the implied fair value of goodwill with the carrying value of goodwill. The implied fair value is determined by allocating the fair value of the reporting unit to all of the assets and liabilities of that unit, the excess of the fair value over amounts assigned to its assets and liabilities is the implied fair value of goodwill. The implied fair value of goodwill determined in this step is compared to the carrying value of goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, an impairment loss is recognized equal to the difference. | ||||||||||||
Pension Plans | ||||||||||||
The cost and obligations of the Company's defined benefit pension plans are calculated using many assumptions to estimate the benefits that the employee earns while working, the amount of which cannot be completely determined until the benefit payments cease. Major assumptions used in the accounting for these employee benefit plans include the discount rate, expected return on plan assets and rate of increase in employee compensation levels. Assumptions are determined based on Company data and appropriate market indicators in consultation with third-party actuaries, and are evaluated each year as of the plans' measurement date. | ||||||||||||
Revenue Recognition | ||||||||||||
Product revenue is associated with the sale of hardware systems, components and spare parts as well as product license revenue. Service revenue is associated with service contracts, repairs, upgrades and field service. Shipping and handling fees, billed to customers, if any, are recognized as revenue. The related shipping and handling costs are recognized in cost of revenue. | ||||||||||||
Revenue from product sales that do not include significant customization is recorded upon delivery and transfer of risk of loss to the customer provided there is evidence of an arrangement, fees are fixed or determinable, collection of the related receivable is reasonably assured and, if applicable, customer acceptance criteria have been successfully demonstrated. Customer acceptance provisions are included in certain arrangements to ensure that the product meets the published specification requirements. Customer acceptance provisions in the Company’s arrangements generally consist of final testing procedures that are carried out either in one of the Company’s facilities or at the customer location. When an arrangement includes acceptance criteria to be carried out in one of the Company’s facilities, the Company recognizes revenue when the acceptance criteria have been successfully demonstrated and delivery and transfer of risk of loss have occurred. When significant on site customer acceptance provisions are present in the arrangement, revenue is recognized upon completion of customer acceptance testing. | ||||||||||||
Revenue from product sales that does include significant customization, which primarily include life science automation systems, is recorded using the percentage of completion method whereby revenue is recorded as work progresses based on a percentage that incurred labor effort to date bear to total projected labor effort. Payments collected from customers in advance of recognizing the related revenue is recorded as deferred revenue. In addition, contracts are reviewed on a regular basis to determine whether a probable future loss exists. If such a loss is estimated by comparing total estimated contract revenue to the total estimated contract costs, a loss will be accrued in the same period the Company determines that the loss is probable. | ||||||||||||
Revenue associated with service agreements is generally recognized ratably over the term of the contract, with payments from customers being recorded as deferred revenue. Revenue from repair services or upgrades of customer-owned equipment is recognized upon completion of the repair effort and upon the shipment of the repaired item back to the customer. In instances where the repair or upgrade includes installation, revenue is recognized when the installation is completed. | ||||||||||||
A portion of the revenue arrangements for sales of life science automation systems are multiple element arrangements that can include product, service, as well as other elements. For revenue arrangements with multiple elements, arrangement consideration is allocated to each element based upon their relative selling price using vendor-specific objective evidence (“VSOE”), or third-party evidence (“TPE”) or based upon the relative selling price using estimated selling prices if VSOE or TPE does not exist. We rely primarily on relative selling prices when we do not have VSOE for a specific element. The Company recognizes revenue on each element of the arrangement in accordance with its policies for revenue recognition. The fair value of any undelivered elements is deferred until the undelivered element is delivered and all other criteria for revenue recognition have been met. | ||||||||||||
Warranty | ||||||||||||
The Company offers warranties on the sales of certain of its products and records an accrual for estimated future claims. Such accruals are based upon historical experience and management's estimate of the level of future claims. | ||||||||||||
Research and Development Expenses | ||||||||||||
Research and development costs are charged to expense when incurred. | ||||||||||||
Stock-Based Compensation | ||||||||||||
The Company measures compensation cost for all employee stock awards at fair value on the date of grant and recognizes compensation expense over the service period for awards expected to vest. The fair value of restricted stock is determined based on the number of shares granted and the quoted price of the Company's common stock on the date of grant, and the fair value of stock options is determined using the Black-Scholes valuation model. Such value is recognized as expense over the service period, net of estimated forfeitures. The estimation of stock awards that will ultimately vest requires significant judgment. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. In addition, for stock-based awards where vesting is dependent upon achieving certain operating performance goals, the Company estimates the likelihood of achieving the performance goals. Actual results, and future changes in estimates, may differ substantially from the Company's current estimates. | ||||||||||||
During the year ended September 30, 2013, the Company granted 1,394,000 shares of restricted stock to members of senior management of which 716,625 shares vest over the service period and the remaining 677,375 shares vest upon the achievement of certain financial performance goals which were measured at the end of fiscal year 2013. Total compensation expense on these awards is a maximum of $15.1 million, net of cancellations. During the year ended September 30, 2012, the Company granted 1,527,000 shares of restricted stock to members of senior management of which 406,750 shares vest over the service period and the remaining 1,120,250 shares vest upon the achievement of certain financial performance goals which will be measured at the end of fiscal year 2014. Total compensation expense on these awards is a maximum of $14.4 million, net of cancellations. Awards subject to service criteria are being recorded to expense ratably over the vesting period. Awards subject to performance criteria are expensed over the related service period when attainment of the performance condition is considered probable. The total amount of compensation recorded depends on the Company's achievement against performance targets. Changes to the projected attainment against performance targets during the vesting period may result in an adjustment to the amount of cumulative compensation recorded as of the date the estimate is revised. | ||||||||||||
During the three months ended December 31, 2011, the Company's Chief Executive Officer was granted an award of 100,000 cash settled phantom units, which are subject to the same vesting terms as the performance-based restricted stock units from fiscal year 2012. The Company's consolidated balance sheet at September 30, 2013 and 2012 includes a liability of approximately $0 and $78,000, respectively, for this potential cash payment. The Company recorded an expense of $78,000 related to this award during the year ended September 30, 2012, but was reversed during the year ended September 30, 2013 because the performance criteria was not met. | ||||||||||||
The following table reflects compensation expense recorded during the years ended September 30, 2013, 2012 and 2011 (in thousands): | ||||||||||||
Year ended September 30, | ||||||||||||
2013 | 2012 | 2011 | ||||||||||
Restricted stock | $ | 7,261 | $ | 8,098 | $ | 6,248 | ||||||
Employee stock purchase plan | 496 | 549 | 504 | |||||||||
$ | 7,757 | $ | 8,647 | $ | 6,752 | |||||||
Valuation Assumptions for Stock Options and Employee Stock Purchase Plans | ||||||||||||
No stock options were granted for the years ended September 30, 2013, 2012 or 2011. | ||||||||||||
The fair value of shares issued under the employee stock purchase plan was estimated on the commencement date of each offering period using the Black-Scholes option-pricing model with the following assumptions: | ||||||||||||
Year ended September 30, | ||||||||||||
2013 | 2012 | 2011 | ||||||||||
Risk-free interest rate | 0.1 | % | 0.1 | % | 0.2 | % | ||||||
Volatility | 32 | % | 45 | % | 50 | % | ||||||
Expected life | 6 months | 6 months | 6 months | |||||||||
Dividend yield | 3.30% - 3.40% | 2.75% - 3.30% | 0% - 3% | |||||||||
The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option; expected volatilities are based on historical volatilities of the Company's common stock; and the expected life represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company's historical exercise patterns. Dividend yields are projected based on the Company's history of dividends declared, and management's intention for future dividend declarations. | ||||||||||||
Equity Incentive Plans | ||||||||||||
The Company's equity incentive plans are intended to attract and retain employees and to provide an incentive for them to assist the Company to achieve long-range performance goals and to enable them to participate in the long-term growth of the Company. The equity incentive plans consist of plans under which employees may be granted options to purchase shares of the Company's stock, restricted stock and other equity incentives. Stock options generally had a vesting period of four years and are exercisable for a period not to exceed seven years from the date of issuance. Restricted stock awards generally vest over two to four years. At September 30, 2013, a total of 3,259,558 shares were reserved and available for the issuance of awards under the plans. | ||||||||||||
Income Taxes | ||||||||||||
The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company's consolidated financial statements contain certain deferred tax assets which have arisen primarily as a result of operating losses, as well as other temporary differences between financial and tax accounting. A valuation allowance is established if the likelihood of realization of the deferred tax assets is not considered more likely than not based on an evaluation of positive and negative evidence and the extent to which that evidence is objectively verifiable. Significant management judgment is required in determining the Company's provision for income taxes, the Company's deferred tax assets and liabilities and any valuation allowance recorded against those net deferred tax assets. The Company evaluates the weight of all available evidence to determine whether it is more likely than not that some portion or all of the net deferred income tax assets will not be realized. | ||||||||||||
The calculation of the Company's tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. If we determine that a tax position will more likely than not be sustained on audit, the second step requires us to estimate and measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as we have to determine the probability of various possible outcomes. We re-evaluate these uncertain tax positions on a quarterly basis. This evaluation is based on factors such as changes in facts or circumstances, changes in tax law, new audit activity, and effectively settled issues. Determining whether an uncertain tax position is effectively settled requires judgment. Such a change in recognition or measurement would result in the recognition of a tax benefit or an additional charge to the tax provision. | ||||||||||||
Earnings Per Share | ||||||||||||
Basic earnings per share is calculated based on the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated based on the weighted average number of common shares and dilutive common equivalent shares assumed outstanding during the period. Shares used to compute diluted earnings per share exclude common share equivalents if their inclusion would have an anti-dilutive effect. | ||||||||||||
Fair Value of Financial Instruments | ||||||||||||
The Company's financial instruments include cash and cash equivalents, restricted cash, marketable securities, derivative instruments, accounts receivable and accounts payable. The carrying amounts of these items reported in the balance sheets approximate their fair value at September 30, 2013 and 2012 because of their short-term nature. In the case of marketable securities and derivative instruments, measurement is based on quoted market prices for identical or similar securities or instruments. | ||||||||||||
Reclassifications | ||||||||||||
In order to conform with the current year presentation, cash distributions received from joint ventures of $5.1 million and $2.4 million in the years ended September 30, 2012 and 2011, respectively, were reclassified from “Undistributed Earnings of Joint Ventures” to “Prepaid Expenses and Other Current Assets” on the Consolidated Statements of Cash Flows. The reclassification of these amounts had no impact on previously reported net cash provided by operating activities, results of operations or financial position for the years ended September 30, 2012 and 2011. | ||||||||||||
Recent Accounting Pronouncements | ||||||||||||
In June 2011, the Financial Accounting Standards Board ("FASB") issued an amendment to the accounting guidance for presentation of comprehensive income. Under the amended guidance, a company may present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. This authoritative guidance eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity. On October 1, 2012 the Company adopted this guidance and elected to present two separate but consecutive statements. | ||||||||||||
In February 2013, the FASB issued guidance to provide information about the amounts reclassified out of accumulated other comprehensive income (“AOCI”) by component. In addition, an entity is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of AOCI by the respective line items of net income, but only if the amount reclassified is required to be reclassified in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. On January 1, 2013 the Company adopted this standard, which had no impact on its financial position or results of operations. |
Acquisitions_and_Divestiture
Acquisitions and Divestiture | 12 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Business Combinations [Abstract] | ' | |||||||
Acquisitions and Divestiture | ' | |||||||
Acquisitions and Divestiture | ||||||||
Acquisition of Matrical | ||||||||
On August 1, 2013, the Company acquired certain assets and assumed certain liabilities of Matrical, Inc.’s life science businesses (collectively “the Matrical assets”) for cash consideration of approximately $9.3 million, net of cash acquired. Matrical, Inc. is a Spokane, Washington-based, privately held company that provides biological sample preparation, management and storage solutions to customers in agricultural biotechnology, biotechnology, life science and pharmaceutical markets. The acquisition of the Matrical assets provides the Company with the opportunity to enhance its existing product offerings in biobanking and sample management. | ||||||||
The assets and liabilities associated with the purchase of the Matrical assets were recorded at their fair values as of the acquisition date. The amounts recorded follow (in thousands): | ||||||||
Accounts receivable | $ | 636 | ||||||
Inventory | 2,095 | |||||||
Prepaid and other current assets | 103 | |||||||
Property, plant and equipment | 534 | |||||||
Completed technology | 500 | |||||||
Customer relationships | 1,500 | |||||||
Goodwill | 7,137 | |||||||
Debt | (902 | ) | ||||||
Accounts payable | (294 | ) | ||||||
Deferred revenue | (412 | ) | ||||||
Customer deposits | (1,249 | ) | ||||||
Other current liabilities | (322 | ) | ||||||
Total purchase price, net of cash acquired | $ | 9,326 | ||||||
In performing the purchase price allocation, the Company considered, among other factors, its intention for future use of the acquired assets, analyses of historical financial performance, and estimates of future cash flows from Matrical’s products and services. The purchase price was allocated based upon the fair value of the identified assets acquired and liabilities assumed as of the acquisition date from a market participant’s perspective. | ||||||||
The Company used the relief-from-royalty method to value the completed technology and the excess earnings method to value the customer relationships. Cash flows were discounted at a rate of 18%. The weighted-average amortization periods are 4.6 years for completed technologies and 7.0 years for customer relationships. The intangible assets acquired will be amortized using the straight-line method because it approximates the pattern in which the economic benefits are expected to be realized. | ||||||||
Goodwill represents the excess of the purchase price over the fair values of the net tangible and intangible assets acquired and is primarily the result of expected synergies from combining the Matrical products with the Company's other life science products. Goodwill arising from the acquisition of the Matrical assets is deductible for tax purposes. | ||||||||
The operating results from the Matrical assets have been included in the results of operations for the Brooks Life Science Systems segment from the date of acquisition. Pro forma results are not provided as the results of operations were not material. | ||||||||
Transaction costs incurred by the Company related to this acquisition were $0.3 million and are included in selling, general and administrative expense. | ||||||||
Acquisition of Crossing | ||||||||
On October 29, 2012, the Company acquired all the outstanding stock of Crossing Automation Inc. (“Crossing”), a U.S. based provider of automation solutions and services primarily to global semiconductor front-end markets. The Company paid, in cash, an aggregate merger consideration of $59.0 million net of cash acquired. Crossing is based in Fremont, California. The acquisition of Crossing provides the Company with the opportunity to enhance its existing capabilities with respect to manufacturing of atmospheric and vacuum automation solutions within the semiconductor front-end market. | ||||||||
The assets and liabilities associated with Crossing were recorded at their fair values as of the acquisition date. The amounts recorded follow (in thousands): | ||||||||
Accounts receivable | $ | 5,356 | ||||||
Inventory | 8,668 | |||||||
Prepaid expenses | 1,968 | |||||||
Property, plant and equipment | 2,270 | |||||||
Completed technology | 10,530 | |||||||
Customer relationships | 20,010 | |||||||
Goodwill | 26,453 | |||||||
Other long term assets | 885 | |||||||
Accounts payable | (3,024 | ) | ||||||
Accrued liabilities | (5,172 | ) | ||||||
Deferred revenue | (319 | ) | ||||||
Other current liabilities | (388 | ) | ||||||
Other long-term liabilities | (8,232 | ) | ||||||
Total purchase price, net of cash acquired | $ | 59,005 | ||||||
In performing the purchase price allocation, the Company considered, among other factors, its intention for future use of the acquired assets, analyses of historical financial performance, and estimates of future cash flows from Crossing’s products and services. The purchase price was allocated based upon the fair value of the identified assets acquired and liabilities assumed as of the acquisition date from a market participant’s perspective. | ||||||||
The Company used the relief-from-royalty method to value the completed technology and the excess earnings method to value the customer relationships. Cash flows were discounted at a rate of 15%. The weighted-average amortization periods are 7.7 years for completed technologies and 8.0 years for customer relationships. The intangible assets acquired will be amortized using methods that approximate the pattern in which the economic benefits are expected to be realized, including variable declining balance and straight-line methods. | ||||||||
Goodwill is primarily the result of expected synergies from combining the operations of Crossing with the Company. Goodwill arising from the acquisition of Crossing is not deductible for tax purposes. | ||||||||
Crossing’s operating results have been included in the results of operations for the Brooks Product Solutions and Brooks Global Services segments from the acquisition date. Revenue from Crossing for the year ended September 30, 2013 was $41.5 million, and the after-tax net loss attributable to Crossing was $2.6 million. The net loss includes the impact of step-up in value of acquired inventories sold in fiscal 2013 which increased the net loss by $2.7 million. The operating results for Crossing also include amortization expense of $3.7 million for the year ended September 30, 2013. | ||||||||
The following pro forma summary presents consolidated information of the Company as if the acquisition of Crossing occurred on October 1, 2011 (in thousands): | ||||||||
Year ended September 30, | ||||||||
2013 | 2012 | |||||||
Revenue | $ | 453,045 | $ | 570,864 | ||||
Net income (loss) attributable to Brooks Automation, Inc. | (3,216 | ) | 135,245 | |||||
The pro forma net income (loss) has been adjusted to reflect additional amortization from adjustments to intangible assets as if those adjustments had been applied as of October 1, 2011. | ||||||||
Transaction costs of $3.6 million incurred by Crossing prior to the closing of the acquisition have been eliminated from pro forma net income (loss) as presented above. These costs include banker fees of $1.5 million and one-time incentive compensation payments related to the transaction of $1.2 million. Transaction costs incurred by the Company related to this acquisition were $0.6 million for the year ended September 30, 2013, and are included in selling, general and administrative expense. | ||||||||
Acquisition of Intellectual Property from Intevac, Inc. | ||||||||
During the three months ended March 31, 2012, the Company acquired primarily intellectual property from Intevac, Inc. for $3.0 million. Management evaluated this asset purchase to determine if this acquisition would be considered an acquisition of a business. Since only a limited amount of assets were acquired, management concluded that the inputs and processes required to meet the definition of a business were not acquired in this transaction, therefore, this transaction was treated as the purchase of an asset group. This asset group includes primarily intellectual property that we use in the development of the Company's next generation of semiconductor automation tools that resides within the Brooks Product Solutions segment. The Company expensed essentially all of this asset purchase as an in-process research and development cost in the three months ended March 31, 2012. | ||||||||
Acquisition of Celigo | ||||||||
On December 30, 2011, the Company acquired the Celigo® automated Cell Cytometer product line (“Celigo”) from Cyntellect, Inc., for $8.7 million in cash, plus a deferred cash payment of $0.5 million that was paid in July 2012. The Celigo product line provides life science customers with cellular imaging in a high-throughput and easy-to-use platform. Celigo's operations were based in San Diego, California, and were integrated into the Company's nearby Poway, California-based life sciences operation shortly after the acquisition. The Celigo product line resides in the Brooks Life Science Systems segment. The acquisition of Celigo provides a complementary analysis tool for customers currently using the Company's automated sample management systems. | ||||||||
The assets and liabilities associated with Celigo were recorded at their fair values as of the acquisition date. The amounts recorded follow (in thousands): | ||||||||
Accounts receivable | $ | 897 | ||||||
Inventory | 1,139 | |||||||
Property, plant and equipment | 202 | |||||||
Completed technology | 3,540 | |||||||
Trademarks and trade names | 70 | |||||||
Goodwill | 3,713 | |||||||
Accounts payable | (13 | ) | ||||||
Deferred revenue | (326 | ) | ||||||
Other current liabilities | (6 | ) | ||||||
Total purchase price, net of cash acquired | $ | 9,216 | ||||||
The estimated fair value attributed to the completed technologies was determined based upon a discounted cash flow forecast. Cash flows were discounted at a rate of 25%. | ||||||||
In 2013, the Company recorded an impairment charge of $2.0 million in the fourth quarter of fiscal 2013, related to long-lived assets acquired with the Celigo product line. The impairment charge is described in "Note 7. Goodwill and Intangible Assets." | ||||||||
Goodwill is primarily the result of expected synergies from combining the Celigo product line with the Company's other Life Science products. Goodwill arising from the acquisition will be deductible for tax purposes. | ||||||||
Celigo's operating results have been included in the Company's results of operations from the acquisition date. Pro forma results are not provided as Celigo's results of operations were not material. Transaction costs related to this acquisition were $0.1 million for the first quarter ended December 31, 2011, and are included in selling, general and administrative expense. There were no transaction costs subsequent to December 31, 2011. | ||||||||
Acquisition of Nexus | ||||||||
On July 25, 2011, the Company acquired all of the outstanding stock of Nexus Biosystems, Inc. (“Nexus”), a privately held company, for $84.9 million, net of cash acquired. Nexus is a U.S. based provider of automation solutions and consumables to the life sciences market, with a product development, service and support operation located in Switzerland, and service and support locations in Japan and Germany. The acquisition significantly enhances the breadth of the Company’s product offering for its main target market within the life sciences industry, specifically biobanking and compound sample management. Shortly after completing the Nexus acquisition, the Company reorganized the management of Nexus and RTS into one operating segment, Brooks Life Science Systems. | ||||||||
The assets and liabilities associated with Nexus were recorded at their fair values as of the acquisition date. The amounts recorded follow (in thousands): | ||||||||
Accounts receivable | $ | 5,708 | ||||||
Inventory | 7,481 | |||||||
Other current assets | 4,522 | |||||||
Property, plant and equipment | 12,527 | |||||||
Completed technology | 6,000 | |||||||
Customer relationships | 31,000 | |||||||
Trademarks and trade names | 100 | |||||||
Goodwill | 33,033 | |||||||
Accounts payable and accrued expenses | (6,563 | ) | ||||||
Deferred revenue | (3,692 | ) | ||||||
Other current liabilities | (1,534 | ) | ||||||
Deferred tax liabilities | (2,584 | ) | ||||||
Other long-term liabilities | (1,070 | ) | ||||||
Total purchase price, net of cash acquired | $ | 84,928 | ||||||
The estimated fair value attributed to the completed technologies was determined based upon a discounted cash flow forecast utilizing the relief from royalty method. The royalty rate was determined to be 6% based on a review of comparable royalty arrangements. Cash flows were discounted at a rate of 17%. The fair value of the completed technologies will be amortized over a period of 6 years on a straight-line basis, which approximates the pattern in which the economic benefits of the completed technologies are expected to be realized. | ||||||||
The estimated fair value attributed to the customer relationships was determined based upon a discounted forecast of estimated net future cash flows to be generated from the relationships discounted at a rate of 17% - 18%. The fair value of customer relationships for systems will be amortized over a period of 6 years, while the estimated fair value of customer relationships for consumables and service are expected to be amortized over a period of 13 years. The amortization will be amortized on a straight-line basis, which approximates the pattern in which the economic benefits of the customer relationships are expected to be realized. | ||||||||
The fair value of the trade name will be amortized over 2 years on a straight-line basis, which approximates the pattern in which the economic benefits of the trade names will be realized. | ||||||||
Goodwill represents the excess of the purchase price over the fair values of the net tangible and intangible assets acquired. Goodwill arising from the acquisition will not be deductible for tax purposes. | ||||||||
Nexus operating results have been included in the Company’s results of operations from the acquisition date. Nexus revenues and net loss for the period from July 26, 2011 to September 30, 2011 was $4.9 million and $(3.2) million, respectively. The net loss includes charges to expense from the step-up of acquired inventories of $0.7 million and $0.6 million of charges for excess and obsolete inventory based on an assessment of inventory performed in the fourth quarter of fiscal year 2011. | ||||||||
The following unaudited pro forma summary presents consolidated information of the Company as if the acquisition of Nexus occurred on October 1, 2010 (in thousands): | ||||||||
Year Ended | ||||||||
September 30, | ||||||||
2011 | ||||||||
Revenue | $ | 720,989 | ||||||
Net income attributable to Brooks Automation, Inc. | 124,114 | |||||||
The pro forma net income has been adjusted to reflect additional amortization and depreciation expense from the adjustments to intangible assets and property, plant and equipment as if those adjustments had been applied as of October 1, 2010. | ||||||||
Transaction costs related to this acquisition were $719,000 for fiscal year 2011, and are included in selling, general and administrative expense. | ||||||||
Acquisition of RTS | ||||||||
On April 1, 2011, the Company acquired all of the outstanding stock of RTS Life Science Limited (“RTS”), a privately held company, for $3.4 million, net of cash acquired. RTS is a provider of automation solutions to the life sciences market, located in Manchester, United Kingdom. The acquisition provides the Company with biobanking and compound sample management, and the ability to leverage the Company’s existing automation technologies with those of RTS. | ||||||||
The assets and liabilities associated with RTS were recorded at their fair values as of the acquisition date. The amounts recorded follow (in thousands): | ||||||||
Accounts receivable | $ | 3,156 | ||||||
Inventory | 1,668 | |||||||
Other current assets | 1,008 | |||||||
Property, plant and equipment | 860 | |||||||
Completed technology | 1,524 | |||||||
Customer relationships | 577 | |||||||
Trademarks and trade names | 64 | |||||||
Goodwill | 3,556 | |||||||
Accounts payable | (1,397 | ) | ||||||
Deferred revenue | (5,232 | ) | ||||||
Other current liabilities | (2,403 | ) | ||||||
Total purchase price, net of cash acquired | $ | 3,381 | ||||||
The completed technology will be amortized to cost of revenue over its estimated useful life of 5 to 7 years, the customer relationships will be amortized to operating expense over 7 years and the trademarks and trade names will be amortized to operating expense over 3 years. Goodwill arising from the acquisition will not be deductible for tax purposes. | ||||||||
RTS’s operating results have been included in the Company’s results of operations from the acquisition date, and were not material. Pro forma results are not provided as RTS’s results of operations were not material. Transaction costs related to this acquisition were $188,000 for fiscal year 2011, and are included in selling, general and administrative expense. | ||||||||
Divestiture | ||||||||
On April 20, 2011, the Company entered into an agreement with affiliates of Celestica Inc. (the “Buyers”) to sell the assets of its extended factory contract manufacturing business (the “Business”). The Buyers also agreed to assume certain liabilities related to the Business (the “Asset Sale”). The Asset Sale was completed on June 28, 2011 (the “Closing”). At the Closing, the Buyers paid the Company a total purchase price of $78 million in cash, plus $1.3 million as consideration for cash acquired in the Asset Sale. An additional $2.5 million of proceeds was paid during the Company’s fourth quarter of 2011, which represents a working capital normalizing adjustment. The Company paid $2.3 million of transaction expenses. During the three months ended June 30, 2011, the Company recorded a gain on this sale of $45.0 million, before income taxes. Income taxes directly attributable to this gain of $2.4 million were also recorded during the three months ended June 30, 2011. | ||||||||
The Company and the Buyers also entered into certain commercial supply and license agreements at the Closing which will govern the ongoing relationship between the Buyers and the Company. Pursuant to those agreements, the Company will supply the Buyers with certain products and has licensed to the Buyers certain intellectual property needed to run the Business and the Buyers will supply certain products to the Company. Due to the significance of these ongoing commercial arrangements, the sale did not qualify for discontinued operations treatment. Therefore, historical financial results of the divested business will not be segregated in the Company’s consolidated financial statements for the historical periods in which this business was part of the Company. |
Marketable_Securities
Marketable Securities | 12 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Investments, Debt and Equity Securities [Abstract] | ' | |||||||||||||||
Marketable Securities | ' | |||||||||||||||
Marketable Securities | ||||||||||||||||
The Company invests in marketable securities and classifies them as available-for-sale. The Company records these securities at fair value. Marketable securities reported as current assets represent investments that mature within one year from the balance sheet date. Long-term marketable securities represent investments with maturity dates greater than one year from the balance sheet date. At the time that the maturity dates of these investments become one year or less, the securities are reclassified to current assets. Unrealized gains and losses are excluded from earnings and reported in a separate component of stockholders’ equity until the security is sold or matures. At the time of sale, any gains or losses, calculated by the specific identification method, will be recognized as a component of operating results. | ||||||||||||||||
The following is a summary of marketable securities (included in short and long-term marketable securities in the Consolidated Balance Sheets), including accrued interest receivable, as of September 30, 2013 and 2012 (in thousands): | ||||||||||||||||
Amortized | Gross | Gross | Fair Value | |||||||||||||
Cost | Unrealized | Unrealized | ||||||||||||||
Gains | Losses | |||||||||||||||
September 30, 2013: | ||||||||||||||||
U.S. Treasury securities and obligations of U.S. government agencies | $ | 19,528 | $ | 6 | $ | (13 | ) | $ | 19,521 | |||||||
Corporate securities | 35,045 | 11 | (47 | ) | 35,009 | |||||||||||
Mortgage-backed securities | 1,093 | 25 | (1 | ) | 1,117 | |||||||||||
Other debt securities | 88 | — | — | 88 | ||||||||||||
Municipal securities | 25,199 | 15 | (7 | ) | 25,207 | |||||||||||
Bank certificate of deposits | 9,451 | — | (2 | ) | 9,449 | |||||||||||
$ | 90,404 | $ | 57 | $ | (70 | ) | $ | 90,391 | ||||||||
September 30, 2012: | ||||||||||||||||
U.S. Treasury securities and obligations of U.S. government agencies | $ | 41,202 | $ | 15 | $ | (2 | ) | $ | 41,215 | |||||||
Corporate securities | 64,102 | 138 | (16 | ) | 64,224 | |||||||||||
Mortgage-backed securities | 1,310 | 42 | (1 | ) | 1,351 | |||||||||||
Other debt securities | 13 | — | — | 13 | ||||||||||||
Municipal securities | 34,777 | 25 | (1 | ) | 34,801 | |||||||||||
Bank certificate of deposits | 3,987 | 1 | — | 3,988 | ||||||||||||
$ | 145,391 | $ | 221 | $ | (20 | ) | $ | 145,592 | ||||||||
Gross realized gains on sales of available-for-sale marketable securities included in “Other income, net” in the Consolidated Statements of Operations was $57,000, $15,000 and $24,000 for the years ended September 30, 2013, 2012 and 2011, respectively. A gross realized loss of $36,000 for the year ended September 30, 2013 was also recorded in "Other income, net." There were no gross realized losses for the years ended September 30, 2012 or 2011. | ||||||||||||||||
The fair value of the marketable securities at September 30, 2013 by contractual maturity, are shown below (in thousands). Expected maturities will differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. | ||||||||||||||||
Fair Value | ||||||||||||||||
Due in one year or less | $ | 45,900 | ||||||||||||||
Due after one year through five years | 41,194 | |||||||||||||||
Due after ten years | 3,297 | |||||||||||||||
$ | 90,391 | |||||||||||||||
Fair_Value_Measurements
Fair Value Measurements | 12 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Fair Value Disclosures [Abstract] | ' | ||||||||||||||||
Fair Value Measurements | ' | ||||||||||||||||
Fair Value Measurements | |||||||||||||||||
The fair value measurement guidance establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: | |||||||||||||||||
Level 1: Quoted prices in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset and liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. | |||||||||||||||||
Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. | |||||||||||||||||
Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. | |||||||||||||||||
Assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2013 and 2012 are summarized as follows (in thousands): | |||||||||||||||||
Fair Value Measurements at Reporting Date Using | |||||||||||||||||
Description | September 30, | Quoted Prices in | Significant Other | Significant | |||||||||||||
2013 | Active Markets for | Observable Inputs | Unobservable Inputs | ||||||||||||||
Identical Assets | (Level 2) | (Level 3) | |||||||||||||||
(Level 1) | |||||||||||||||||
Assets | |||||||||||||||||
Cash equivalents | $ | 7,754 | $ | 6,152 | $ | 1,602 | $ | — | |||||||||
Available-for-sale securities | 90,391 | 2,199 | 88,192 | — | |||||||||||||
Foreign exchange contracts | 31 | — | 31 | ||||||||||||||
Total Assets | $ | 98,176 | $ | 8,351 | $ | 89,825 | $ | — | |||||||||
Liabilities | |||||||||||||||||
Foreign exchange contracts | $ | 5 | $ | — | $ | 5 | $ | — | |||||||||
Fair Value Measurements at Reporting Date Using | |||||||||||||||||
Description | September 30, | Quoted Prices in | Significant Other | Significant | |||||||||||||
2012 | Active Markets for | Observable Inputs | Unobservable Inputs | ||||||||||||||
Identical Assets | (Level 2) | (Level 3) | |||||||||||||||
(Level 1) | |||||||||||||||||
Assets | |||||||||||||||||
Cash equivalents | $ | 17,508 | $ | 17,508 | $ | — | $ | — | |||||||||
Available-for-sale securities | 145,592 | 60,231 | 85,361 | — | |||||||||||||
Foreign exchange contracts | 10 | — | 10 | — | |||||||||||||
Total Assets | $ | 163,110 | $ | 77,739 | $ | 85,371 | $ | — | |||||||||
Liabilities | |||||||||||||||||
Foreign exchange contracts | $ | 13 | $ | — | $ | 13 | $ | — | |||||||||
Cash Equivalents | |||||||||||||||||
Cash equivalents of $6.2 million and $17.5 million at September 30, 2013 and 2012, respectively, consisting primarily of Money Market Funds, are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. Cash equivalents of $1.6 million at September 30, 2013 consisting of Bank Certificate of Deposits and Municipal Securities, are classified within Level 2 of the hierarchy because they are not actively traded. | |||||||||||||||||
Available-For-Sale Securities | |||||||||||||||||
Available-for-sale securities of $2.2 million and $60.2 million at September 30, 2013 and 2012, respectively, consisting of highly rated Corporate Bonds, are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets of identical assets or liabilities. Available-for-sale securities of $88.2 million and $85.4 million at September 30, 2013 and 2012, respectively, consisting of Mortgage-Backed Securities, Municipal Securities, Bank Certificate of Deposits, Commercial Paper and U.S. Treasury Securities and Obligations of U.S. Government Agencies are classified within Level 2 of the fair value hierarchy because they are not actively traded and are valued using matrix pricing and benchmarking. Matrix pricing is a mathematical technique used to value securities by relying on the securities’ relationship to other benchmark quoted prices. | |||||||||||||||||
Foreign Exchange Contracts | |||||||||||||||||
Foreign exchange contract assets and liabilities are classified within Level 2 of the fair value hierarchy because there may not be an active market for each contract. However, the inputs used to calculate the value of the contract were obtained from an active market. |
Property_Plant_and_Equipment
Property, Plant and Equipment | 12 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Property, Plant and Equipment [Abstract] | ' | |||||||
Property, Plant and Equipment | ' | |||||||
Property, Plant and Equipment | ||||||||
Property, plant and equipment as of September 30, 2013 and 2012 were as follows (in thousands): | ||||||||
September 30, | ||||||||
2013 | 2012 | |||||||
Buildings and land | $ | 38,539 | $ | 55,352 | ||||
Computer equipment and software | 72,927 | 70,719 | ||||||
Machinery and equipment | 55,375 | 51,813 | ||||||
Furniture and fixtures | 10,298 | 10,908 | ||||||
Leasehold improvements | 16,522 | 18,938 | ||||||
Capital projects in progress | 2,098 | 2,614 | ||||||
195,759 | 210,344 | |||||||
Less accumulated depreciation and amortization | (147,889 | ) | (145,866 | ) | ||||
Property, plant and equipment, net | $ | 47,870 | $ | 64,478 | ||||
Depreciation expense was $14.0 million, $13.4 million and $12.6 million for the years ended September 30, 2013, 2012 and 2011, respectively. |
Goodwill_and_Intangible_Assets
Goodwill and Intangible Assets | 12 Months Ended | |||||||||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | |||||||||||||||||||||||
Goodwill and Intangible Assets | ' | |||||||||||||||||||||||
Goodwill and Intangible Assets | ||||||||||||||||||||||||
The Company performed its goodwill impairment test as of September 30, 2013 and 2012, and determined that no adjustment to goodwill was necessary. As of September 30, 2013, the fair value of all reporting units exceeded the respective carrying values by at least 10%. | ||||||||||||||||||||||||
The fair values of the reporting units in the Brooks Product Solutions and Brooks Global Services segments exceeded their carrying values by amounts ranging from 18% to 114% at September 30, 2013. | ||||||||||||||||||||||||
The fair value of the Brooks Life Science Systems reporting unit exceeded its carrying value by 10% at September 30, 2013. The observable inputs used in the Company's DCF for analysis for the Brooks Life Science Systems reporting unit include a discount rate 18%. In addition, the Company determined the terminal value using the Gordon growth method and a terminal growth rate of 3%. The Gordon growth method assumes that the reporting unit will grow and generate free cash flow at a constant rate. The Company believes that the Gordon growth method is the most appropriate method for determining the terminal value because the terminal value was calculated at the point in which the Company has assumed that the Brooks Life Science Systems reporting unit has reached a stable growth rate. | ||||||||||||||||||||||||
In fiscal 2013, the Company experienced a decline in revenue and operating profit for the products in the Brooks Life Science Systems reporting unit. The cash flow assumptions in the Company's DCF Method analysis for the Brooks Life Science Systems reporting unit project growth in the Company's current automated sample management systems and the development of new automated sample management systems that would allow the Company to address a broader automated sample management market than it can address with its current products. While the Company believes its assumptions are reasonable, actual results could differ from projections. To the extent that the operating results of the Brooks Life Science Systems reporting unit do not improve as expected and new life science products being designed to expand the markets the Company serve are not introduced in a timely manner or accepted by the market, the Company may be required to write down all or a portion of the goodwill and other long-lived assets associated with this reporting unit, which would adversely impact its earnings. | ||||||||||||||||||||||||
The components of the Company’s goodwill by business segment at September 30, 2013 and 2012 are as follows (in thousands): | ||||||||||||||||||||||||
Brooks | Brooks | Brooks | Contract Manufacturing | Other | Total | |||||||||||||||||||
Product | Global | Life Science | ||||||||||||||||||||||
Solutions | Services | Systems | ||||||||||||||||||||||
Gross goodwill at September 30, 2011 | $ | 485,844 | $ | 151,238 | $ | 36,589 | $ | 18,593 | $ | 7,421 | $ | 699,685 | ||||||||||||
Acquisitions and adjustments during fiscal 2012 | — | — | 3,713 | — | — | 3,713 | ||||||||||||||||||
Gross goodwill at September 30, 2012 | 485,844 | 151,238 | 40,302 | 18,593 | 7,421 | 703,398 | ||||||||||||||||||
Acquisitions and adjustments during fiscal 2013 | 20,899 | 5,554 | 7,137 | — | — | 33,590 | ||||||||||||||||||
Gross goodwill at September 30, 2013 | $ | 506,743 | $ | 156,792 | $ | 47,439 | $ | 18,593 | $ | 7,421 | $ | 736,988 | ||||||||||||
Accumulated goodwill impairments at September 30, 2011 | $ | (437,706 | ) | $ | (151,238 | ) | $ | — | $ | (18,593 | ) | $ | (7,421 | ) | $ | (614,958 | ) | |||||||
Impairments recorded during fiscal 2012 | — | — | — | — | — | — | ||||||||||||||||||
Accumulated goodwill impairments at September 30, 2012 | (437,706 | ) | (151,238 | ) | — | (18,593 | ) | (7,421 | ) | (614,958 | ) | |||||||||||||
Impairments recorded during fiscal 2013 | — | — | — | — | — | — | ||||||||||||||||||
Accumulated goodwill impairments at September 30, 2013 | $ | (437,706 | ) | $ | (151,238 | ) | $ | — | $ | (18,593 | ) | $ | (7,421 | ) | $ | (614,958 | ) | |||||||
Goodwill, less accumulated impairments at September 30, 2012 | $ | 48,138 | $ | — | $ | 40,302 | $ | — | $ | — | $ | 88,440 | ||||||||||||
Goodwill, less accumulated impairments at September 30, 2013 | $ | 69,037 | $ | 5,554 | $ | 47,439 | $ | — | $ | — | $ | 122,030 | ||||||||||||
The Company is required to test certain long-lived assets when indicators of impairment are present. The Company determined that impairment indicators were present for the long-lived assets related to the Celigo product line as of September 30, 2013. The long-lived assets in question were tested for recoverability by comparing the sum of the undiscounted cash flows directly attributable to the assets to their carrying values, which resulted in the conclusion that the carrying amounts of the assets were not recoverable. The fair values of the assets were then evaluated to determine the amount of the impairment, if any. The fair value of the assets was based primarily on market-based valuation techniques. As a result of this analysis, management determined that an impairment loss of $2.0 million had occurred as of September 30, 2013, and allocated the loss amount to the long-lived assets in the impaired asset group based on the carrying value of each asset, with no asset reduced below its respective fair value. The impairment loss was recorded in the Brooks Life Science Systems segment. The impairment charge was allocated as follows (in thousands): | ||||||||||||||||||||||||
Year Ended September 30, 2013 | ||||||||||||||||||||||||
Reported as cost of revenue: | ||||||||||||||||||||||||
Completed technology intangible asset impairment | $ | 1,910 | ||||||||||||||||||||||
Reported as selling, general and administrative expense: | ||||||||||||||||||||||||
Trademarks and trade name intangible asset impairment | 50 | |||||||||||||||||||||||
Total impairment charges | $ | 1,960 | ||||||||||||||||||||||
Components of the Company’s identifiable intangible assets are as follows (in thousands): | ||||||||||||||||||||||||
30-Sep-13 | September 30, 2012 | |||||||||||||||||||||||
Cost | Accumulated | Net Book | Cost | Accumulated | Net Book | |||||||||||||||||||
Amortization | Value | Amortization | Value | |||||||||||||||||||||
Patents | $ | 7,808 | $ | 7,196 | $ | 612 | $ | 7,808 | $ | 7,093 | $ | 715 | ||||||||||||
Completed technology | 65,594 | 48,898 | 16,696 | 54,583 | 42,751 | 11,832 | ||||||||||||||||||
Trademarks and trade names | 4,013 | 4,003 | 10 | 4,014 | 3,880 | 134 | ||||||||||||||||||
Customer relationships | 70,490 | 27,720 | 42,770 | 48,654 | 21,935 | 26,719 | ||||||||||||||||||
$ | 147,905 | $ | 87,817 | $ | 60,088 | $ | 115,059 | $ | 75,659 | $ | 39,400 | |||||||||||||
In connection with the acquisition of Crossing during fiscal year 2013, the Company allocated a portion of the purchase price to the following intangible assets: Completed Technology - $10.5 million and Customer Relationships - $20.0 million. These intangible assets support the products and services provided by the Brooks Products Solutions segment of $24.6 million and the Brooks Global Services segment of $5.9 million. In connection with the acquisition of Matrical during fiscal year 2013, the Company allocated a portion of the purchase price to the following intangible assets: Completed Technology - $0.5 million and Customer Relationships - $1.5 million. These intangible assets support the products and services provided by the Brooks Life Science Systems segment. | ||||||||||||||||||||||||
In connection with the acquisition of Celigo during fiscal year 2012, the Company allocated a portion of the purchase price to the following intangible assets: Completed Technology - $3.5 million and Trademarks and Trade Names - $0.1 million. These intangible assets support the products and services provided by the Brooks Life Science Systems segment. | ||||||||||||||||||||||||
For details regarding these intangible assets see "Note 3. Acquisitions." | ||||||||||||||||||||||||
Amortization expense for intangible assets was $10.1 million, $8.2 million and $4.6 million for the years ended September 30, 2013, 2012 and 2011, respectively. | ||||||||||||||||||||||||
Estimated future amortization expense for the intangible assets recorded by the Company as of September 30, 2013 is as follows (in millions): | ||||||||||||||||||||||||
Year ended September 30, | ||||||||||||||||||||||||
2014 | $10.10 | |||||||||||||||||||||||
2015 | 9.4 | |||||||||||||||||||||||
2016 | 8.7 | |||||||||||||||||||||||
2017 | 8 | |||||||||||||||||||||||
2018 | 6.1 | |||||||||||||||||||||||
Thereafter | 17.8 | |||||||||||||||||||||||
$60.10 |
Investment_in_Affiliates
Investment in Affiliates | 12 Months Ended |
Sep. 30, 2013 | |
Equity Method Investments and Joint Ventures [Abstract] | ' |
Investment in Affiliates | ' |
Investment in Affiliates | |
Joint Ventures | |
The Company participates in a 50% joint venture, ULVAC Cryogenics, Inc. (“UCI”) with ULVAC Corporation of Chigasaki, Japan. UCI manufactures and sells cryogenic vacuum pumps, principally to ULVAC Corporation. At September 30, 2013 and 2012, the carrying value of the Company's investment in UCI was $22.7 million and $27.4 million, respectively. For the years ended September 30, 2013, 2012 and 2011, the Company recorded income associated with UCI of $2.6 million, $2.0 million and $4.3 million, respectively. For the years ended September 30, 2013, 2012 and 2011, management fee payments received by the Company from UCI were $0.6 million, $1.0 million and $1.1 million, respectively. For the years ended September 30, 2013, 2012 and 2011, the Company incurred charges from UCI for products or services of $0.5 million, $0.8 million and $0.4 million, respectively. At September 30, 2013 and 2012 the Company owed UCI $26,000 and $73,000, respectively, in connection with accounts payable for unpaid products and services. During the fiscal years ended September 30, 2013 and 2012, the Company received $5.0 million and $5.1 million, respectively, of cash dividends from UCI. | |
The Company participates in a 50% joint venture with Yaskawa Electric Corporation (“Yaskawa”) called Yaskawa Brooks Automation, Inc. (“YBA”) to exclusively market and sell Yaskawa's semiconductor robotics products and Brooks' automation hardware products to semiconductor customers in Japan. At September 30, 2013 and 2012, the carrying value of the Company's investment in YBA was $3.0 million and $4.0 million, respectively. For the years ended September 30, 2013, 2012 and 2011, the Company recorded income (expense) associated with YBA of $(0.2) million, $0.1 million and $0.5 million, respectively. For the years ended September 30, 2013, 2012 and 2011, the Company earned revenue for sales to YBA of $6.3 million, $8.0 million and $9.6 million, respectively. The amount due from YBA included in accounts receivable at September 30, 2013 and 2012 was $2.3 million and $2.0 million, respectively. For the years ended September 30, 2013, 2012 and 2011, the Company incurred charges from YBA for products and services of $0.5 million, $0.5 million and $0.3 million, respectively. At September 30, 2013 and 2012 the Company owed YBA $47,000 and $58,000, respectively, in connection with accounts payable for unpaid products and services. | |
These investments are accounted for using the equity method. Under this method of accounting, the Company records in income its proportionate share of the earnings (losses) of the joint ventures with a corresponding increase (decrease) in the carrying value of the investment. |
Earnings_per_Share
Earnings per Share | 12 Months Ended | |||||||||||
Sep. 30, 2013 | ||||||||||||
Earnings Per Share [Abstract] | ' | |||||||||||
Earnings per Share | ' | |||||||||||
Earnings per Share | ||||||||||||
Below is a reconciliation of weighted average common shares outstanding for purposes of calculating basic and diluted earnings per share (in thousands, except per share data): | ||||||||||||
Year ended September 30, | ||||||||||||
2013 | 2012 | 2011 | ||||||||||
Net (loss) income attributable to Brooks Automation, Inc. | $ | (2,215 | ) | $ | 136,789 | $ | 130,385 | |||||
Weighted average common shares outstanding used in computing basic earnings per share | 65,912 | 65,128 | 64,549 | |||||||||
Dilutive common stock options and restricted stock awards | — | 594 | 454 | |||||||||
Weighted average common shares outstanding used in computing diluted earnings per share | 65,912 | 65,722 | 65,003 | |||||||||
Basic net (loss) income per share attributable to Brooks Automation, Inc. common stockholders | $ | (0.03 | ) | $ | 2.1 | $ | 2.02 | |||||
Diluted net (loss) income per share attributable to Brooks Automation, Inc. common stockholders | $ | (0.03 | ) | $ | 2.08 | $ | 2.01 | |||||
Options to purchase approximately 43,000, 238,000 and 387,000 shares of common stock and 3,006,000, 2,000 and 413,000 shares of restricted stock were excluded from the computation of diluted earnings per share attributable to Brooks Automation, Inc. common stockholders for the years ended September 30, 2013, 2012 and 2011, respectively, as their effect would be anti-dilutive. All outstanding stock options and unvested shares of restricted stock were excluded from the computation of diluted earnings per share for the year ended September 30, 2013 as a result of the net loss for that period. |
Investment_in_Variable_Interes
Investment in Variable Interest Entity | 12 Months Ended |
Sep. 30, 2013 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' |
Investment in Variable Interest Entity | ' |
Investment in Variable Interest Entity | |
In 2012, the Company provided a strategic partner (the “Borrower”) in the life science industry a loan of $3.0 million to support their future product development and other working capital requirements. The loan bears interest at a rate of 9%. The outstanding principal and interest under the loan is payable in May 2015. The Company also received warrants to purchase the Borrower's common stock in the event of an equity offering by the Borrower. The Company determined that the loan and the warrants had fair values of $2.8 million and $0.2 million, respectively, as of September 30, 2012. At September 30, 2013, the loan and warrants had carrying values of $2.9 million and $0.2 million, respectively. The loan and the warrants are recorded as long-term other assets in the Consolidated Balance Sheets. The loan agreement also provides the Company with certain other rights related to conversion of the loan, first refusal to acquire the Borrower and a redemption premium. The loan is secured by a security agreement that gives the Company the first interest in all of the assets of the Borrower. | |
The Company determined that the level of equity investment at risk is not sufficient for the entity to finance its activities without additional financial support and as a result, represents a variable interest entity. However, the Company does not have the power to direct the activities that most significantly impact the Borrower's economic performance and would not absorb the majority of the expected losses from the Borrower, and therefore does not qualify as the primary beneficiary. The Company has no future contractual funding commitments to the Borrower and as a result, the Company's exposure to loss is limited to the outstanding principal and interest under the loan. |
Derivative_Instruments
Derivative Instruments | 12 Months Ended | ||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' | ||||||||||||||||||||
Derivative Instruments | ' | ||||||||||||||||||||
Derivative Instruments | |||||||||||||||||||||
The Company has transactions and balances denominated in currencies other than the U.S. dollar. Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies. These transactions and balances, including short-term advances between the Company and its subsidiaries, subject the Company's operations to exposure from exchange rate fluctuations. The impact of currency exchange rate movement can be positive or negative in any period. The Company mitigates the impact of potential currency translation gains and losses on short-term intercompany advances through timely settlement of each transaction, generally within 30 days. The Company also enters into foreign exchange contracts to reduce its exposure to currency translation. Under forward contract arrangements, the Company typically agrees to purchase a fixed amount of U.S. Dollars in exchange for a fixed amount of a foreign currency on specified dates with maturities of three months or less. These transactions do not qualify for hedge accounting. | |||||||||||||||||||||
The Company had the following notional amounts outstanding under foreign currency contracts that do not qualify for hedge accounting at September 30, 2013 and 2012 (in thousands): | |||||||||||||||||||||
September 30, 2013: | |||||||||||||||||||||
Buy Currency | Notional Amount | Sell Currency | Maturity | Notional Amount | Fair Value of | Fair Value of | |||||||||||||||
of Buy Currency in U.S. Dollars | of Sell Currency | Assets | Liabilities | ||||||||||||||||||
in U.S. Dollars | |||||||||||||||||||||
U.S. Dollar | $ | 2,770 | Japanese Yen | October 2013 to December 2013 | $ | 2,762 | $ | 8 | $ | — | |||||||||||
Korean Won | 686 | U.S. Dollar | October 2013 | 688 | — | 2 | |||||||||||||||
U.S. Dollar | 301 | Israeli Shekel | October 2013 | 304 | — | 3 | |||||||||||||||
U.S. Dollar | 231 | Singapore Dollar | October 2013 | 231 | — | — | |||||||||||||||
$ | 3,988 | $ | 3,985 | $ | 8 | $ | 5 | ||||||||||||||
September 30, 2012: | |||||||||||||||||||||
Buy Currency | Notional Amount | Sell Currency | Maturity | Notional Amount | Fair Value of | Fair Value of | |||||||||||||||
of Buy Currency in U.S. Dollars | of Sell Currency | Assets | Liabilities | ||||||||||||||||||
in U.S. Dollars | |||||||||||||||||||||
U.S. Dollar | $ | 2,791 | Taiwan Dollar | October 2012 | $ | 2,786 | $ | 5 | $ | — | |||||||||||
U.S. Dollar | 1,842 | Israeli Shekel | October 2012 | 1,854 | — | 12 | |||||||||||||||
U.S. Dollar | 1,058 | Singapore Dollar | October 2012 | 1,056 | 2 | — | |||||||||||||||
U.S. Dollar | 806 | Korean Won | October 2012 | 803 | 3 | — | |||||||||||||||
U.S. Dollar | 611 | Japanese Yen | October 2012 | 611 | — | — | |||||||||||||||
U.S. Dollar | 524 | British Pound | October 2012 | 525 | — | 1 | |||||||||||||||
$ | 7,632 | $ | 7,635 | $ | 10 | $ | 13 | ||||||||||||||
The Company recorded net gains (losses) of $0.1 million and $(0.2) million related to these contracts during the years ended September 30, 2013 and 2012, respectively. These amounts are recorded in the Company's Consolidated Statements of Operations as a component of other income, net. | |||||||||||||||||||||
The Company also periodically enters into contracts to provide products and services that are denominated in non-functional currencies. In June 2013, the Company entered into foreign exchange contracts to reduce its exposure to changes in foreign exchange rates associated with an order for multiple automated sample management systems. The Company concluded that these foreign currency contracts meet the criteria to qualify as a cash flow hedge. Accordingly, the Company reflected changes in the fair value of the effective portion of these foreign currency contracts in accumulated other comprehensive income. Amounts recorded in accumulated other comprehensive income will be reclassified to revenue in the consolidated statement of income when the forecasted transaction occurs. | |||||||||||||||||||||
The Company had the following notional amounts outstanding under foreign currency contracts that qualify for cash flow hedge accounting at September 30, 2013 (in thousands): | |||||||||||||||||||||
Buy Currency | Notional Amount | Sell Currency | Maturity | Notional Amount | Fair Value of | Fair Value of | |||||||||||||||
of Buy Currency in U.S. Dollars | of Sell Currency | Assets | Liabilities | ||||||||||||||||||
in U.S. Dollars | |||||||||||||||||||||
U.S. Dollar | $ | 2,037 | Japanese Yen | Apr-14 | $ | 2,014 | $ | 23 | $ | — | |||||||||||
The Company expects to classify the accumulated gain into revenue in April 2014. The Company did not recognize any amounts related to ineffectiveness in the results of operations for the year ended September 30, 2013. | |||||||||||||||||||||
There were no cash flow hedges outstanding at September 30, 2012. | |||||||||||||||||||||
The fair values of the forward contracts described above are recorded in the Company's Consolidated Balance Sheets as prepaid expenses and other current assets and accrued expenses and other current liabilities. |
Income_Taxes
Income Taxes | 12 Months Ended | |||||||||||
Sep. 30, 2013 | ||||||||||||
Income Tax Disclosure [Abstract] | ' | |||||||||||
Income Taxes | ' | |||||||||||
Income Taxes | ||||||||||||
The components of the income tax provision (benefit) are as follows (in thousands): | ||||||||||||
Year Ended September 30, | ||||||||||||
2013 | 2012 | 2011 | ||||||||||
Current income tax provision (benefit): | ||||||||||||
Federal | $ | 15 | $ | 15 | $ | 16 | ||||||
State | 70 | 213 | 1,356 | |||||||||
Foreign | 681 | (1,374 | ) | 858 | ||||||||
Total current income tax provision (benefit) | 766 | (1,146 | ) | 2,230 | ||||||||
Deferred income tax (benefit): | ||||||||||||
Federal | (2,523 | ) | (118,432 | ) | — | |||||||
State | (90 | ) | (291 | ) | — | |||||||
Foreign | (323 | ) | (3,413 | ) | (276 | ) | ||||||
Total deferred income tax (benefit) | (2,936 | ) | (122,136 | ) | (276 | ) | ||||||
Income tax provision (benefit) | $ | (2,170 | ) | $ | (123,282 | ) | $ | 1,954 | ||||
The components of income (loss) before income taxes and equity in earnings of joint ventures are as follows (in thousands): | ||||||||||||
Year Ended September 30, | ||||||||||||
2013 | 2012 | 2011 | ||||||||||
Domestic | $ | (6,968 | ) | $ | 2,204 | $ | 111,053 | |||||
Foreign | 206 | 9,216 | 16,523 | |||||||||
$ | (6,762 | ) | $ | 11,420 | $ | 127,576 | ||||||
The differences between the income tax provision (benefit) and income taxes computed using the applicable U.S. statutory federal tax rate is as follows (in thousands): | ||||||||||||
Year Ended September 30, | ||||||||||||
2013 | 2012 | 2011 | ||||||||||
Income tax provision computed at federal statutory rate | $ | (1,535 | ) | $ | 4,728 | $ | 45,736 | |||||
State income taxes, net of federal benefit | (8 | ) | 260 | 1,848 | ||||||||
Foreign income taxed at different rates | 493 | (832 | ) | (1,546 | ) | |||||||
Dividends | 115 | 956 | (219 | ) | ||||||||
Change in deferred tax asset valuation allowance | 523 | (125,479 | ) | (42,608 | ) | |||||||
Reduction in uncertain tax positions | (1,022 | ) | (3,732 | ) | (3,719 | ) | ||||||
Nondeductible compensation | 474 | 1,339 | 295 | |||||||||
Tax credits generated | (2,002 | ) | (1,195 | ) | (1,179 | ) | ||||||
Travel and entertainment | 124 | 139 | 119 | |||||||||
Merger costs | 251 | — | 315 | |||||||||
Other | 417 | 534 | 2,912 | |||||||||
Income tax provision (benefit) | $ | (2,170 | ) | $ | (123,282 | ) | $ | 1,954 | ||||
The Company has not provided for U.S. income taxes on the unremitted earnings of certain foreign subsidiaries as these earnings are considered to be indefinitely reinvested. These earnings amounted to approximately $17.5 million at September 30, 2013. It is not practicable to compute the estimated deferred tax liability on these earnings. | ||||||||||||
The significant components of the net deferred tax assets and liabilities are as follows (in thousands): | ||||||||||||
September 30, | ||||||||||||
2013 | 2012 | |||||||||||
Accruals and reserves not currently deductible | $ | 11,050 | $ | 10,489 | ||||||||
Federal, state and foreign tax credits | 20,084 | 18,963 | ||||||||||
Other assets | 1,859 | 1,655 | ||||||||||
Net operating loss carryforwards | 101,717 | 101,713 | ||||||||||
Inventory reserves and valuation | 9,052 | 8,790 | ||||||||||
Deferred tax assets | 143,762 | 141,610 | ||||||||||
Depreciation and intangible amortization | 12,208 | 5,418 | ||||||||||
Deferred tax liabilities | 12,208 | 5,418 | ||||||||||
Valuation allowance | (16,509 | ) | (16,035 | ) | ||||||||
Net deferred tax asset | $ | 115,045 | $ | 120,157 | ||||||||
Management has considered the weight of all available evidence in determining whether a valuation allowance is required against its deferred tax assets at September 30, 2013. After consideration of both positive and negative evidence management has concluded that it is more likely than not that a substantial portion of its deferred tax assets will be realized. The positive evidence considered was three year U.S. historical cumulative profitability, projected future taxable income and length of carry-forward periods of net operating losses and tax credits. The primary negative evidence considered is the volatile semiconductor industry in which the Company operates. | ||||||||||||
The Company recorded a tax benefit of $121.8 million resulting from the reduction in the valuation allowance during the fiscal year ended September 30, 2012. The Company has continued to maintain a valuation allowance in the U.S. against certain tax credits and state net operating losses due to the uncertainty of their realization based on long-term Company forecasts and the expiration dates on these attributes. The Company has also continued to maintain a valuation allowance in certain jurisdictions that have not generated historical cumulative profitability. | ||||||||||||
If future operating results of the U.S. or these foreign jurisdictions deviate from expectations, it is reasonably possible that there could be a further change in the valuation allowance in the future. A change in the valuation allowance, in whole or in part, would result in a non-cash income tax expense or benefit during the period of change. | ||||||||||||
As of September 30, 2013, the Company had federal, state and foreign net operating loss carryforwards of approximately $242.0 million, $122.2 million and $37.3 million, respectively, and federal and state research and development tax credit carryforwards of approximately $24.0 million available to reduce future tax liabilities, which expire at various dates through 2033. The net operating loss carryforward includes excess deductions related to stock compensation in the amount of $11.7 million which have not been recognized for financial statement purposes. The benefits of these tax deductions will be credited to additional paid-in capital upon being realized. | ||||||||||||
The Company has performed studies to determine if there are any annual limitations on the federal net operating losses under section 382 of the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”). As a result of these studies, the Company has determined that ownership changes have occurred primarily in connection with acquisitions when the Company has issued stock to the sellers, as well as ownership changes in the subsidiaries acquired by the Company. Certain limitations have been calculated and the benefits of the net operating losses that will expire before utilization have not been recorded as deferred tax assets in the financial statements. The Company's U.S. net operating losses expire at various dates through 2030. | ||||||||||||
A reconciliation of the beginning and ending amount of the consolidated liability for unrecognized income tax benefits during the fiscal years ended September 30, 2013, 2012 and 2011 is as follows (in thousands): | ||||||||||||
Unrecognized Tax | Interest | Total | ||||||||||
Benefit | and | |||||||||||
Penalties | ||||||||||||
Balance at October 1, 2010 | $ | 12,816 | $ | 2,152 | $ | 14,968 | ||||||
Additions for tax positions of prior years | 184 | 447 | 631 | |||||||||
Additions for tax positions related to current year | 242 | — | 242 | |||||||||
Reductions from lapses in statutes of limitations | (961 | ) | — | (961 | ) | |||||||
Reductions from settlements with taxing authorities | (3,392 | ) | (610 | ) | (4,002 | ) | ||||||
Foreign exchange rate adjustment | 122 | — | 122 | |||||||||
Balance at September 30, 2011 | 9,011 | 1,989 | 11,000 | |||||||||
Additions for tax positions of prior years | 242 | 247 | 489 | |||||||||
Reductions from lapses in statutes of limitations | (3,125 | ) | (607 | ) | (3,732 | ) | ||||||
Foreign exchange rate adjustment | (167 | ) | 15 | (152 | ) | |||||||
Balance at September 30, 2012 | 5,961 | 1,644 | 7,605 | |||||||||
Additions for tax positions of prior years | — | 228 | 228 | |||||||||
Additions for tax positions related to acquired entities | 116 | — | 116 | |||||||||
Reductions from lapses in statutes of limitations | (944 | ) | (78 | ) | (1,022 | ) | ||||||
Foreign exchange rate adjustment | 14 | — | 14 | |||||||||
Balance at September 30, 2013 | $ | 5,147 | $ | 1,794 | $ | 6,941 | ||||||
As of September 30, 2013 all of the Company's unrecognized tax benefits, if recognized, would affect the effective tax rate. The Company recognizes interest related to unrecognized benefits as a component of tax expense, of which $0.2 million, $0.2 million and $0.4 million was recognized for the years ended September 30, 2013, 2012 and 2011, respectively. | ||||||||||||
The Company is subject to U.S. federal income tax and various state, local and international income taxes in various jurisdictions. The amount of income taxes paid is subject to the Company's interpretation of applicable tax laws in the jurisdictions in which it files. In the normal course of business, the Company is subject to examination by taxing authorities throughout the world. The statute of limitations lapsed on several uncertain tax positions in the foreign jurisdictions related to transfer pricing and income tax withholding during fiscal year 2013 that resulted in a $1.0 million reduction in gross unrecognized tax benefits that impacted the effective tax rate. The Company is subject to income tax audits in various global jurisdictions in which it operates. In the Company's U.S. and international jurisdictions, the years that may be examined vary, with the earliest tax year being 2007. Based on the outcome of these examinations, or the expiration of statutes of limitations for specific jurisdictions, it is reasonably possible that the related unrecognized tax benefits could change from those recorded in the Company's statement of financial position. The Company currently anticipates that it is reasonably possible that the unrecognized tax benefit will be reduced by approximately $1.3 million during the next twelve months primarily as the result of statutes of limitations expiring. |
Postretirement_Benefits
Postretirement Benefits | 12 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | ' | |||||||||||||||
Postretirement Benefits | ' | |||||||||||||||
Postretirement Benefits | ||||||||||||||||
Defined Benefit Pension Plans | ||||||||||||||||
The Company has two active defined benefit pension plans (collectively, the “Plans”). The Plans cover substantially all of the Company’s employees in Switzerland and Taiwan. Retirement benefits are generally earned based on years of service and compensation during active employment; however, the level of benefits varies within the Plans. Eligibility is determined in accordance with local statutory requirements. | ||||||||||||||||
In connection with actions taken under the Company’s restructuring programs, the number of employees accumulating benefits under the Switzerland Plan has declined significantly. As a result, a partial settlement event occurred and resulted in accelerated amortization of approximately $0.1 million of prior pension losses. The settlement loss, recorded in the quarter ended December 31, 2012, is included in restructuring and other charges in the Consolidated Statements of Operations. | ||||||||||||||||
In addition, the Company had a plan that was acquired through its purchase of Helix Technology Corporation that covered certain employees in the United States. The Company settled its pension obligation with the participants in the quarter ended September 30, 2012 which resulted in accelerated cash payments of approximately $6.4 million and $8.9 million of accelerated amortization of prior pension losses which is included as a pension settlement charge in the Consolidated Statements of Operations. | ||||||||||||||||
The Company uses a September 30th measurement date in the determination of net periodic benefit costs, benefit obligations and the value of plan assets for all plans. The following tables set forth the funded status and amounts recognized in the Company’s Consolidated Balance Sheets at September 30, 2013 and 2012 (in thousands): | ||||||||||||||||
September 30, | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Benefit obligation at beginning of year | $ | 10,181 | $ | 28,068 | ||||||||||||
Service cost | 604 | 787 | ||||||||||||||
Interest cost | 148 | 984 | ||||||||||||||
Actuarial (gain) loss | (670 | ) | 1,235 | |||||||||||||
Benefits paid | (1,421 | ) | (2,203 | ) | ||||||||||||
Settlement loss | — | 1,040 | ||||||||||||||
Settlements paid | (1,383 | ) | (18,928 | ) | ||||||||||||
Curtailment gain | (500 | ) | — | |||||||||||||
Foreign currency translation | 148 | (802 | ) | |||||||||||||
Benefit obligation at end of year | $ | 7,107 | $ | 10,181 | ||||||||||||
September 30, | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Fair value of assets at beginning of year | $ | 8,015 | $ | 20,173 | ||||||||||||
Actual return on plan assets | 304 | 1,446 | ||||||||||||||
Disbursements | (1,573 | ) | (2,463 | ) | ||||||||||||
Employer contributions | 292 | 7,684 | ||||||||||||||
Employee contributions | 194 | 334 | ||||||||||||||
Settlements paid | (1,383 | ) | (18,928 | ) | ||||||||||||
Foreign currency translation | 147 | (231 | ) | |||||||||||||
Fair value of assets at end of year | $ | 5,996 | $ | 8,015 | ||||||||||||
September 30, | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Funded status/accrued benefit liability | $ | (1,111 | ) | $ | (2,166 | ) | ||||||||||
The following table provides pension amounts recorded within the account line items of the Company’s consolidated balance sheets (in thousands): | ||||||||||||||||
September 30, | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Accrued compensation and benefits | $ | 296 | $ | 478 | ||||||||||||
Long-term pension liability | 815 | 1,688 | ||||||||||||||
In addition, accumulated other comprehensive income at September 30, 2013 and 2012 includes unrecognized net actuarial gains (losses) of $0.5 million and $(1.1) million, respectively. | ||||||||||||||||
The components of the Company’s net pension cost for the years ended September 30, 2013, 2012 and 2011 is as follows (in thousands): | ||||||||||||||||
Year ended September 30, | ||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||
Service cost | $ | 604 | $ | 787 | $ | 216 | ||||||||||
Interest cost | 148 | 984 | 796 | |||||||||||||
Expected return on assets | (247 | ) | (1,072 | ) | (764 | ) | ||||||||||
Amortization of losses | 4 | 620 | 458 | |||||||||||||
Other | 160 | — | — | |||||||||||||
Net periodic pension cost | 669 | 1,319 | 706 | |||||||||||||
Settlement loss | 87 | 8,937 | — | |||||||||||||
Total pension cost | $ | 756 | $ | 10,256 | $ | 706 | ||||||||||
Other changes in Plan assets and benefit obligations recognized in other comprehensive loss (in thousands): | ||||||||||||||||
September 30, | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Net (gain) loss | $ | (791 | ) | $ | 1,226 | |||||||||||
Amortization of net loss | (3 | ) | (620 | ) | ||||||||||||
Curtailment loss | (675 | ) | — | |||||||||||||
Settlement loss | (87 | ) | (8,937 | ) | ||||||||||||
Total recognized in other comprehensive income (loss) | (1,556 | ) | (8,331 | ) | ||||||||||||
Total recognized in net periodic pension cost and other comprehensive income (loss) | $ | (887 | ) | $ | (7,012 | ) | ||||||||||
Certain information for the Plans with respect to accumulated benefit obligations follows (in thousands): | ||||||||||||||||
September 30, | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Projected benefit obligation | $ | 7,107 | $ | 10,181 | ||||||||||||
Accumulated benefit obligation | 6,272 | 8,906 | ||||||||||||||
Fair value of plan assets | 5,996 | 8,015 | ||||||||||||||
Weighted-average assumptions used to determine net cost at September 30, 2013, 2012 and 2011 follows: | ||||||||||||||||
Year Ended September 30, | ||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||
Discount rate | 2.15 | % | 3.51 | % | 3.99 | % | ||||||||||
Expected return on plan assets | 2.17 | % | 2.18 | % | 4.68 | % | ||||||||||
Rate of compensation increase | 1.89 | % | 1.84 | % | 1.79 | % | ||||||||||
The expected return on plan assets is based on an evaluation of fixed income yield curves and equity return assumption studies applied to the asset allocation. | ||||||||||||||||
Weighted-average assumptions used to determine the pension obligation at September 30, 2013, 2012 and 2011 follows: | ||||||||||||||||
Year Ended September 30, | ||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||
Discount rate | 2.15 | % | 1.89 | % | 3.76 | % | ||||||||||
Rate of compensation increase | 1.89 | % | 1.84 | % | 1.79 | % | ||||||||||
Compensation increase assumptions for the periodic pension cost and pension obligation apply to the Switzerland Plan and Taiwan Plan only. | ||||||||||||||||
The Company bases its determination of pension expense or benefit on a market-related valuation of assets, which reduces year-to-year volatility. This market-related valuation recognizes investment gains or losses over a five-year period from the year in which they occur. Investment gains or losses for this purpose are the difference between the expected return calculated using the market-related value of assets and the actual return on assets. Since the market-related value of assets recognizes gains or losses over a five-year period, the future value of assets will be impacted as previously deferred gains or losses are recognized. As of September 30, 2013, under the Plans, the Company had cumulative investment gains of approximately $0.1 million, which remain to be recognized in the calculation of the market-related value of assets. The Company also had cumulative other actuarial gains of $0.4 million at September 30, 2013, which are amortized into net periodic benefit costs over the average remaining service period of active participants in the plans. | ||||||||||||||||
Plan Assets | ||||||||||||||||
The fair value of plan assets for the Switzerland Plan and Taiwan Plan were $5.5 million and $0.5 million, respectively, at September 30, 2013. As is customary with Swiss pension plans, the assets of the Switzerland Plan are invested in a collective fund with multiple employers through a Swiss insurance company. The Company does not have any rights to the assets of the plan. Investment holdings are primarily in highly rated debt securities. The assets of the Taiwan Plan are invested with a trustee that has been selected by the Taiwan government. The Company has no investment authority over the assets of either the Switzerland Plan or the Taiwan Plan. The asset allocation of the plan assets at September 30, 2013 was as follows: | ||||||||||||||||
Percentage of | ||||||||||||||||
Plan Assets at | ||||||||||||||||
September 30, | ||||||||||||||||
2013 | ||||||||||||||||
Debt securities | 75 | % | ||||||||||||||
Equity securities | 5 | |||||||||||||||
Cash | 2 | |||||||||||||||
Other | 18 | |||||||||||||||
100 | % | |||||||||||||||
The fair value of pension assets by asset category and by level at September 30, 2013 were as follows (in thousands): | ||||||||||||||||
As of September 30, 2013 | ||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Swiss Life collective foundation | $ | — | $ | 5,474 | $ | — | $ | 5,474 | ||||||||
Taiwan collective trust | — | 522 | — | 522 | ||||||||||||
Total | $ | — | $ | 5,996 | $ | — | $ | 5,996 | ||||||||
See "Note 5. Fair Value Measurements" for a description of the levels of inputs used to determine fair value measurements. | ||||||||||||||||
During the first quarter of fiscal year 2013, the Company made contributions of $0.1 million to the Switzerland Plan in connection with the settlement, which was in addition to the $0.2 million of required minimum contributions made to both Plans throughout fiscal year 2013. The Company made required minimum contributions throughout fiscal year 2013 to all of its plans of $0.3 million. The Company expects to contribute $0.2 million to its plans in fiscal 2014 to meet minimum funding targets. | ||||||||||||||||
Expected benefit payments over the next ten years are anticipated to be paid as follows (in thousands): | ||||||||||||||||
2014 | $ | 232 | ||||||||||||||
2015 | 56 | |||||||||||||||
2016 | 57 | |||||||||||||||
2017 | 58 | |||||||||||||||
2018 | 59 | |||||||||||||||
2019-2023 | 583 | |||||||||||||||
Defined Contribution Plans | ||||||||||||||||
The Company sponsors defined contribution plans that meet the requirements of Section 401(k) of the Internal Revenue Code. All United States employees of the Company who meet minimum age and service requirements are eligible to participate in the plan. The plan allows employees to invest, on a pre-tax basis, a percentage of their annual salary subject to statutory limitations. | ||||||||||||||||
The Company’s contribution expense for worldwide defined contribution plans was $3.2 million, $3.1 million and $2.9 million for the years ended September 30, 2013, 2012 and 2011, respectively. |
Stockholders_Equity
Stockholders' Equity | 12 Months Ended | ||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||
Equity [Abstract] | ' | ||||||||||||||||||||
Stockholders' Equity | ' | ||||||||||||||||||||
Stockholders’ Equity | |||||||||||||||||||||
Preferred Stock | |||||||||||||||||||||
At September 30, 2013 and 2012 there were one million shares of preferred stock, $0.01 par value per share authorized; no shares were issued or outstanding at September 30, 2013 or 2012. Preferred stock may be issued at the discretion of the Board of Directors without stockholder approval with such designations, rights and preferences as the Board of Directors may determine. | |||||||||||||||||||||
Accumulated Other Comprehensive Income | |||||||||||||||||||||
The following is a summary of the components of accumulated other comprehensive income, net of tax, at September 30 (in thousands): | |||||||||||||||||||||
Currency Translation Adjustments | Unrealized Gains (Losses) on Available-for-Sale Securities | Unrealized Gains on Cash Flow Hedges | Pension Liability Adjustments | Total | |||||||||||||||||
Balance at September 30, 2010 | $ | 25,970 | $ | 253 | $ | — | $ | (8,357 | ) | $ | 17,866 | ||||||||||
Other comprehensive income before reclassifications | 947 | (421 | ) | — | (1,044 | ) | (518 | ) | |||||||||||||
Amounts reclassified from accumulated other comprehensive income | — | (24 | ) | — | — | (24 | ) | ||||||||||||||
Balance at September 30, 2011 | 26,917 | (192 | ) | — | (9,401 | ) | 17,324 | ||||||||||||||
Other comprehensive income before reclassifications | (2,406 | ) | 408 | — | (606 | ) | (2,604 | ) | |||||||||||||
Amounts reclassified from accumulated other comprehensive income | — | (15 | ) | — | 8,937 | 8,922 | |||||||||||||||
Balance at September 30, 2012 | 24,511 | 201 | — | (1,070 | ) | 23,642 | |||||||||||||||
Other comprehensive income before reclassifications | (2,113 | ) | (114 | ) | 14 | 1,109 | (1,104 | ) | |||||||||||||
Amounts reclassified from accumulated other comprehensive income | — | (21 | ) | — | 87 | 66 | |||||||||||||||
Balance at September 30, 2013 | $ | 22,398 | $ | 66 | $ | 14 | $ | 126 | $ | 22,604 | |||||||||||
Reclassifications from AOCI to net income related to available-for-sale securities result from sale of these securities as described in “Note 4. Marketable Securities.” Reclassifications from AOCI to net income related to the Company’s pension plans relate to settlement losses under defined benefit pension plans as described in “Note 13. Postretirement Benefits.” |
Stock_Plans
Stock Plans | 12 Months Ended | ||||||||||||
Sep. 30, 2013 | |||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ' | ||||||||||||
Stock Plans | ' | ||||||||||||
Stock Plans | |||||||||||||
Amended and Restated 2000 Equity Incentive Plan | |||||||||||||
The purposes of the Amended and Restated 2000 Equity Incentive Plan (the “2000 Plan”), are to attract and retain employees and to provide an incentive for them to assist the Company to achieve long-range performance goals and to enable them to participate in the long-term growth of the Company. Under the 2000 Plan the Company may grant (i) incentive stock options intended to qualify under Section 422 of the Internal Revenue Code, and (ii) options that are not qualified as incentive stock options (“nonqualified stock options”) and (iii) stock appreciation rights, performance awards and restricted stock. All employees of the Company or any affiliate of the Company, independent directors, consultants and advisors are eligible to participate in the 2000 Plan. Options under the 2000 Plan generally vest over four years and expire seven years from the date of grant. A total of 9,000,000 shares of common stock was reserved for issuance under the 2000 Plan. As of September 30, 2013, no options are outstanding and 2,792,393 shares remain available for grant. | |||||||||||||
During the year ended September 30, 2013, the Company issued 392,931 shares of restricted stock or units under the Amended and Restated 2000 Equity Incentive Plan, net of cancellations. These restricted stock awards generally have the following vesting schedules: immediate; three year vesting in which one-third vest at the end of Year 1, one-third vest at the end of Year 2 and one-third vest at the end of Year 3; and three year vesting in which one-half vest at the end of Year 2 and one-half vest at the end of Year 3. Compensation expense related to these awards is being recognized on a straight line basis over the vesting period, based on the fair market value of the Company’s common stock on the date of grant. In addition, in fiscal 2013, the Company granted 562,125 restricted stock awards net of cancellations to senior management, the number of shares ultimately issued was measured at the end of fiscal year 2013 and was dependent upon the achievement of certain financial performance goals. These awards are expensed over the related service period when attainment of the performance condition is considered probable. The total amount of compensation recorded will depend on the Company’s achievement of performance targets. Changes to the projected attainment of performance targets during the vesting period may result in an adjustment to the amount of cumulative compensation recorded as of the date the estimate is revised. | |||||||||||||
Stock Options of Acquired Companies | |||||||||||||
In connection with the acquisition of Helix on October 26, 2005, the Company assumed the outstanding options of multiple stock option plans that were adopted by Helix. At acquisition, 689,622 options to purchase Helix common stock were outstanding and converted into 765,480 options to purchase the Company’s common stock. A total of 15,540 options are outstanding and 467,165 shares remain available for grant under the Helix plans as of September 30, 2013. The Company does not intend to issue any additional options under the Helix stock option plan. | |||||||||||||
Stock Option Activity | |||||||||||||
The following table summarizes stock option activity for all the above plans for the year ended September 30, 2013: | |||||||||||||
2013 | |||||||||||||
Shares | Weighted- | Weighted | Aggregate | ||||||||||
Average | Average Price | Intrinsic Value | |||||||||||
Remaining | (In Thousands) | ||||||||||||
Contractual Term | |||||||||||||
Options outstanding at September 30, 2012 | 193,182 | $ | 13.11 | ||||||||||
Exercised | (8,600 | ) | $ | 7.75 | |||||||||
Forfeited/expired | (169,042 | ) | $ | 13.13 | |||||||||
Options outstanding at September 30, 2013 | 15,540 | 0.8 years | $ | 15.86 | $ | — | |||||||
Vested at September 30, 2013 | 15,540 | 0.8 years | $ | 15.86 | $ | — | |||||||
Options exercisable at September 30, 2013 | 15,540 | 0.8 years | $ | 15.86 | $ | — | |||||||
Options available for future grant | 3,259,558 | ||||||||||||
The aggregate intrinsic value in the table above represents the total intrinsic value, based on the Company’s closing stock price of $9.31 as of September 30, 2013, which would have been received by the option holders had all option holders exercised their options as of that date. | |||||||||||||
No stock options were granted in fiscal 2013, 2012 or 2011. The total intrinsic value of options exercised during fiscal 2013, 2012 or 2011 was $19,000, $56,000 and $15,000, respectively. The total cash received from participants as a result of stock option exercises during fiscal 2013, 2012 or 2011 was $67,000, $103,000 and $6,000, respectively. | |||||||||||||
As of September 30, 2013, there was no future compensation cost related to stock options as all outstanding stock options have vested. | |||||||||||||
The Company settles employee stock option exercises with newly issued common shares. | |||||||||||||
Restricted Stock Activity | |||||||||||||
A summary of the status of the Company’s restricted stock as of September 30, 2013 and changes during the year is as follows: | |||||||||||||
2013 | |||||||||||||
Shares | Weighted | ||||||||||||
Average | |||||||||||||
Grant-Date | |||||||||||||
Fair Value | |||||||||||||
Outstanding at September 30, 2012 | 2,732,448 | $ | 10.47 | ||||||||||
Awards granted | 1,471,977 | $ | 9.33 | ||||||||||
Awards vested | (755,187 | ) | $ | 9.67 | |||||||||
Awards canceled | (533,825 | ) | $ | 11.41 | |||||||||
Outstanding at September 30, 2013 | 2,915,413 | $ | 11.25 | ||||||||||
The weighted average grant date fair value of restricted stock granted during fiscal 2012 and fiscal 2011 was $11.80 and $11.27 per share, respectively. The fair value of restricted stock awards vested during fiscal 2013, 2012 and 2011 was $7.3 million, $5.6 million and $7.4 million, respectively. | |||||||||||||
As of September 30, 2013, the unrecognized compensation cost related to restricted stock that is expected to vest is $5.6 million and will be recognized over an estimated weighted average amortization period of 1.5 years. | |||||||||||||
1995 Employee Stock Purchase Plan | |||||||||||||
On February 22, 1996, the stockholders approved the 1995 Employee Stock Purchase Plan (the “1995 Plan”) which enables eligible employees to purchase shares of the Company’s common stock. Under the 1995 Plan, eligible employees may purchase up to an aggregate of 3,000,000 shares during six-month offering periods commencing on February 1 and August 1 of each year at a price per share of 85% of the lower of the fair market value price per share on the first or last day of each six-month offering period. On February 8, 2012, the stockholders approved an amendment to the 1995 Plan to increase the number of shares of the Company’s common stock available for issuance by 1,000,000 shares, from 3,000,000 to 4,000,000 shares. Participating employees may elect to have up to 10% of their base pay withheld and applied toward the purchase of such shares. The rights of participating employees under the 1995 Plan terminate upon voluntary withdrawal from the plan at any time or upon termination of employment. As of September 30, 2013, 3,134,074 shares of common stock have been purchased under the 1995 Plan and 865,926 shares remain available for purchase. |
Restructuring_and_Other_Charge
Restructuring and Other Charges | 12 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Restructuring and Related Activities [Abstract] | ' | |||||||||||||||
Restructuring and Other Charges | ' | |||||||||||||||
Restructuring and Other Charges | ||||||||||||||||
Fiscal 2013 Activities | ||||||||||||||||
The Company recorded a restructuring charge of $6.5 million for fiscal 2013. These charges relate primarily to workforce reductions implemented to consolidate the operations of Crossing and the Company, to transition internal manufacturing of the Polycold product line (certain of the Company’s cryopump and cryochiller products) to a third party contract manufacturer and other programs designed to improve the Company’s cost structure. Restructuring charges also included facility related costs incurred in connection with the consolidation of Crossing facilities with the Company’s facilities. | ||||||||||||||||
Restructuring costs recorded in fiscal 2013 consist of $5.6 million of severance costs and $0.8 million of facility related costs. Severance costs incurred in fiscal 2013 relate to the elimination of approximately 200 positions. The Brooks Product Solutions segment incurred a severance charge of $2.6 million; the Brooks Global Services segment incurred a severance charge of $1.1 million; and the Company incurred $1.5 million related to the elimination of corporate positions. The Brooks Life Science Systems segment incurred severance charges of $0.4 million, mainly due to the consolidation of administrative functions. Restructuring and other charges recorded in fiscal 2013 also include $0.1 million related to a partial settlement of a defined benefit pension plan that covers substantially all of the Company’s Swiss employees. | ||||||||||||||||
Total severance charges related to the outsourcing of the Polycold manufacturing operation are expected to be $1.3 million, including severance and retention bonuses. This charge is being amortized over the period from notification of the closing to the actual service end date. In the fourth quarter of 2013, the Company extended the service end date from September 2013 to September 2014 as a result of changes in the transition plan with the third party contract manufacturer. The Company has expensed $0.6 million of the total charge as of September 30, 2013, and will expense the balance ratably through fiscal 2014. | ||||||||||||||||
Fiscal 2012 Activities | ||||||||||||||||
The Company recorded a restructuring charge of $3.3 million for fiscal year 2012. These charges are related primarily to a series of workforce reductions implemented to improve the Company’s cost structure by eliminating 118 employees. The Brooks Product Solutions segment incurred a severance charge of $1.3 million; the Brooks Global Services segment incurred a severance charge of $1.0 million; and the Company incurred $0.7 million to eliminate corporate support positions. These workforce reductions were implemented to better align resources with future requirements. The Brooks Life Science Systems segment incurred severance charges of $0.3 million to eliminate 14 positions, mainly due to the consolidation of administrative functions. | ||||||||||||||||
Fiscal 2011 Activities | ||||||||||||||||
The Company recorded a charge to operations of $1.0 million in the year ended September 30, 2011 for restructuring costs. Of this amount, $0.7 million related to workforce reductions and $0.3 million related to facility costs. The severance costs are comprised of $0.3 million of severance for the elimination of 19 employees, and $0.4 million of adjustments for contingent severance arrangements for corporate management positions eliminated in prior periods. The facility costs relate to facilities exited in previous years. The costs for these exited facilities ended as of September 30, 2011. | ||||||||||||||||
The activity related to the Company’s restructuring and other charges are below (in thousands): | ||||||||||||||||
Fiscal 2013 Activity | ||||||||||||||||
Balance | Expense | Utilization | Balance | |||||||||||||
September 30, | September 30, | |||||||||||||||
2012 | 2013 | |||||||||||||||
Facilities and other | $ | — | $ | 818 | $ | (663 | ) | $ | 155 | |||||||
Workforce-related | 2,098 | 5,560 | (6,401 | ) | 1,257 | |||||||||||
$ | 2,098 | $ | 6,378 | $ | (7,064 | ) | $ | 1,412 | ||||||||
Fiscal 2012 Activity | ||||||||||||||||
Balance | Expense | Utilization | Balance | |||||||||||||
September 30, | September 30, | |||||||||||||||
2011 | 2012 | |||||||||||||||
Workforce-related | $ | 293 | $ | 3,275 | $ | (1,470 | ) | $ | 2,098 | |||||||
Fiscal 2011 Activity | ||||||||||||||||
Balance | Expense | Utilization | Balance | |||||||||||||
September 30, | September 30, | |||||||||||||||
2010 | 2011 | |||||||||||||||
Facilities and other | $ | 3,509 | $ | 310 | $ | (3,819 | ) | $ | — | |||||||
Workforce-related | — | 726 | (433 | ) | 293 | |||||||||||
$ | 3,509 | $ | 1,036 | $ | (4,252 | ) | $ | 293 | ||||||||
Unpaid severance charges as of September 30, 2013 of $0.8 million are expected to be paid during fiscal year 2014 and the remaining $0.5 million is expected to be paid during fiscal year 2015. |
Segment_and_Geographic_Informa
Segment and Geographic Information | 12 Months Ended | |||||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||||
Segment Reporting [Abstract] | ' | |||||||||||||||||||
Segment and Geographic Information | ' | |||||||||||||||||||
Segment and Geographic Information | ||||||||||||||||||||
The Company reports financial results in four segments: Brooks Product Solutions, Brooks Global Services, Brooks Life Science Systems and Contract Manufacturing. This financial reporting structure was implemented effective as of the beginning of the Company’s fourth quarter of fiscal year 2011 in response to changes in its management structure as well as the acquisition of two life science companies in the second half of fiscal 2011. | ||||||||||||||||||||
The Brooks Product Solutions segment provides a variety of products critical to technology equipment productivity and availability. Those products include atmospheric and vacuum tool automation systems, atmospheric and vacuum robots and robotic modules and cryogenic vacuum pumping, thermal management and vacuum measurement solutions which are used to create, measure and control critical process vacuum applications. | ||||||||||||||||||||
The Brooks Global Services segment provides an extensive range of support services including on-and off-site repair services, on-and off-site diagnostic support services, and installation services that enable our customers to maximize process tool uptime and productivity. This segment also provides end-user customers with spare parts support services that maximize tool productivity. | ||||||||||||||||||||
The Brooks Life Science Systems segment provides automated sample management systems for automated cold sample storage, equipment for sample preparation and handling, consumables, and parts and support services to a wide range of life science customers including pharmaceutical companies, biotechnology companies, biobanks, national laboratories, research institutes and research universities. | ||||||||||||||||||||
The Contract Manufacturing segment provided services to build equipment front-end modules, vacuum transport modules and other subassemblies which enabled the Company's customers to effectively source high quality and high reliability process tools for semiconductor market applications. The Company sold this business unit to Celestica Inc. on June 28, 2011. | ||||||||||||||||||||
The Company evaluates performance and allocates resources based on revenue, operating income (loss) and returns on invested assets. Operating income (loss) for each segment includes selling, general and administrative expenses directly attributable to the segment. The profits reported on intercompany transactions are based on the transfer prices charged which approximates fair value to third parties. Other unallocated corporate expenses, amortization of acquired intangible assets (excluding completed technology), restructuring and other charges, pension settlement and in-process research and development are excluded from the segments’ operating income (loss). The Company’s indirect overhead costs, which include various general and administrative expenses, are allocated among the segments based upon various cost drivers associated with the respective administrative function, including segment revenue, segment headcount, or an analysis of the segments that benefit from a specific administrative function. Segment assets exclude cash, cash equivalents, restricted cash, marketable securities, deferred tax assets and investments in joint ventures. | ||||||||||||||||||||
Financial information for the Company’s business segments is as follows (in thousands): | ||||||||||||||||||||
Brooks | Brooks | Brooks | Contract Manufacturing | Total | ||||||||||||||||
Product | Global | Life Science | ||||||||||||||||||
Solutions | Services | Systems | ||||||||||||||||||
Year ended September 30, 2013 | ||||||||||||||||||||
Revenue | ||||||||||||||||||||
Product | $ | 317,916 | $ | 13,152 | $ | 31,336 | $ | — | $ | 362,404 | ||||||||||
Services | — | 76,596 | 11,952 | — | 88,548 | |||||||||||||||
$ | 317,916 | $ | 89,748 | $ | 43,288 | $ | — | $ | 450,952 | |||||||||||
Gross profit | $ | 104,350 | $ | 27,492 | $ | 14,140 | $ | — | $ | 145,982 | ||||||||||
Segment operating income (loss) | $ | 8,509 | $ | 10,172 | $ | (12,380 | ) | $ | — | $ | 6,301 | |||||||||
Depreciation expense | $ | 9,022 | $ | 2,746 | $ | 2,256 | $ | — | $ | 14,024 | ||||||||||
Assets | $ | 254,424 | $ | 59,875 | $ | 105,221 | $ | — | $ | 419,520 | ||||||||||
Year ended September 30, 2012 | ||||||||||||||||||||
Revenue | ||||||||||||||||||||
Product | $ | 380,888 | $ | 11,324 | $ | 39,749 | $ | — | $ | 431,961 | ||||||||||
Services | — | 74,628 | 12,862 | — | 87,490 | |||||||||||||||
$ | 380,888 | $ | 85,952 | $ | 52,611 | $ | — | $ | 519,451 | |||||||||||
Gross profit | $ | 127,472 | $ | 25,599 | $ | 20,415 | $ | — | $ | 173,486 | ||||||||||
Segment operating income (loss) | $ | 21,319 | $ | 9,404 | $ | (3,139 | ) | $ | — | $ | 27,584 | |||||||||
Depreciation expense | $ | 8,952 | $ | 2,344 | $ | 2,111 | $ | — | $ | 13,407 | ||||||||||
Assets | $ | 218,799 | $ | 56,120 | $ | 107,530 | $ | — | $ | 382,449 | ||||||||||
Year ended September 30, 2011 | ||||||||||||||||||||
Revenue | ||||||||||||||||||||
Product | $ | 451,287 | $ | 14,786 | $ | 7,715 | $ | 137,329 | $ | 611,117 | ||||||||||
Services | — | 74,058 | 2,930 | $ | — | 76,988 | ||||||||||||||
$ | 451,287 | $ | 88,844 | $ | 10,645 | $ | 137,329 | $ | 688,105 | |||||||||||
Gross profit | $ | 171,801 | $ | 31,750 | $ | 2,260 | $ | 17,210 | $ | 223,021 | ||||||||||
Segment operating income (loss) | $ | 64,921 | $ | 13,293 | $ | (4,684 | ) | $ | 10,649 | $ | 84,179 | |||||||||
Depreciation expense | $ | 8,597 | $ | 2,481 | $ | 543 | $ | 1,000 | $ | 12,621 | ||||||||||
Assets | $ | 235,322 | $ | 52,354 | $ | 101,331 | $ | — | $ | 389,007 | ||||||||||
Revenue from the Brooks Product Solutions segment for the fiscal year ended September 30, 2011 includes intercompany sales of $49.2 million from this segment to the Contract Manufacturing segment. This intercompany revenue has been eliminated from the revenue of Contract Manufacturing. | ||||||||||||||||||||
Revenue for the Contract Manufacturing segment for the fiscal year ended September 30, 2011 excludes intercompany sales of $10.7 million from this segment to the Brooks Product Solutions segment. | ||||||||||||||||||||
A reconciliation of the Company’s reportable segment operating income and segment assets to the corresponding consolidated amounts as of and for the years ended September 30, 2013, 2012 and 2011 is as follows (in thousands): | ||||||||||||||||||||
As of and for the Year Ended | ||||||||||||||||||||
September 30, | ||||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||
Segment operating income | $ | 6,301 | $ | 27,584 | $ | 84,179 | ||||||||||||||
Other unallocated corporate expenses(1) | 3,002 | (1,833 | ) | 1,135 | ||||||||||||||||
Amortization of acquired intangible assets | 5,853 | 4,618 | 2,411 | |||||||||||||||||
Restructuring and other charges | 6,465 | 3,275 | 1,036 | |||||||||||||||||
Pension settlement | — | 8,937 | — | |||||||||||||||||
In-process research and development | — | 3,026 | — | |||||||||||||||||
Total operating income (loss) | $ | (9,019 | ) | $ | 9,561 | $ | 79,597 | |||||||||||||
Segment assets | $ | 419,520 | $ | 382,449 | ||||||||||||||||
Cash, cash equivalents, restricted cash and marketable securities | 173,539 | 200,994 | ||||||||||||||||||
Deferred tax assets | 115,985 | 120,157 | ||||||||||||||||||
Investments in joint ventures | 25,687 | 31,428 | ||||||||||||||||||
Other unallocated corporate net assets | 2,032 | 6,932 | ||||||||||||||||||
Total assets | $ | 736,763 | $ | 741,960 | ||||||||||||||||
______________ | ||||||||||||||||||||
-1 | Other unallocated corporate expenses for the year ended September 30, 2012 includes a credit of $3.3 million related to insurance proceeds received as reimbursement of litigation costs previously incurred. | |||||||||||||||||||
Net revenue based upon the source of the order by geographic area is as follows (in thousands): | ||||||||||||||||||||
Year Ended September 30, | ||||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||
North America | $ | 193,222 | $ | 230,735 | $ | 349,456 | ||||||||||||||
Asia/Pacific | 165,452 | 194,711 | 244,524 | |||||||||||||||||
Europe | 92,278 | 94,005 | 94,125 | |||||||||||||||||
$ | 450,952 | $ | 519,451 | $ | 688,105 | |||||||||||||||
Property, plant and equipment by geographic area are as follows (in thousands): | ||||||||||||||||||||
September 30, | ||||||||||||||||||||
2013 | 2012 | |||||||||||||||||||
North America | $ | 38,869 | $ | 51,546 | ||||||||||||||||
Asia/Pacific | 1,646 | 2,123 | ||||||||||||||||||
Europe | 7,355 | 10,809 | ||||||||||||||||||
$ | 47,870 | $ | 64,478 | |||||||||||||||||
Significant_Customers
Significant Customers | 12 Months Ended |
Sep. 30, 2013 | |
Risks and Uncertainties [Abstract] | ' |
Significant Customers | ' |
Significant Customers | |
The Company had one customer that accounted for more than 10% of revenue, at 11%, in the year ended September 30, 2013. The Company had one customer that accounted for more than 10% of revenue, at 13%, in the year ended September 30, 2012. The Company had two customers that each accounted for more than 10% of revenue, at 15% and 13%, respectively, in the year ended September 30, 2011. The Company did not have any customers that accounted for more than 10% of its accounts receivable balance at September 30, 2013 or 2012. |
Other_Balance_Sheet_Informatio
Other Balance Sheet Information | 12 Months Ended | ||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' | ||||||||||||||||||||
Other Balance Sheet Information | ' | ||||||||||||||||||||
Other Balance Sheet Information | |||||||||||||||||||||
The following is a summary of accounts receivable at September 30, 2013 and 2012 (in thousands): | |||||||||||||||||||||
September 30, | |||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||
Accounts receivable | $ | 78,460 | $ | 79,706 | |||||||||||||||||
Less allowance for doubtful accounts | (863 | ) | (851 | ) | |||||||||||||||||
Less allowance for sales returns | (114 | ) | — | ||||||||||||||||||
$ | 77,483 | $ | 78,855 | ||||||||||||||||||
The allowance for doubtful accounts activity for the years ended September 30, 2013, 2012 and 2011 were as follows (in thousands): | |||||||||||||||||||||
Description | Balance at | Provisions | Reversals of | Write-offs and | Balance at | ||||||||||||||||
Beginning of | Bad Debt | Adjustments | End of | ||||||||||||||||||
Period | Expense | Period | |||||||||||||||||||
2013 Allowance for doubtful accounts | $ | 851 | $ | 48 | $ | (143 | ) | $ | 107 | $ | 863 | ||||||||||
2012 Allowance for doubtful accounts | 617 | 367 | (130 | ) | (3 | ) | 851 | ||||||||||||||
2011 Allowance for doubtful accounts | 491 | — | — | 126 | 617 | ||||||||||||||||
As part of the acquisition of Crossing in fiscal year 2013, the Company acquired a contract in which a certain customer has a right of return on the purchase of spare parts. The allowance for returns activity for the year ended September 30, 2013 was as follows (in thousands): | |||||||||||||||||||||
Description | Balance at | Provisions | Write-offs and | Balance at | |||||||||||||||||
Beginning of | Adjustments | End of | |||||||||||||||||||
Period | Period | ||||||||||||||||||||
2013 Allowance for sales returns | $ | — | $ | 72 | $ | 42 | $ | 114 | |||||||||||||
The following is a summary of inventories at September 30, 2013 and 2012 (in thousands): | |||||||||||||||||||||
September 30, | |||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||
Inventories | |||||||||||||||||||||
Raw materials and purchased parts | $ | 60,106 | $ | 64,732 | |||||||||||||||||
Work-in-process | 20,256 | 20,800 | |||||||||||||||||||
Finished goods | 17,357 | 17,453 | |||||||||||||||||||
$ | 97,719 | $ | 102,985 | ||||||||||||||||||
Reserves for excess and obsolete inventory were $24.3 million and $23.2 million at September 30, 2013 and 2012, respectively. The Company recorded charges to reserves for excess and obsolete inventory of $5.4 million, $4.3 million and $2.2 million in fiscal 2013, 2012 and 2011, respectively. The Company reduced the reserves for excess and obsolete inventory by $4.3 million, $5.8 million and $3.5 million, in fiscal 2013, 2012 and 2011, respectively, for disposals of inventory. | |||||||||||||||||||||
The Company provides for the estimated cost of product warranties, primarily from historical information, at the time product revenue is recognized and retrofit accruals at the time retrofit programs are established. The Company’s warranty obligation is affected by product failure rates, utilization levels, material usage, service delivery costs incurred in correcting a product failure, and supplier warranties on parts delivered to the Company. Product warranty and retrofit activity on a gross basis for the years ended September 30, 2013, 2012 and 2011 is as follows (in thousands): | |||||||||||||||||||||
Balance at September 30, 2010 | $ | 8,195 | |||||||||||||||||||
Adjustments for acquisitions and divestitures | 698 | ||||||||||||||||||||
Accruals for warranties during the year | 11,299 | ||||||||||||||||||||
Costs incurred during the year | (12,754 | ) | |||||||||||||||||||
Balance at September 30, 2011 | 7,438 | ||||||||||||||||||||
Adjustments for acquisitions and divestitures | 7 | ||||||||||||||||||||
Accruals for warranties during the year | 13,751 | ||||||||||||||||||||
Costs incurred during the year | (13,867 | ) | |||||||||||||||||||
Balance at September 30, 2012 | 7,329 | ||||||||||||||||||||
Adjustments for acquisitions and divestitures | 1,187 | ||||||||||||||||||||
Accruals for warranties during the year | 10,111 | ||||||||||||||||||||
Costs incurred during the year | (11,278 | ) | |||||||||||||||||||
Balance at September 30, 2013 | $ | 7,349 | |||||||||||||||||||
Sale_of_Building_and_Land
Sale of Building and Land | 12 Months Ended | |||
Sep. 30, 2013 | ||||
Real Estate [Abstract] | ' | |||
Sale of Building and Land | ' | |||
Sale of Building and Land | ||||
On September 27, 2013, the Company completed a Purchase and Sale Agreement ("Agreement") to sell a portion of its Chelmsford, Massachusetts campus to a real estate investment trust for $11.3 million. The property sold is an underutilized building and the related land. The components of the gain on the sale is as follows (in thousands): | ||||
Sale proceeds | $ | 11,275 | ||
Net book value of building and land | (6,095 | ) | ||
Deferred leasing costs and other | (3,718 | ) | ||
Direct transaction costs | (437 | ) | ||
Gain on the sale of building and land | $ | 1,025 | ||
In December 2012, the Company entered into an agreement to lease this property to an unrelated third party. Unamortized deferred costs of $3.7 million, consisting of primarily of commissions and tenant allowances, were written off and included in the determination of the gain on the sale. Direct transaction costs, consisting of broker commissions and legal fees were also included in the determination of the gain on the sale. | ||||
In addition, in fiscal year 2013, the Company sold certain buildings in Oberdiessbach, Switzerland for total proceeds of $3.2 million. The sale of these assets resulted in a gain of $0.2 million. | ||||
Gains related to the sale of these buildings are recorded in the Company's Consolidated Statements of Operations as a component of other income (expense), net. |
Commitments_and_Contingencies
Commitments and Contingencies | 12 Months Ended | |||
Sep. 30, 2013 | ||||
Commitments and Contingencies Disclosure [Abstract] | ' | |||
Commitments and Contingencies | ' | |||
Commitments and Contingencies | ||||
Lease Commitments | ||||
The Company leases manufacturing and office facilities and certain equipment under operating leases that expire through 2022. Rental expense under operating leases, excluding expense recorded as a component of restructuring, for the years ended September 30, 2013, 2012 and 2011 was $8.4 million, $4.8 million and $4.9 million, respectively. Future minimum lease commitments on non-cancelable operating leases are as follows (in thousands): | ||||
Operating | ||||
Leases | ||||
Year ended September 30, 2014 | $ | 7,199 | ||
2015 | 5,084 | |||
2016 | 2,728 | |||
2017 | 1,557 | |||
2018 | 1,359 | |||
Thereafter | 1,625 | |||
$ | 19,552 | |||
The Company is a guarantor on a lease in Mexico that expires in January 2015. As of September 30, 2013, the remaining payments under this lease are approximately $0.5 million. | ||||
Letters of Credit | ||||
At September 30, 2013, the Company had $5.7 million of outstanding letters of credit. | ||||
Purchase Commitments | ||||
The Company has non-cancelable contracts and purchase orders for inventory of $68.6 million at September 30, 2013. | ||||
Contingencies | ||||
The Company is subject to various legal proceedings, both asserted and unasserted, that arise in the ordinary course of business. The Company cannot predict the ultimate outcome of such legal proceedings or in certain instances provide reasonable ranges of potential losses. However, as of the date of this report, the Company believes that none of these claims will have a material adverse effect on its consolidated financial condition or results of operations. In the event of unexpected subsequent developments and given the inherent unpredictability of these legal proceedings, there can be no assurance that the Company's assessment of any claim will reflect the ultimate outcome and an adverse outcome in certain matters could, from time to time, have a material adverse effect on the Company's consolidated financial condition or results of operations in particular quarterly or annual periods. |
Subsequent_Events
Subsequent Events | 12 Months Ended |
Sep. 30, 2013 | |
Subsequent Events [Abstract] | ' |
Subsequent Events | ' |
Subsequent Events | |
On November 12, 2013, the Company’s Board of Directors declared a cash dividend of $0.08 per share payable on December 27, 2013 to common stockholders of record on December 6, 2013. Dividends are declared at the discretion of the Company’s Board of Directors and depend on actual cash from operations, the Company’s financial condition and capital requirements and any other factors the Company’s Board of Directors may consider relevant. Future dividend declarations, as well as the record and payment dates for such dividends, will be determined by the Company’s Board of Directors on a quarterly basis. |
Summary_of_Significant_Account1
Summary of Significant Accounting Policies (Policies) | 12 Months Ended | ||||||||
Sep. 30, 2013 | |||||||||
Accounting Policies [Abstract] | ' | ||||||||
Principles of Consolidation and Basis of Presentation | ' | ||||||||
Principles of Consolidation and Basis of Presentation | |||||||||
The consolidated financial statements include the accounts of the Company and all majority-owned subsidiaries. All intercompany accounts and transactions are eliminated. Equity investments in which the Company exercises significant influence but does not control and is not the primary beneficiary are accounted for using the equity method. | |||||||||
Use of Estimates | ' | ||||||||
Use of Estimates | |||||||||
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates are associated with accounts receivable, inventories, intangible assets, goodwill, deferred income taxes, warranty obligations, revenue recognized using the percentage of completion method and stock-based compensation expense on performance-based awards. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. | |||||||||
Foreign Currency Translation | ' | ||||||||
Foreign Currency Translation | |||||||||
Some transactions of the Company and its subsidiaries are made in currencies different from their functional currency. Foreign currency gains (losses) on these transactions or balances are recorded in “Other (income) expense, net” when incurred. Net foreign currency transaction losses included in income (loss) before income taxes and equity in earnings of joint ventures totaled $0.9 million, $0.4 million and $0.1 million for the years ended September 30, 2013, 2012 and 2011, respectively. For non-U.S. subsidiaries, assets and liabilities are translated at period-end exchange rates, and statements of operations items are translated at the average exchange rates for the period. The local currency is considered to be the functional currency for all of our foreign subsidiaries and, accordingly, translation adjustments are reported in “Accumulated other comprehensive income.” Foreign currency translation adjustments are one of the components of comprehensive net income (loss). | |||||||||
Derivative Financial Instruments | ' | ||||||||
Derivative Financial Instruments | |||||||||
All derivatives, whether designated in a hedging relationship or not, are recorded on the consolidated balance sheets at fair value. The accounting for changes in fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must designate the hedging instrument, based on the exposure being hedged, as a fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation. Certain derivatives held by the Company are not designated as hedges but are used in managing exposure to changes in foreign exchange rates. | |||||||||
A fair value hedge is a derivative instrument designated for the purpose of hedging the exposure of changes in fair value of an asset or a liability resulting from a particular risk. If the derivative is designated as a fair value hedge, the changes in the fair value of the derivative and of the hedged item attributable to the hedged risk are both recognized in the same caption in the consolidated statements of operations and comprehensive income. | |||||||||
A cash flow hedge is a derivative instrument designated for the purpose of hedging the exposure to variability in future cash flows resulting from a particular risk. If the derivative is designated as a cash flow hedge, the effective portions of changes in the fair value of the derivative are recorded in accumulated other comprehensive income and are recognized in the results of operations when the hedged item affects earnings. Ineffective portions of changes in the fair value of cash flow hedges are recognized in the results of operations. | |||||||||
A hedge of a net investment in a foreign operation is achieved through a derivative instrument designated for the purpose of hedging the exposure of changes in value of investments in foreign subsidiaries. If the derivative is designated as a hedge of a net investment in a foreign operation, the effective portions of changes in the fair value of the derivative are recorded in other comprehensive income as a part of the currency translation adjustment. Ineffective portions of net investment hedges are recognized in the results of operations. | |||||||||
For derivative instruments not designated as hedging instruments, changes in fair value are recognized in the Consolidated Statements of Operations as gains and losses consistent with the classification of the underlying risk. | |||||||||
Cash and Cash Equivalents | ' | ||||||||
Cash and Cash Equivalents | |||||||||
Cash and cash equivalents include cash and highly liquid investments with original maturities of three months or less. At September 30, 2013 and 2012, cash equivalents were $7.8 million and $17.5 million, respectively. Cash equivalents are held at cost which approximates fair value due to their short-term maturities and varying interest rates. | |||||||||
Concentration of Credit Risk | ' | ||||||||
Concentration of Credit Risk | |||||||||
Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of trade receivables and temporary and long-term cash investments in treasury bills and commercial paper. The Company restricts its investments to U.S. government and its agencies, municipalities, corporate securities and mutual funds that invest in U.S. government securities. The Company's customers are concentrated in the semiconductor industry, and relatively few customers account for a significant portion of the Company's revenue. The Company's top ten largest customers account for approximately 39% of revenue for the year ended September 30, 2013. One of the Company's customers accounted for 11% of revenue for the year ended September 30, 2013. The Company regularly monitors the creditworthiness of its customers and believes that it has adequately provided for exposure to potential credit losses. | |||||||||
Accounts Receivable and Allowance for Doubtful Accounts | ' | ||||||||
Accounts Receivable and Allowance for Doubtful Accounts and Sales Returns | |||||||||
Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in its existing accounts receivable. The Company determines the allowance based on a number of factors, including an evaluation of customer credit worthiness, the age of the outstanding receivable, economic trends and historical experience. The Company reviews its allowance for doubtful accounts on a quarterly basis and changes in estimates are reflected in the period in which they become known. Accounts receivable balances are written-off against the allowance for doubtful accounts when the Company determines that the receivable is not recoverable. Provisions for doubtful accounts are recorded in "General and Administrative Expenses" in the Consolidated Statements of Operations. The allowance for sales returns is the Company's best estimate of probable returns from one of its semiconductor customers. Provisions for sales returns are recorded in "Revenue" in the Consolidated Statements of Operations. The Company does not have any off-balance-sheet credit exposure related to its customers. | |||||||||
Inventories | ' | ||||||||
Inventories | |||||||||
Inventories are stated at the lower of cost or market, cost being determined using a standard costing system which approximates cost based on a first-in, first-out method. The Company provides inventory reserves for excess, obsolete or damaged inventory based on changes in customer demand, technology and other economic factors. | |||||||||
Fixed Assets, Intangible Assets and Impairment of Long-lived Assets | ' | ||||||||
Fixed Assets, Intangible Assets and Impairment of Long-lived Assets | |||||||||
Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method. Depreciable lives are summarized below: | |||||||||
Buildings | 20 - 40 years | ||||||||
Computer equipment and software | 2 - 7 years | ||||||||
Machinery and equipment | 2 - 10 years | ||||||||
Furniture and fixtures | 3 - 10 years | ||||||||
Leasehold improvements are amortized over the shorter of their estimated useful lives or the term of the respective leases. Equipment used for demonstrations to customers is included in machinery and equipment and is depreciated over its estimated useful life. Repair and maintenance costs are expensed as incurred. | |||||||||
The Company has developed software for internal use. Internal and external labor costs incurred during the application development stage of a project are capitalized. Costs incurred prior to application development and post implementation are expensed as incurred. Training and data conversion costs are expensed as incurred. | |||||||||
When an asset is retired, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts, and any resulting gain or loss is included in the determination of operating profit (loss). | |||||||||
As a result of the Company's acquisitions, the Company has identified finite-lived intangible assets other than goodwill. Finite-lived intangible assets are valued based on estimates of future cash flows and amortized over their estimated useful life using methods that approximate the pattern in which the economic benefits are expected to be realized. | |||||||||
Finite-lived intangibles assets and fixed assets are tested for impairment when indicators of impairment are present. For purposes of this test, long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. When the Company determines that indicators of potential impairment exist, the next step of the impairment test requires that the potentially impaired long-lived asset group is tested for recoverability. The test for recoverability compares the undiscounted future cash flows of the long-lived asset group to its carrying value. The future cash flow period is based on the future service life of the primary asset within the long-lived asset group. If the carrying values of the long-lived asset group exceed the future cash flows, the assets are considered to be potentially impaired. The next step in the impairment process is to determine the fair value of the individual net assets within the long-lived asset group. If the aggregate fair values of the individual net assets of the group are less than their carrying values, an impairment is recorded equal to the excess of the aggregate carrying value of the group over the aggregate fair value. The loss is allocated to each asset within the group based on their relative carrying values, with no asset reduced below its fair value. | |||||||||
The amortizable lives of intangible assets, including those identified as a result of purchase accounting, are summarized as follows: | |||||||||
Patents | 7 - 15 years | ||||||||
Completed technology | 2 - 10 years | ||||||||
License agreements | 5 years | ||||||||
Trademarks and trade names | 2 - 6 years | ||||||||
Non-competition agreements | 3 - 5 years | ||||||||
Customer relationships | 4 - 13 years | ||||||||
Goodwill | ' | ||||||||
Goodwill | |||||||||
Goodwill represents the excess of purchase price over the fair value of net tangible and identifiable intangible assets of the businesses the Company acquired. The Company performs an annual impairment test of its goodwill on September 30 of each fiscal year unless interim indicators of impairment exist. | |||||||||
The testing of goodwill for impairment is performed at a level referred to as a reporting unit. A reporting unit is either the “operating segment level” or one level below, which is referred to as a “component.” The level at which the impairment test is performed requires an assessment as to whether the operations below the operating segment constitute a self-sustaining business, testing is generally required to be performed at this level. The Company currently has five reporting units that have goodwill, including three components that are part of the Brooks Product Solutions operating segment, one reporting unit that is the Brooks Global Services operating segment and one reporting unit that is the Brooks Life Science Systems operating segment. | |||||||||
The Company determines the fair value of its reporting units using an Income Approach, specifically the Discounted Cash Flow Method (“DCF Method”). The DCF Method includes future cash flow projections, which are discounted to present value, and an estimate of terminal values, which are also discounted to present value. Terminal values represent the present value an investor would pay today for the rights to the cash flows of the business for the years subsequent to the discrete cash flow projection period. The Company considers the DCF Method to be the most appropriate valuation indicator as the DCF analyses are based on management's long-term financial projections. Given the dynamic nature of the cyclical semiconductor equipment market, management's projections as of the valuation date are considered more objective since other market metrics for peer companies fluctuate over the cycle. However, the Company also uses market-based valuation techniques to test the reasonableness of the reporting unit fair values determined by the DCF Method and compares the aggregate fair value of its reporting units plus its net corporate assets to its overall market capitalization. | |||||||||
Goodwill impairment testing is a two-step process. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of each reporting unit to its respective carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered impaired. If the reporting unit's carrying amount exceeds the fair value, the second step of the goodwill impairment test must be completed to measure the amount of the impairment loss, if any. The second step compares the implied fair value of goodwill with the carrying value of goodwill. The implied fair value is determined by allocating the fair value of the reporting unit to all of the assets and liabilities of that unit, the excess of the fair value over amounts assigned to its assets and liabilities is the implied fair value of goodwill. The implied fair value of goodwill determined in this step is compared to the carrying value of goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, an impairment loss is recognized equal to the difference. | |||||||||
Pension Plans | ' | ||||||||
Pension Plans | |||||||||
The cost and obligations of the Company's defined benefit pension plans are calculated using many assumptions to estimate the benefits that the employee earns while working, the amount of which cannot be completely determined until the benefit payments cease. Major assumptions used in the accounting for these employee benefit plans include the discount rate, expected return on plan assets and rate of increase in employee compensation levels. Assumptions are determined based on Company data and appropriate market indicators in consultation with third-party actuaries, and are evaluated each year as of the plans' measurement date. | |||||||||
Revenue Recognition | ' | ||||||||
Revenue Recognition | |||||||||
Product revenue is associated with the sale of hardware systems, components and spare parts as well as product license revenue. Service revenue is associated with service contracts, repairs, upgrades and field service. Shipping and handling fees, billed to customers, if any, are recognized as revenue. The related shipping and handling costs are recognized in cost of revenue. | |||||||||
Revenue from product sales that do not include significant customization is recorded upon delivery and transfer of risk of loss to the customer provided there is evidence of an arrangement, fees are fixed or determinable, collection of the related receivable is reasonably assured and, if applicable, customer acceptance criteria have been successfully demonstrated. Customer acceptance provisions are included in certain arrangements to ensure that the product meets the published specification requirements. Customer acceptance provisions in the Company’s arrangements generally consist of final testing procedures that are carried out either in one of the Company’s facilities or at the customer location. When an arrangement includes acceptance criteria to be carried out in one of the Company’s facilities, the Company recognizes revenue when the acceptance criteria have been successfully demonstrated and delivery and transfer of risk of loss have occurred. When significant on site customer acceptance provisions are present in the arrangement, revenue is recognized upon completion of customer acceptance testing. | |||||||||
Revenue from product sales that does include significant customization, which primarily include life science automation systems, is recorded using the percentage of completion method whereby revenue is recorded as work progresses based on a percentage that incurred labor effort to date bear to total projected labor effort. Payments collected from customers in advance of recognizing the related revenue is recorded as deferred revenue. In addition, contracts are reviewed on a regular basis to determine whether a probable future loss exists. If such a loss is estimated by comparing total estimated contract revenue to the total estimated contract costs, a loss will be accrued in the same period the Company determines that the loss is probable. | |||||||||
Revenue associated with service agreements is generally recognized ratably over the term of the contract, with payments from customers being recorded as deferred revenue. Revenue from repair services or upgrades of customer-owned equipment is recognized upon completion of the repair effort and upon the shipment of the repaired item back to the customer. In instances where the repair or upgrade includes installation, revenue is recognized when the installation is completed. | |||||||||
Warranty | ' | ||||||||
Warranty | |||||||||
The Company offers warranties on the sales of certain of its products and records an accrual for estimated future claims. Such accruals are based upon historical experience and management's estimate of the level of future claims. | |||||||||
Research and Development Expenses | ' | ||||||||
Research and Development Expenses | |||||||||
Research and development costs are charged to expense when incurred. | |||||||||
Stock-Based Compensation | ' | ||||||||
Stock-Based Compensation | |||||||||
The Company measures compensation cost for all employee stock awards at fair value on the date of grant and recognizes compensation expense over the service period for awards expected to vest. The fair value of restricted stock is determined based on the number of shares granted and the quoted price of the Company's common stock on the date of grant, and the fair value of stock options is determined using the Black-Scholes valuation model. Such value is recognized as expense over the service period, net of estimated forfeitures. The estimation of stock awards that will ultimately vest requires significant judgment. The Company considers many factors when estimating expected forfeitures, including types of awards, employee class, and historical experience. In addition, for stock-based awards where vesting is dependent upon achieving certain operating performance goals, the Company estimates the likelihood of achieving the performance goals. Actual results, and future changes in estimates, may differ substantially from the Company's current estimates. | |||||||||
During the year ended September 30, 2013, the Company granted 1,394,000 shares of restricted stock to members of senior management of which 716,625 shares vest over the service period and the remaining 677,375 shares vest upon the achievement of certain financial performance goals which were measured at the end of fiscal year 2013. Total compensation expense on these awards is a maximum of $15.1 million, net of cancellations. During the year ended September 30, 2012, the Company granted 1,527,000 shares of restricted stock to members of senior management of which 406,750 shares vest over the service period and the remaining 1,120,250 shares vest upon the achievement of certain financial performance goals which will be measured at the end of fiscal year 2014. Total compensation expense on these awards is a maximum of $14.4 million, net of cancellations. Awards subject to service criteria are being recorded to expense ratably over the vesting period. Awards subject to performance criteria are expensed over the related service period when attainment of the performance condition is considered probable. The total amount of compensation recorded depends on the Company's achievement against performance targets. Changes to the projected attainment against performance targets during the vesting period may result in an adjustment to the amount of cumulative compensation recorded as of the date the estimate is revised. | |||||||||
During the three months ended December 31, 2011, the Company's Chief Executive Officer was granted an award of 100,000 cash settled phantom units, which are subject to the same vesting terms as the performance-based restricted stock units from fiscal year 2012. The Company's consolidated balance sheet at September 30, 2013 and 2012 includes a liability of approximately $0 and $78,000, respectively, for this potential cash payment. The Company recorded an expense of $78,000 related to this award during the year ended September 30, 2012, but was reversed during the year ended September 30, 2013 because the performance criteria was not met. | |||||||||
Valuation Assumptions for Stock Options and Employee Stock Purchase Plans | ' | ||||||||
Valuation Assumptions for Stock Options and Employee Stock Purchase Plans | |||||||||
No stock options were granted for the years ended September 30, 2013, 2012 or 2011. | |||||||||
The fair value of shares issued under the employee stock purchase plan was estimated on the commencement date of each offering period using the Black-Scholes option-pricing model with the following assumptions: | |||||||||
Year ended September 30, | |||||||||
2013 | 2012 | 2011 | |||||||
Risk-free interest rate | 0.1 | % | 0.1 | % | 0.2 | % | |||
Volatility | 32 | % | 45 | % | 50 | % | |||
Expected life | 6 months | 6 months | 6 months | ||||||
Dividend yield | 3.30% - 3.40% | 2.75% - 3.30% | 0% - 3% | ||||||
The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option; expected volatilities are based on historical volatilities of the Company's common stock; and the expected life represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company's historical exercise patterns. Dividend yields are projected based on the Company's history of dividends declared, and management's intention for future dividend declarations. | |||||||||
Equity Incentive Plans | ' | ||||||||
Equity Incentive Plans | |||||||||
The Company's equity incentive plans are intended to attract and retain employees and to provide an incentive for them to assist the Company to achieve long-range performance goals and to enable them to participate in the long-term growth of the Company. The equity incentive plans consist of plans under which employees may be granted options to purchase shares of the Company's stock, restricted stock and other equity incentives. Stock options generally had a vesting period of four years and are exercisable for a period not to exceed seven years from the date of issuance. Restricted stock awards generally vest over two to four years. At September 30, 2013, a total of 3,259,558 shares were reserved and available for the issuance of awards under the plans. | |||||||||
Income Taxes | ' | ||||||||
Income Taxes | |||||||||
The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company's consolidated financial statements contain certain deferred tax assets which have arisen primarily as a result of operating losses, as well as other temporary differences between financial and tax accounting. A valuation allowance is established if the likelihood of realization of the deferred tax assets is not considered more likely than not based on an evaluation of positive and negative evidence and the extent to which that evidence is objectively verifiable. Significant management judgment is required in determining the Company's provision for income taxes, the Company's deferred tax assets and liabilities and any valuation allowance recorded against those net deferred tax assets. The Company evaluates the weight of all available evidence to determine whether it is more likely than not that some portion or all of the net deferred income tax assets will not be realized. | |||||||||
The calculation of the Company's tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. If we determine that a tax position will more likely than not be sustained on audit, the second step requires us to estimate and measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as we have to determine the probability of various possible outcomes. We re-evaluate these uncertain tax positions on a quarterly basis. This evaluation is based on factors such as changes in facts or circumstances, changes in tax law, new audit activity, and effectively settled issues. Determining whether an uncertain tax position is effectively settled requires judgment. Such a change in recognition or measurement would result in the recognition of a tax benefit or an additional charge to the tax provision. | |||||||||
Earnings Per Share | ' | ||||||||
Earnings Per Share | |||||||||
Basic earnings per share is calculated based on the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated based on the weighted average number of common shares and dilutive common equivalent shares assumed outstanding during the period. Shares used to compute diluted earnings per share exclude common share equivalents if their inclusion would have an anti-dilutive effect. | |||||||||
Fair Value of Financial Instruments | ' | ||||||||
Fair Value of Financial Instruments | |||||||||
The Company's financial instruments include cash and cash equivalents, restricted cash, marketable securities, derivative instruments, accounts receivable and accounts payable. The carrying amounts of these items reported in the balance sheets approximate their fair value at September 30, 2013 and 2012 because of their short-term nature. In the case of marketable securities and derivative instruments, measurement is based on quoted market prices for identical or similar securities or instruments. | |||||||||
Reclassifications | ' | ||||||||
Reclassifications | |||||||||
In order to conform with the current year presentation, cash distributions received from joint ventures of $5.1 million and $2.4 million in the years ended September 30, 2012 and 2011, respectively, were reclassified from “Undistributed Earnings of Joint Ventures” to “Prepaid Expenses and Other Current Assets” on the Consolidated Statements of Cash Flows. The reclassification of these amounts had no impact on previously reported net cash provided by operating activities, results of operations or financial position for the years ended September 30, 2012 and 2011. | |||||||||
Recent Accounting Pronouncements | ' | ||||||||
Recent Accounting Pronouncements | |||||||||
In June 2011, the Financial Accounting Standards Board ("FASB") issued an amendment to the accounting guidance for presentation of comprehensive income. Under the amended guidance, a company may present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. This authoritative guidance eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity. On October 1, 2012 the Company adopted this guidance and elected to present two separate but consecutive statements. | |||||||||
In February 2013, the FASB issued guidance to provide information about the amounts reclassified out of accumulated other comprehensive income (“AOCI”) by component. In addition, an entity is required to present, either on the face of the financial statements or in the notes, significant amounts reclassified out of AOCI by the respective line items of net income, but only if the amount reclassified is required to be reclassified in its entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about those amounts. On January 1, 2013 the Company adopted this standard, which had no impact on its financial position or results of operations. |
Summary_of_Significant_Account2
Summary of Significant Accounting Policies (Tables) | 12 Months Ended | |||||||||||
Sep. 30, 2013 | ||||||||||||
Accounting Policies [Abstract] | ' | |||||||||||
Summary of Depreciable Lives | ' | |||||||||||
Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method. Depreciable lives are summarized below: | ||||||||||||
Buildings | 20 - 40 years | |||||||||||
Computer equipment and software | 2 - 7 years | |||||||||||
Machinery and equipment | 2 - 10 years | |||||||||||
Furniture and fixtures | 3 - 10 years | |||||||||||
Summary of Amortizable Lives of Intangible Assets | ' | |||||||||||
The amortizable lives of intangible assets, including those identified as a result of purchase accounting, are summarized as follows: | ||||||||||||
Patents | 7 - 15 years | |||||||||||
Completed technology | 2 - 10 years | |||||||||||
License agreements | 5 years | |||||||||||
Trademarks and trade names | 2 - 6 years | |||||||||||
Non-competition agreements | 3 - 5 years | |||||||||||
Customer relationships | 4 - 13 years | |||||||||||
Compensation Expense | ' | |||||||||||
The following table reflects compensation expense recorded during the years ended September 30, 2013, 2012 and 2011 (in thousands): | ||||||||||||
Year ended September 30, | ||||||||||||
2013 | 2012 | 2011 | ||||||||||
Restricted stock | $ | 7,261 | $ | 8,098 | $ | 6,248 | ||||||
Employee stock purchase plan | 496 | 549 | 504 | |||||||||
$ | 7,757 | $ | 8,647 | $ | 6,752 | |||||||
Fair Value of Shares Issued under Employee Stock Purchase Plan Estimated using Black-Scholes Option Pricing Model | ' | |||||||||||
The fair value of shares issued under the employee stock purchase plan was estimated on the commencement date of each offering period using the Black-Scholes option-pricing model with the following assumptions: | ||||||||||||
Year ended September 30, | ||||||||||||
2013 | 2012 | 2011 | ||||||||||
Risk-free interest rate | 0.1 | % | 0.1 | % | 0.2 | % | ||||||
Volatility | 32 | % | 45 | % | 50 | % | ||||||
Expected life | 6 months | 6 months | 6 months | |||||||||
Dividend yield | 3.30% - 3.40% | 2.75% - 3.30% | 0% - 3% | |||||||||
Acquisitions_and_Divestiture_T
Acquisitions and Divestiture (Tables) | 12 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Business Combinations [Abstract] | ' | |||||||
Amounts of Assets and Liabilities at Fair Value as of Acquisition Date | ' | |||||||
The assets and liabilities associated with the purchase of the Matrical assets were recorded at their fair values as of the acquisition date. The amounts recorded follow (in thousands): | ||||||||
Accounts receivable | $ | 636 | ||||||
Inventory | 2,095 | |||||||
Prepaid and other current assets | 103 | |||||||
Property, plant and equipment | 534 | |||||||
Completed technology | 500 | |||||||
Customer relationships | 1,500 | |||||||
Goodwill | 7,137 | |||||||
Debt | (902 | ) | ||||||
Accounts payable | (294 | ) | ||||||
Deferred revenue | (412 | ) | ||||||
Customer deposits | (1,249 | ) | ||||||
Other current liabilities | (322 | ) | ||||||
Total purchase price, net of cash acquired | $ | 9,326 | ||||||
The assets and liabilities associated with Celigo were recorded at their fair values as of the acquisition date. The amounts recorded follow (in thousands): | ||||||||
Accounts receivable | $ | 897 | ||||||
Inventory | 1,139 | |||||||
Property, plant and equipment | 202 | |||||||
Completed technology | 3,540 | |||||||
Trademarks and trade names | 70 | |||||||
Goodwill | 3,713 | |||||||
Accounts payable | (13 | ) | ||||||
Deferred revenue | (326 | ) | ||||||
Other current liabilities | (6 | ) | ||||||
Total purchase price, net of cash acquired | $ | 9,216 | ||||||
The assets and liabilities associated with Crossing were recorded at their fair values as of the acquisition date. The amounts recorded follow (in thousands): | ||||||||
Accounts receivable | $ | 5,356 | ||||||
Inventory | 8,668 | |||||||
Prepaid expenses | 1,968 | |||||||
Property, plant and equipment | 2,270 | |||||||
Completed technology | 10,530 | |||||||
Customer relationships | 20,010 | |||||||
Goodwill | 26,453 | |||||||
Other long term assets | 885 | |||||||
Accounts payable | (3,024 | ) | ||||||
Accrued liabilities | (5,172 | ) | ||||||
Deferred revenue | (319 | ) | ||||||
Other current liabilities | (388 | ) | ||||||
Other long-term liabilities | (8,232 | ) | ||||||
Total purchase price, net of cash acquired | $ | 59,005 | ||||||
Pro Forma Information for Crossing Acquisition | ' | |||||||
The following pro forma summary presents consolidated information of the Company as if the acquisition of Crossing occurred on October 1, 2011 (in thousands): | ||||||||
Year ended September 30, | ||||||||
2013 | 2012 | |||||||
Revenue | $ | 453,045 | $ | 570,864 | ||||
Net income (loss) attributable to Brooks Automation, Inc. | (3,216 | ) | 135,245 | |||||
Marketable_Securities_Tables
Marketable Securities (Tables) | 12 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Investments, Debt and Equity Securities [Abstract] | ' | |||||||||||||||
Summary of Marketable Securities Including Accrued Interest Receivable | ' | |||||||||||||||
The following is a summary of marketable securities (included in short and long-term marketable securities in the Consolidated Balance Sheets), including accrued interest receivable, as of September 30, 2013 and 2012 (in thousands): | ||||||||||||||||
Amortized | Gross | Gross | Fair Value | |||||||||||||
Cost | Unrealized | Unrealized | ||||||||||||||
Gains | Losses | |||||||||||||||
September 30, 2013: | ||||||||||||||||
U.S. Treasury securities and obligations of U.S. government agencies | $ | 19,528 | $ | 6 | $ | (13 | ) | $ | 19,521 | |||||||
Corporate securities | 35,045 | 11 | (47 | ) | 35,009 | |||||||||||
Mortgage-backed securities | 1,093 | 25 | (1 | ) | 1,117 | |||||||||||
Other debt securities | 88 | — | — | 88 | ||||||||||||
Municipal securities | 25,199 | 15 | (7 | ) | 25,207 | |||||||||||
Bank certificate of deposits | 9,451 | — | (2 | ) | 9,449 | |||||||||||
$ | 90,404 | $ | 57 | $ | (70 | ) | $ | 90,391 | ||||||||
September 30, 2012: | ||||||||||||||||
U.S. Treasury securities and obligations of U.S. government agencies | $ | 41,202 | $ | 15 | $ | (2 | ) | $ | 41,215 | |||||||
Corporate securities | 64,102 | 138 | (16 | ) | 64,224 | |||||||||||
Mortgage-backed securities | 1,310 | 42 | (1 | ) | 1,351 | |||||||||||
Other debt securities | 13 | — | — | 13 | ||||||||||||
Municipal securities | 34,777 | 25 | (1 | ) | 34,801 | |||||||||||
Bank certificate of deposits | 3,987 | 1 | — | 3,988 | ||||||||||||
$ | 145,391 | $ | 221 | $ | (20 | ) | $ | 145,592 | ||||||||
Fair Value of Marketable Securities by Contractual Maturity | ' | |||||||||||||||
The fair value of the marketable securities at September 30, 2013 by contractual maturity, are shown below (in thousands). Expected maturities will differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. | ||||||||||||||||
Fair Value | ||||||||||||||||
Due in one year or less | $ | 45,900 | ||||||||||||||
Due after one year through five years | 41,194 | |||||||||||||||
Due after ten years | 3,297 | |||||||||||||||
$ | 90,391 | |||||||||||||||
Fair_Value_Measurements_Tables
Fair Value Measurements (Tables) | 12 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Fair Value Disclosures [Abstract] | ' | ||||||||||||||||
Assets and Liabilities Measured at Fair Value on a Recurring Basis | ' | ||||||||||||||||
Assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2013 and 2012 are summarized as follows (in thousands): | |||||||||||||||||
Fair Value Measurements at Reporting Date Using | |||||||||||||||||
Description | September 30, | Quoted Prices in | Significant Other | Significant | |||||||||||||
2013 | Active Markets for | Observable Inputs | Unobservable Inputs | ||||||||||||||
Identical Assets | (Level 2) | (Level 3) | |||||||||||||||
(Level 1) | |||||||||||||||||
Assets | |||||||||||||||||
Cash equivalents | $ | 7,754 | $ | 6,152 | $ | 1,602 | $ | — | |||||||||
Available-for-sale securities | 90,391 | 2,199 | 88,192 | — | |||||||||||||
Foreign exchange contracts | 31 | — | 31 | ||||||||||||||
Total Assets | $ | 98,176 | $ | 8,351 | $ | 89,825 | $ | — | |||||||||
Liabilities | |||||||||||||||||
Foreign exchange contracts | $ | 5 | $ | — | $ | 5 | $ | — | |||||||||
Fair Value Measurements at Reporting Date Using | |||||||||||||||||
Description | September 30, | Quoted Prices in | Significant Other | Significant | |||||||||||||
2012 | Active Markets for | Observable Inputs | Unobservable Inputs | ||||||||||||||
Identical Assets | (Level 2) | (Level 3) | |||||||||||||||
(Level 1) | |||||||||||||||||
Assets | |||||||||||||||||
Cash equivalents | $ | 17,508 | $ | 17,508 | $ | — | $ | — | |||||||||
Available-for-sale securities | 145,592 | 60,231 | 85,361 | — | |||||||||||||
Foreign exchange contracts | 10 | — | 10 | — | |||||||||||||
Total Assets | $ | 163,110 | $ | 77,739 | $ | 85,371 | $ | — | |||||||||
Liabilities | |||||||||||||||||
Foreign exchange contracts | $ | 13 | $ | — | $ | 13 | $ | — | |||||||||
Property_Plant_and_Equipment_T
Property, Plant and Equipment (Tables) | 12 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Property, Plant and Equipment [Abstract] | ' | |||||||
Property, Plant and Equipment | ' | |||||||
Property, plant and equipment as of September 30, 2013 and 2012 were as follows (in thousands): | ||||||||
September 30, | ||||||||
2013 | 2012 | |||||||
Buildings and land | $ | 38,539 | $ | 55,352 | ||||
Computer equipment and software | 72,927 | 70,719 | ||||||
Machinery and equipment | 55,375 | 51,813 | ||||||
Furniture and fixtures | 10,298 | 10,908 | ||||||
Leasehold improvements | 16,522 | 18,938 | ||||||
Capital projects in progress | 2,098 | 2,614 | ||||||
195,759 | 210,344 | |||||||
Less accumulated depreciation and amortization | (147,889 | ) | (145,866 | ) | ||||
Property, plant and equipment, net | $ | 47,870 | $ | 64,478 | ||||
Goodwill_and_Intangible_Assets1
Goodwill and Intangible Assets (Tables) | 12 Months Ended | |||||||||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | |||||||||||||||||||||||
Components of Goodwill By Business Segment | ' | |||||||||||||||||||||||
The components of the Company’s goodwill by business segment at September 30, 2013 and 2012 are as follows (in thousands): | ||||||||||||||||||||||||
Brooks | Brooks | Brooks | Contract Manufacturing | Other | Total | |||||||||||||||||||
Product | Global | Life Science | ||||||||||||||||||||||
Solutions | Services | Systems | ||||||||||||||||||||||
Gross goodwill at September 30, 2011 | $ | 485,844 | $ | 151,238 | $ | 36,589 | $ | 18,593 | $ | 7,421 | $ | 699,685 | ||||||||||||
Acquisitions and adjustments during fiscal 2012 | — | — | 3,713 | — | — | 3,713 | ||||||||||||||||||
Gross goodwill at September 30, 2012 | 485,844 | 151,238 | 40,302 | 18,593 | 7,421 | 703,398 | ||||||||||||||||||
Acquisitions and adjustments during fiscal 2013 | 20,899 | 5,554 | 7,137 | — | — | 33,590 | ||||||||||||||||||
Gross goodwill at September 30, 2013 | $ | 506,743 | $ | 156,792 | $ | 47,439 | $ | 18,593 | $ | 7,421 | $ | 736,988 | ||||||||||||
Accumulated goodwill impairments at September 30, 2011 | $ | (437,706 | ) | $ | (151,238 | ) | $ | — | $ | (18,593 | ) | $ | (7,421 | ) | $ | (614,958 | ) | |||||||
Impairments recorded during fiscal 2012 | — | — | — | — | — | — | ||||||||||||||||||
Accumulated goodwill impairments at September 30, 2012 | (437,706 | ) | (151,238 | ) | — | (18,593 | ) | (7,421 | ) | (614,958 | ) | |||||||||||||
Impairments recorded during fiscal 2013 | — | — | — | — | — | — | ||||||||||||||||||
Accumulated goodwill impairments at September 30, 2013 | $ | (437,706 | ) | $ | (151,238 | ) | $ | — | $ | (18,593 | ) | $ | (7,421 | ) | $ | (614,958 | ) | |||||||
Goodwill, less accumulated impairments at September 30, 2012 | $ | 48,138 | $ | — | $ | 40,302 | $ | — | $ | — | $ | 88,440 | ||||||||||||
Goodwill, less accumulated impairments at September 30, 2013 | $ | 69,037 | $ | 5,554 | $ | 47,439 | $ | — | $ | — | $ | 122,030 | ||||||||||||
Schedule of Impaired Intangible Assets | ' | |||||||||||||||||||||||
The impairment loss was recorded in the Brooks Life Science Systems segment. The impairment charge was allocated as follows (in thousands): | ||||||||||||||||||||||||
Year Ended September 30, 2013 | ||||||||||||||||||||||||
Reported as cost of revenue: | ||||||||||||||||||||||||
Completed technology intangible asset impairment | $ | 1,910 | ||||||||||||||||||||||
Reported as selling, general and administrative expense: | ||||||||||||||||||||||||
Trademarks and trade name intangible asset impairment | 50 | |||||||||||||||||||||||
Total impairment charges | $ | 1,960 | ||||||||||||||||||||||
Components of Identifiable Intangible Assets | ' | |||||||||||||||||||||||
Components of the Company’s identifiable intangible assets are as follows (in thousands): | ||||||||||||||||||||||||
30-Sep-13 | September 30, 2012 | |||||||||||||||||||||||
Cost | Accumulated | Net Book | Cost | Accumulated | Net Book | |||||||||||||||||||
Amortization | Value | Amortization | Value | |||||||||||||||||||||
Patents | $ | 7,808 | $ | 7,196 | $ | 612 | $ | 7,808 | $ | 7,093 | $ | 715 | ||||||||||||
Completed technology | 65,594 | 48,898 | 16,696 | 54,583 | 42,751 | 11,832 | ||||||||||||||||||
Trademarks and trade names | 4,013 | 4,003 | 10 | 4,014 | 3,880 | 134 | ||||||||||||||||||
Customer relationships | 70,490 | 27,720 | 42,770 | 48,654 | 21,935 | 26,719 | ||||||||||||||||||
$ | 147,905 | $ | 87,817 | $ | 60,088 | $ | 115,059 | $ | 75,659 | $ | 39,400 | |||||||||||||
Estimated Future Amortization Expense for Intangible Assets | ' | |||||||||||||||||||||||
Estimated future amortization expense for the intangible assets recorded by the Company as of September 30, 2013 is as follows (in millions): | ||||||||||||||||||||||||
Year ended September 30, | ||||||||||||||||||||||||
2014 | $10.10 | |||||||||||||||||||||||
2015 | 9.4 | |||||||||||||||||||||||
2016 | 8.7 | |||||||||||||||||||||||
2017 | 8 | |||||||||||||||||||||||
2018 | 6.1 | |||||||||||||||||||||||
Thereafter | 17.8 | |||||||||||||||||||||||
$60.10 |
Earnings_Per_Share_Tables
Earnings Per Share (Tables) | 12 Months Ended | |||||||||||
Sep. 30, 2013 | ||||||||||||
Earnings Per Share [Abstract] | ' | |||||||||||
Reconciliation of Weighted Average Shares Outstanding for Calculating Basic and Diluted Earnings Per Share | ' | |||||||||||
Below is a reconciliation of weighted average common shares outstanding for purposes of calculating basic and diluted earnings per share (in thousands, except per share data): | ||||||||||||
Year ended September 30, | ||||||||||||
2013 | 2012 | 2011 | ||||||||||
Net (loss) income attributable to Brooks Automation, Inc. | $ | (2,215 | ) | $ | 136,789 | $ | 130,385 | |||||
Weighted average common shares outstanding used in computing basic earnings per share | 65,912 | 65,128 | 64,549 | |||||||||
Dilutive common stock options and restricted stock awards | — | 594 | 454 | |||||||||
Weighted average common shares outstanding used in computing diluted earnings per share | 65,912 | 65,722 | 65,003 | |||||||||
Basic net (loss) income per share attributable to Brooks Automation, Inc. common stockholders | $ | (0.03 | ) | $ | 2.1 | $ | 2.02 | |||||
Diluted net (loss) income per share attributable to Brooks Automation, Inc. common stockholders | $ | (0.03 | ) | $ | 2.08 | $ | 2.01 | |||||
Derivative_Instruments_Tables
Derivative Instruments (Tables) | 12 Months Ended | ||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' | ||||||||||||||||||||
Notional Amounts Outstanding under Foreign Currency Contracts | ' | ||||||||||||||||||||
The Company had the following notional amounts outstanding under foreign currency contracts that qualify for cash flow hedge accounting at September 30, 2013 (in thousands): | |||||||||||||||||||||
Buy Currency | Notional Amount | Sell Currency | Maturity | Notional Amount | Fair Value of | Fair Value of | |||||||||||||||
of Buy Currency in U.S. Dollars | of Sell Currency | Assets | Liabilities | ||||||||||||||||||
in U.S. Dollars | |||||||||||||||||||||
U.S. Dollar | $ | 2,037 | Japanese Yen | Apr-14 | $ | 2,014 | $ | 23 | $ | — | |||||||||||
The Company had the following notional amounts outstanding under foreign currency contracts that do not qualify for hedge accounting at September 30, 2013 and 2012 (in thousands): | |||||||||||||||||||||
September 30, 2013: | |||||||||||||||||||||
Buy Currency | Notional Amount | Sell Currency | Maturity | Notional Amount | Fair Value of | Fair Value of | |||||||||||||||
of Buy Currency in U.S. Dollars | of Sell Currency | Assets | Liabilities | ||||||||||||||||||
in U.S. Dollars | |||||||||||||||||||||
U.S. Dollar | $ | 2,770 | Japanese Yen | October 2013 to December 2013 | $ | 2,762 | $ | 8 | $ | — | |||||||||||
Korean Won | 686 | U.S. Dollar | October 2013 | 688 | — | 2 | |||||||||||||||
U.S. Dollar | 301 | Israeli Shekel | October 2013 | 304 | — | 3 | |||||||||||||||
U.S. Dollar | 231 | Singapore Dollar | October 2013 | 231 | — | — | |||||||||||||||
$ | 3,988 | $ | 3,985 | $ | 8 | $ | 5 | ||||||||||||||
September 30, 2012: | |||||||||||||||||||||
Buy Currency | Notional Amount | Sell Currency | Maturity | Notional Amount | Fair Value of | Fair Value of | |||||||||||||||
of Buy Currency in U.S. Dollars | of Sell Currency | Assets | Liabilities | ||||||||||||||||||
in U.S. Dollars | |||||||||||||||||||||
U.S. Dollar | $ | 2,791 | Taiwan Dollar | October 2012 | $ | 2,786 | $ | 5 | $ | — | |||||||||||
U.S. Dollar | 1,842 | Israeli Shekel | October 2012 | 1,854 | — | 12 | |||||||||||||||
U.S. Dollar | 1,058 | Singapore Dollar | October 2012 | 1,056 | 2 | — | |||||||||||||||
U.S. Dollar | 806 | Korean Won | October 2012 | 803 | 3 | — | |||||||||||||||
U.S. Dollar | 611 | Japanese Yen | October 2012 | 611 | — | — | |||||||||||||||
U.S. Dollar | 524 | British Pound | October 2012 | 525 | — | 1 | |||||||||||||||
$ | 7,632 | $ | 7,635 | $ | 10 | $ | 13 | ||||||||||||||
Income_Taxes_Tables
Income Taxes (Tables) | 12 Months Ended | |||||||||||
Sep. 30, 2013 | ||||||||||||
Income Tax Disclosure [Abstract] | ' | |||||||||||
Components of Income Tax Provision (Benefit) | ' | |||||||||||
The components of the income tax provision (benefit) are as follows (in thousands): | ||||||||||||
Year Ended September 30, | ||||||||||||
2013 | 2012 | 2011 | ||||||||||
Current income tax provision (benefit): | ||||||||||||
Federal | $ | 15 | $ | 15 | $ | 16 | ||||||
State | 70 | 213 | 1,356 | |||||||||
Foreign | 681 | (1,374 | ) | 858 | ||||||||
Total current income tax provision (benefit) | 766 | (1,146 | ) | 2,230 | ||||||||
Deferred income tax (benefit): | ||||||||||||
Federal | (2,523 | ) | (118,432 | ) | — | |||||||
State | (90 | ) | (291 | ) | — | |||||||
Foreign | (323 | ) | (3,413 | ) | (276 | ) | ||||||
Total deferred income tax (benefit) | (2,936 | ) | (122,136 | ) | (276 | ) | ||||||
Income tax provision (benefit) | $ | (2,170 | ) | $ | (123,282 | ) | $ | 1,954 | ||||
Components of Income Before Income Taxes and Equity in Earnings of Joint Ventures | ' | |||||||||||
The components of income (loss) before income taxes and equity in earnings of joint ventures are as follows (in thousands): | ||||||||||||
Year Ended September 30, | ||||||||||||
2013 | 2012 | 2011 | ||||||||||
Domestic | $ | (6,968 | ) | $ | 2,204 | $ | 111,053 | |||||
Foreign | 206 | 9,216 | 16,523 | |||||||||
$ | (6,762 | ) | $ | 11,420 | $ | 127,576 | ||||||
Differences between Income Tax Provision (benefit) and Income Taxes Computed using Applicable U.S. Statutory Federal Tax Rate | ' | |||||||||||
The differences between the income tax provision (benefit) and income taxes computed using the applicable U.S. statutory federal tax rate is as follows (in thousands): | ||||||||||||
Year Ended September 30, | ||||||||||||
2013 | 2012 | 2011 | ||||||||||
Income tax provision computed at federal statutory rate | $ | (1,535 | ) | $ | 4,728 | $ | 45,736 | |||||
State income taxes, net of federal benefit | (8 | ) | 260 | 1,848 | ||||||||
Foreign income taxed at different rates | 493 | (832 | ) | (1,546 | ) | |||||||
Dividends | 115 | 956 | (219 | ) | ||||||||
Change in deferred tax asset valuation allowance | 523 | (125,479 | ) | (42,608 | ) | |||||||
Reduction in uncertain tax positions | (1,022 | ) | (3,732 | ) | (3,719 | ) | ||||||
Nondeductible compensation | 474 | 1,339 | 295 | |||||||||
Tax credits generated | (2,002 | ) | (1,195 | ) | (1,179 | ) | ||||||
Travel and entertainment | 124 | 139 | 119 | |||||||||
Merger costs | 251 | — | 315 | |||||||||
Other | 417 | 534 | 2,912 | |||||||||
Income tax provision (benefit) | $ | (2,170 | ) | $ | (123,282 | ) | $ | 1,954 | ||||
Significant Components of Net Deferred Tax Assets and Liabilities | ' | |||||||||||
The significant components of the net deferred tax assets and liabilities are as follows (in thousands): | ||||||||||||
September 30, | ||||||||||||
2013 | 2012 | |||||||||||
Accruals and reserves not currently deductible | $ | 11,050 | $ | 10,489 | ||||||||
Federal, state and foreign tax credits | 20,084 | 18,963 | ||||||||||
Other assets | 1,859 | 1,655 | ||||||||||
Net operating loss carryforwards | 101,717 | 101,713 | ||||||||||
Inventory reserves and valuation | 9,052 | 8,790 | ||||||||||
Deferred tax assets | 143,762 | 141,610 | ||||||||||
Depreciation and intangible amortization | 12,208 | 5,418 | ||||||||||
Deferred tax liabilities | 12,208 | 5,418 | ||||||||||
Valuation allowance | (16,509 | ) | (16,035 | ) | ||||||||
Net deferred tax asset | $ | 115,045 | $ | 120,157 | ||||||||
Reconciliation of Beginning and Ending Amount of Consolidated Liability for Unrecognized Income Tax Benefits | ' | |||||||||||
A reconciliation of the beginning and ending amount of the consolidated liability for unrecognized income tax benefits during the fiscal years ended September 30, 2013, 2012 and 2011 is as follows (in thousands): | ||||||||||||
Unrecognized Tax | Interest | Total | ||||||||||
Benefit | and | |||||||||||
Penalties | ||||||||||||
Balance at October 1, 2010 | $ | 12,816 | $ | 2,152 | $ | 14,968 | ||||||
Additions for tax positions of prior years | 184 | 447 | 631 | |||||||||
Additions for tax positions related to current year | 242 | — | 242 | |||||||||
Reductions from lapses in statutes of limitations | (961 | ) | — | (961 | ) | |||||||
Reductions from settlements with taxing authorities | (3,392 | ) | (610 | ) | (4,002 | ) | ||||||
Foreign exchange rate adjustment | 122 | — | 122 | |||||||||
Balance at September 30, 2011 | 9,011 | 1,989 | 11,000 | |||||||||
Additions for tax positions of prior years | 242 | 247 | 489 | |||||||||
Reductions from lapses in statutes of limitations | (3,125 | ) | (607 | ) | (3,732 | ) | ||||||
Foreign exchange rate adjustment | (167 | ) | 15 | (152 | ) | |||||||
Balance at September 30, 2012 | 5,961 | 1,644 | 7,605 | |||||||||
Additions for tax positions of prior years | — | 228 | 228 | |||||||||
Additions for tax positions related to acquired entities | 116 | — | 116 | |||||||||
Reductions from lapses in statutes of limitations | (944 | ) | (78 | ) | (1,022 | ) | ||||||
Foreign exchange rate adjustment | 14 | — | 14 | |||||||||
Balance at September 30, 2013 | $ | 5,147 | $ | 1,794 | $ | 6,941 | ||||||
Postretirement_Benefits_Tables
Postretirement Benefits (Tables) | 12 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Compensation and Retirement Disclosure [Abstract] | ' | |||||||||||||||
Funded Status and Amounts Recognized in Consolidated Balance Sheet | ' | |||||||||||||||
The Company uses a September 30th measurement date in the determination of net periodic benefit costs, benefit obligations and the value of plan assets for all plans. The following tables set forth the funded status and amounts recognized in the Company’s Consolidated Balance Sheets at September 30, 2013 and 2012 (in thousands): | ||||||||||||||||
September 30, | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Benefit obligation at beginning of year | $ | 10,181 | $ | 28,068 | ||||||||||||
Service cost | 604 | 787 | ||||||||||||||
Interest cost | 148 | 984 | ||||||||||||||
Actuarial (gain) loss | (670 | ) | 1,235 | |||||||||||||
Benefits paid | (1,421 | ) | (2,203 | ) | ||||||||||||
Settlement loss | — | 1,040 | ||||||||||||||
Settlements paid | (1,383 | ) | (18,928 | ) | ||||||||||||
Curtailment gain | (500 | ) | — | |||||||||||||
Foreign currency translation | 148 | (802 | ) | |||||||||||||
Benefit obligation at end of year | $ | 7,107 | $ | 10,181 | ||||||||||||
September 30, | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Fair value of assets at beginning of year | $ | 8,015 | $ | 20,173 | ||||||||||||
Actual return on plan assets | 304 | 1,446 | ||||||||||||||
Disbursements | (1,573 | ) | (2,463 | ) | ||||||||||||
Employer contributions | 292 | 7,684 | ||||||||||||||
Employee contributions | 194 | 334 | ||||||||||||||
Settlements paid | (1,383 | ) | (18,928 | ) | ||||||||||||
Foreign currency translation | 147 | (231 | ) | |||||||||||||
Fair value of assets at end of year | $ | 5,996 | $ | 8,015 | ||||||||||||
September 30, | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Funded status/accrued benefit liability | $ | (1,111 | ) | $ | (2,166 | ) | ||||||||||
Pension Amounts Recorded Within Account Line Items of Consolidated Balance Sheets | ' | |||||||||||||||
The following table provides pension amounts recorded within the account line items of the Company’s consolidated balance sheets (in thousands): | ||||||||||||||||
September 30, | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Accrued compensation and benefits | $ | 296 | $ | 478 | ||||||||||||
Long-term pension liability | 815 | 1,688 | ||||||||||||||
Net Periodic Pension Cost | ' | |||||||||||||||
The components of the Company’s net pension cost for the years ended September 30, 2013, 2012 and 2011 is as follows (in thousands): | ||||||||||||||||
Year ended September 30, | ||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||
Service cost | $ | 604 | $ | 787 | $ | 216 | ||||||||||
Interest cost | 148 | 984 | 796 | |||||||||||||
Expected return on assets | (247 | ) | (1,072 | ) | (764 | ) | ||||||||||
Amortization of losses | 4 | 620 | 458 | |||||||||||||
Other | 160 | — | — | |||||||||||||
Net periodic pension cost | 669 | 1,319 | 706 | |||||||||||||
Settlement loss | 87 | 8,937 | — | |||||||||||||
Total pension cost | $ | 756 | $ | 10,256 | $ | 706 | ||||||||||
Other changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Loss | ' | |||||||||||||||
Other changes in Plan assets and benefit obligations recognized in other comprehensive loss (in thousands): | ||||||||||||||||
September 30, | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Net (gain) loss | $ | (791 | ) | $ | 1,226 | |||||||||||
Amortization of net loss | (3 | ) | (620 | ) | ||||||||||||
Curtailment loss | (675 | ) | — | |||||||||||||
Settlement loss | (87 | ) | (8,937 | ) | ||||||||||||
Total recognized in other comprehensive income (loss) | (1,556 | ) | (8,331 | ) | ||||||||||||
Total recognized in net periodic pension cost and other comprehensive income (loss) | $ | (887 | ) | $ | (7,012 | ) | ||||||||||
Certain Information for the Plan with Respect to Accumulated Benefit Obligations | ' | |||||||||||||||
Certain information for the Plans with respect to accumulated benefit obligations follows (in thousands): | ||||||||||||||||
September 30, | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Projected benefit obligation | $ | 7,107 | $ | 10,181 | ||||||||||||
Accumulated benefit obligation | 6,272 | 8,906 | ||||||||||||||
Fair value of plan assets | 5,996 | 8,015 | ||||||||||||||
Weighted-Average Assumptions Used to Determine Net Cost or Pension Obligation | ' | |||||||||||||||
Weighted-average assumptions used to determine net cost at September 30, 2013, 2012 and 2011 follows: | ||||||||||||||||
Year Ended September 30, | ||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||
Discount rate | 2.15 | % | 3.51 | % | 3.99 | % | ||||||||||
Expected return on plan assets | 2.17 | % | 2.18 | % | 4.68 | % | ||||||||||
Rate of compensation increase | 1.89 | % | 1.84 | % | 1.79 | % | ||||||||||
Weighted-average assumptions used to determine the pension obligation at September 30, 2013, 2012 and 2011 follows: | ||||||||||||||||
Year Ended September 30, | ||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||
Discount rate | 2.15 | % | 1.89 | % | 3.76 | % | ||||||||||
Rate of compensation increase | 1.89 | % | 1.84 | % | 1.79 | % | ||||||||||
Asset Allocation of Plan Assets | ' | |||||||||||||||
The asset allocation of the plan assets at September 30, 2013 was as follows: | ||||||||||||||||
Percentage of | ||||||||||||||||
Plan Assets at | ||||||||||||||||
September 30, | ||||||||||||||||
2013 | ||||||||||||||||
Debt securities | 75 | % | ||||||||||||||
Equity securities | 5 | |||||||||||||||
Cash | 2 | |||||||||||||||
Other | 18 | |||||||||||||||
100 | % | |||||||||||||||
Fair Value of Pension Assets by Asset Category and by Level | ' | |||||||||||||||
The fair value of pension assets by asset category and by level at September 30, 2013 were as follows (in thousands): | ||||||||||||||||
As of September 30, 2013 | ||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Swiss Life collective foundation | $ | — | $ | 5,474 | $ | — | $ | 5,474 | ||||||||
Taiwan collective trust | — | 522 | — | 522 | ||||||||||||
Total | $ | — | $ | 5,996 | $ | — | $ | 5,996 | ||||||||
Expected Benefit Payments over the Next Ten Years | ' | |||||||||||||||
Expected benefit payments over the next ten years are anticipated to be paid as follows (in thousands): | ||||||||||||||||
2014 | $ | 232 | ||||||||||||||
2015 | 56 | |||||||||||||||
2016 | 57 | |||||||||||||||
2017 | 58 | |||||||||||||||
2018 | 59 | |||||||||||||||
2019-2023 | 583 | |||||||||||||||
Stock_Plans_Tables
Stock Plans (Tables) | 12 Months Ended | ||||||||||||
Sep. 30, 2013 | |||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ' | ||||||||||||
Stock Option Activity | ' | ||||||||||||
The following table summarizes stock option activity for all the above plans for the year ended September 30, 2013: | |||||||||||||
2013 | |||||||||||||
Shares | Weighted- | Weighted | Aggregate | ||||||||||
Average | Average Price | Intrinsic Value | |||||||||||
Remaining | (In Thousands) | ||||||||||||
Contractual Term | |||||||||||||
Options outstanding at September 30, 2012 | 193,182 | $ | 13.11 | ||||||||||
Exercised | (8,600 | ) | $ | 7.75 | |||||||||
Forfeited/expired | (169,042 | ) | $ | 13.13 | |||||||||
Options outstanding at September 30, 2013 | 15,540 | 0.8 years | $ | 15.86 | $ | — | |||||||
Vested at September 30, 2013 | 15,540 | 0.8 years | $ | 15.86 | $ | — | |||||||
Options exercisable at September 30, 2013 | 15,540 | 0.8 years | $ | 15.86 | $ | — | |||||||
Options available for future grant | 3,259,558 | ||||||||||||
Restricted Stock Activity | ' | ||||||||||||
A summary of the status of the Company’s restricted stock as of September 30, 2013 and changes during the year is as follows: | |||||||||||||
2013 | |||||||||||||
Shares | Weighted | ||||||||||||
Average | |||||||||||||
Grant-Date | |||||||||||||
Fair Value | |||||||||||||
Outstanding at September 30, 2012 | 2,732,448 | $ | 10.47 | ||||||||||
Awards granted | 1,471,977 | $ | 9.33 | ||||||||||
Awards vested | (755,187 | ) | $ | 9.67 | |||||||||
Awards canceled | (533,825 | ) | $ | 11.41 | |||||||||
Outstanding at September 30, 2013 | 2,915,413 | $ | 11.25 | ||||||||||
Restructuring_and_Other_Charge1
Restructuring and Other Charges (Tables) | 12 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Restructuring and Related Activities [Abstract] | ' | |||||||||||||||
Activity Related to Restructuring Accruals | ' | |||||||||||||||
The activity related to the Company’s restructuring and other charges are below (in thousands): | ||||||||||||||||
Fiscal 2013 Activity | ||||||||||||||||
Balance | Expense | Utilization | Balance | |||||||||||||
September 30, | September 30, | |||||||||||||||
2012 | 2013 | |||||||||||||||
Facilities and other | $ | — | $ | 818 | $ | (663 | ) | $ | 155 | |||||||
Workforce-related | 2,098 | 5,560 | (6,401 | ) | 1,257 | |||||||||||
$ | 2,098 | $ | 6,378 | $ | (7,064 | ) | $ | 1,412 | ||||||||
Fiscal 2012 Activity | ||||||||||||||||
Balance | Expense | Utilization | Balance | |||||||||||||
September 30, | September 30, | |||||||||||||||
2011 | 2012 | |||||||||||||||
Workforce-related | $ | 293 | $ | 3,275 | $ | (1,470 | ) | $ | 2,098 | |||||||
Fiscal 2011 Activity | ||||||||||||||||
Balance | Expense | Utilization | Balance | |||||||||||||
September 30, | September 30, | |||||||||||||||
2010 | 2011 | |||||||||||||||
Facilities and other | $ | 3,509 | $ | 310 | $ | (3,819 | ) | $ | — | |||||||
Workforce-related | — | 726 | (433 | ) | 293 | |||||||||||
$ | 3,509 | $ | 1,036 | $ | (4,252 | ) | $ | 293 | ||||||||
Segment_and_Geographic_Informa1
Segment and Geographic Information (Tables) | 12 Months Ended | |||||||||||||||||||
Sep. 30, 2013 | ||||||||||||||||||||
Segment Reporting [Abstract] | ' | |||||||||||||||||||
Financial Information for Business Segments | ' | |||||||||||||||||||
Financial information for the Company’s business segments is as follows (in thousands): | ||||||||||||||||||||
Brooks | Brooks | Brooks | Contract Manufacturing | Total | ||||||||||||||||
Product | Global | Life Science | ||||||||||||||||||
Solutions | Services | Systems | ||||||||||||||||||
Year ended September 30, 2013 | ||||||||||||||||||||
Revenue | ||||||||||||||||||||
Product | $ | 317,916 | $ | 13,152 | $ | 31,336 | $ | — | $ | 362,404 | ||||||||||
Services | — | 76,596 | 11,952 | — | 88,548 | |||||||||||||||
$ | 317,916 | $ | 89,748 | $ | 43,288 | $ | — | $ | 450,952 | |||||||||||
Gross profit | $ | 104,350 | $ | 27,492 | $ | 14,140 | $ | — | $ | 145,982 | ||||||||||
Segment operating income (loss) | $ | 8,509 | $ | 10,172 | $ | (12,380 | ) | $ | — | $ | 6,301 | |||||||||
Depreciation expense | $ | 9,022 | $ | 2,746 | $ | 2,256 | $ | — | $ | 14,024 | ||||||||||
Assets | $ | 254,424 | $ | 59,875 | $ | 105,221 | $ | — | $ | 419,520 | ||||||||||
Year ended September 30, 2012 | ||||||||||||||||||||
Revenue | ||||||||||||||||||||
Product | $ | 380,888 | $ | 11,324 | $ | 39,749 | $ | — | $ | 431,961 | ||||||||||
Services | — | 74,628 | 12,862 | — | 87,490 | |||||||||||||||
$ | 380,888 | $ | 85,952 | $ | 52,611 | $ | — | $ | 519,451 | |||||||||||
Gross profit | $ | 127,472 | $ | 25,599 | $ | 20,415 | $ | — | $ | 173,486 | ||||||||||
Segment operating income (loss) | $ | 21,319 | $ | 9,404 | $ | (3,139 | ) | $ | — | $ | 27,584 | |||||||||
Depreciation expense | $ | 8,952 | $ | 2,344 | $ | 2,111 | $ | — | $ | 13,407 | ||||||||||
Assets | $ | 218,799 | $ | 56,120 | $ | 107,530 | $ | — | $ | 382,449 | ||||||||||
Year ended September 30, 2011 | ||||||||||||||||||||
Revenue | ||||||||||||||||||||
Product | $ | 451,287 | $ | 14,786 | $ | 7,715 | $ | 137,329 | $ | 611,117 | ||||||||||
Services | — | 74,058 | 2,930 | $ | — | 76,988 | ||||||||||||||
$ | 451,287 | $ | 88,844 | $ | 10,645 | $ | 137,329 | $ | 688,105 | |||||||||||
Gross profit | $ | 171,801 | $ | 31,750 | $ | 2,260 | $ | 17,210 | $ | 223,021 | ||||||||||
Segment operating income (loss) | $ | 64,921 | $ | 13,293 | $ | (4,684 | ) | $ | 10,649 | $ | 84,179 | |||||||||
Depreciation expense | $ | 8,597 | $ | 2,481 | $ | 543 | $ | 1,000 | $ | 12,621 | ||||||||||
Assets | $ | 235,322 | $ | 52,354 | $ | 101,331 | $ | — | $ | 389,007 | ||||||||||
Reconciliation of Reportable Segment Operating Income to Corresponding Consolidated Amounts | ' | |||||||||||||||||||
As of and for the Year Ended | ||||||||||||||||||||
September 30, | ||||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||
Segment operating income | $ | 6,301 | $ | 27,584 | $ | 84,179 | ||||||||||||||
Other unallocated corporate expenses(1) | 3,002 | (1,833 | ) | 1,135 | ||||||||||||||||
Amortization of acquired intangible assets | 5,853 | 4,618 | 2,411 | |||||||||||||||||
Restructuring and other charges | 6,465 | 3,275 | 1,036 | |||||||||||||||||
Pension settlement | — | 8,937 | — | |||||||||||||||||
In-process research and development | — | 3,026 | — | |||||||||||||||||
Total operating income (loss) | $ | (9,019 | ) | $ | 9,561 | $ | 79,597 | |||||||||||||
Reconciliation of Reportable Segment Assets to Corresponding Consolidated Amounts | ' | |||||||||||||||||||
Segment assets | $ | 419,520 | $ | 382,449 | ||||||||||||||||
Cash, cash equivalents, restricted cash and marketable securities | 173,539 | 200,994 | ||||||||||||||||||
Deferred tax assets | 115,985 | 120,157 | ||||||||||||||||||
Investments in joint ventures | 25,687 | 31,428 | ||||||||||||||||||
Other unallocated corporate net assets | 2,032 | 6,932 | ||||||||||||||||||
Total assets | $ | 736,763 | $ | 741,960 | ||||||||||||||||
Net Revenues by Geographic Area | ' | |||||||||||||||||||
Net revenue based upon the source of the order by geographic area is as follows (in thousands): | ||||||||||||||||||||
Year Ended September 30, | ||||||||||||||||||||
2013 | 2012 | 2011 | ||||||||||||||||||
North America | $ | 193,222 | $ | 230,735 | $ | 349,456 | ||||||||||||||
Asia/Pacific | 165,452 | 194,711 | 244,524 | |||||||||||||||||
Europe | 92,278 | 94,005 | 94,125 | |||||||||||||||||
$ | 450,952 | $ | 519,451 | $ | 688,105 | |||||||||||||||
Long-Lived Assets, Consisting of Property, Plant and Equipment by Geographic Area | ' | |||||||||||||||||||
roperty, plant and equipment by geographic area are as follows (in thousands): | ||||||||||||||||||||
September 30, | ||||||||||||||||||||
2013 | 2012 | |||||||||||||||||||
North America | $ | 38,869 | $ | 51,546 | ||||||||||||||||
Asia/Pacific | 1,646 | 2,123 | ||||||||||||||||||
Europe | 7,355 | 10,809 | ||||||||||||||||||
$ | 47,870 | $ | 64,478 | |||||||||||||||||
Other_Balance_Sheet_Informatio1
Other Balance Sheet Information (Tables) | 12 Months Ended | ||||||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' | ||||||||||||||||||||
Summary of Accounts Receivable | ' | ||||||||||||||||||||
The following is a summary of accounts receivable at September 30, 2013 and 2012 (in thousands): | |||||||||||||||||||||
September 30, | |||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||
Accounts receivable | $ | 78,460 | $ | 79,706 | |||||||||||||||||
Less allowance for doubtful accounts | (863 | ) | (851 | ) | |||||||||||||||||
Less allowance for sales returns | (114 | ) | — | ||||||||||||||||||
$ | 77,483 | $ | 78,855 | ||||||||||||||||||
Allowance for Doubtful Accounts Activity | ' | ||||||||||||||||||||
The allowance for doubtful accounts activity for the years ended September 30, 2013, 2012 and 2011 were as follows (in thousands): | |||||||||||||||||||||
Description | Balance at | Provisions | Reversals of | Write-offs and | Balance at | ||||||||||||||||
Beginning of | Bad Debt | Adjustments | End of | ||||||||||||||||||
Period | Expense | Period | |||||||||||||||||||
2013 Allowance for doubtful accounts | $ | 851 | $ | 48 | $ | (143 | ) | $ | 107 | $ | 863 | ||||||||||
2012 Allowance for doubtful accounts | 617 | 367 | (130 | ) | (3 | ) | 851 | ||||||||||||||
2011 Allowance for doubtful accounts | 491 | — | — | 126 | 617 | ||||||||||||||||
As part of the acquisition of Crossing in fiscal year 2013, the Company acquired a contract in which a certain customer has a right of return on the purchase of spare parts. The allowance for returns activity for the year ended September 30, 2013 was as follows (in thousands): | |||||||||||||||||||||
Description | Balance at | Provisions | Write-offs and | Balance at | |||||||||||||||||
Beginning of | Adjustments | End of | |||||||||||||||||||
Period | Period | ||||||||||||||||||||
2013 Allowance for sales returns | $ | — | $ | 72 | $ | 42 | $ | 114 | |||||||||||||
Summary of Inventories | ' | ||||||||||||||||||||
The following is a summary of inventories at September 30, 2013 and 2012 (in thousands): | |||||||||||||||||||||
September 30, | |||||||||||||||||||||
2013 | 2012 | ||||||||||||||||||||
Inventories | |||||||||||||||||||||
Raw materials and purchased parts | $ | 60,106 | $ | 64,732 | |||||||||||||||||
Work-in-process | 20,256 | 20,800 | |||||||||||||||||||
Finished goods | 17,357 | 17,453 | |||||||||||||||||||
$ | 97,719 | $ | 102,985 | ||||||||||||||||||
Product Warranty and Retrofit Activity on a Gross Basis | ' | ||||||||||||||||||||
The Company provides for the estimated cost of product warranties, primarily from historical information, at the time product revenue is recognized and retrofit accruals at the time retrofit programs are established. The Company’s warranty obligation is affected by product failure rates, utilization levels, material usage, service delivery costs incurred in correcting a product failure, and supplier warranties on parts delivered to the Company. Product warranty and retrofit activity on a gross basis for the years ended September 30, 2013, 2012 and 2011 is as follows (in thousands): | |||||||||||||||||||||
Balance at September 30, 2010 | $ | 8,195 | |||||||||||||||||||
Adjustments for acquisitions and divestitures | 698 | ||||||||||||||||||||
Accruals for warranties during the year | 11,299 | ||||||||||||||||||||
Costs incurred during the year | (12,754 | ) | |||||||||||||||||||
Balance at September 30, 2011 | 7,438 | ||||||||||||||||||||
Adjustments for acquisitions and divestitures | 7 | ||||||||||||||||||||
Accruals for warranties during the year | 13,751 | ||||||||||||||||||||
Costs incurred during the year | (13,867 | ) | |||||||||||||||||||
Balance at September 30, 2012 | 7,329 | ||||||||||||||||||||
Adjustments for acquisitions and divestitures | 1,187 | ||||||||||||||||||||
Accruals for warranties during the year | 10,111 | ||||||||||||||||||||
Costs incurred during the year | (11,278 | ) | |||||||||||||||||||
Balance at September 30, 2013 | $ | 7,349 | |||||||||||||||||||
Sale_of_Building_and_Land_Tabl
Sale of Building and Land (Tables) | 12 Months Ended | |||
Sep. 30, 2013 | ||||
Real Estate [Abstract] | ' | |||
Schedule of Realized Gain on Sale of Building and Land | ' | |||
On September 27, 2013, the Company completed a Purchase and Sale Agreement ("Agreement") to sell a portion of its Chelmsford, Massachusetts campus to a real estate investment trust for $11.3 million. The property sold is an underutilized building and the related land. The components of the gain on the sale is as follows (in thousands): | ||||
Sale proceeds | $ | 11,275 | ||
Net book value of building and land | (6,095 | ) | ||
Deferred leasing costs and other | (3,718 | ) | ||
Direct transaction costs | (437 | ) | ||
Gain on the sale of building and land | $ | 1,025 | ||
Commitments_and_Contingencies_
Commitments and Contingencies (Tables) | 12 Months Ended | |||
Sep. 30, 2013 | ||||
Commitments and Contingencies Disclosure [Abstract] | ' | |||
Future Minimum Lease Commitments on Non-cancelable Operating Leases, Lease Income and Sublease Income | ' | |||
Future minimum lease commitments on non-cancelable operating leases are as follows (in thousands): | ||||
Operating | ||||
Leases | ||||
Year ended September 30, 2014 | $ | 7,199 | ||
2015 | 5,084 | |||
2016 | 2,728 | |||
2017 | 1,557 | |||
2018 | 1,359 | |||
Thereafter | 1,625 | |||
$ | 19,552 | |||
Summary_of_Significant_Account3
Summary of Significant Accounting Policies - Additional Information (Detail) (USD $) | 12 Months Ended | 3 Months Ended | 12 Months Ended | 12 Months Ended | |||||||||||||||||||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2011 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2011 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | |
reporting_unit | Restricted stock | Restricted stock | Restricted stock | Restricted stock | Restricted stock | Restricted stock | Restricted stock | Restricted stock | Restricted stock | Restricted stock | Restricted stock | Restricted stock | Restricted stock | Restricted stock | Top Ten Largest Customers | Customer 1 | Customer 1 | Brooks Product Solutions | Brooks Global Services | Brooks Life Science Systems | |||
Minimum | Maximum | Senior Management | Senior Management | Senior Management | Senior Management | Senior Management | Senior Management | Senior Management | Senior Management | Chief Executive Officer | Chief Executive Officer | Chief Executive Officer | reporting_unit | reporting_unit | reporting_unit | ||||||||
Maximum | Maximum | Awards subject to service criteria | Awards subject to service criteria | Awards subject to performance criteria | Awards subject to performance criteria | Phantom Stock Units | Phantom Stock Units | Phantom Stock Units | |||||||||||||||
Accounting Policies [Abstract] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net foreign currency transaction losses | $900,000 | $400,000 | $100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cash equivalents | 7,800,000 | 17,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cash distributions received from joint ventures reclassified on cash flows | ' | 5,100,000 | 2,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Number of Reporting Units, Goodwill Balances | 5 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3 | 1 | 1 |
Concentration Risk [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of revenues by customer | 11.00% | 13.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 39.00% | 11.00% | 15.00% | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restricted stocks granted | ' | ' | ' | 1,471,977 | ' | ' | 1,394,000 | 1,527,000 | ' | ' | ' | ' | ' | ' | 100,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Restricted stocks vested | ' | ' | ' | 755,187 | ' | ' | ' | ' | ' | ' | 716,625 | 406,750 | 677,375 | 1,120,250 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total compensation expense on awards | 7,757,000 | 8,647,000 | 6,752,000 | ' | ' | ' | ' | ' | 15,100,000 | 14,400,000 | ' | ' | ' | ' | ' | 78,000 | ' | ' | ' | ' | ' | ' | ' |
Liability related to potential cash payment | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $78,000 | $0 | ' | ' | ' | ' | ' | ' |
Equity incentive plan, vesting period | ' | ' | ' | ' | '2 years | '4 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares available for grant | 3,259,558 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Summary_of_Significant_Account4
Summary of Significant Accounting Policies - Summary of Depreciable Lives (Detail) | 12 Months Ended |
Sep. 30, 2013 | |
Buildings | Minimum | ' |
Property, Plant and Equipment [Line Items] | ' |
Depreciable lives | '20 years |
Buildings | Maximum | ' |
Property, Plant and Equipment [Line Items] | ' |
Depreciable lives | '40 years |
Computer equipment and software | Minimum | ' |
Property, Plant and Equipment [Line Items] | ' |
Depreciable lives | '2 years |
Computer equipment and software | Maximum | ' |
Property, Plant and Equipment [Line Items] | ' |
Depreciable lives | '7 years |
Machinery and equipment | Minimum | ' |
Property, Plant and Equipment [Line Items] | ' |
Depreciable lives | '2 years |
Machinery and equipment | Maximum | ' |
Property, Plant and Equipment [Line Items] | ' |
Depreciable lives | '10 years |
Furniture and fixtures | Minimum | ' |
Property, Plant and Equipment [Line Items] | ' |
Depreciable lives | '3 years |
Furniture and fixtures | Maximum | ' |
Property, Plant and Equipment [Line Items] | ' |
Depreciable lives | '10 years |
Summary_of_Significant_Account5
Summary of Significant Accounting Policies - Summary of Amortizable Lives of Intangible Assets (Detail) | 12 Months Ended |
Sep. 30, 2013 | |
Patents | Minimum | ' |
Finite-Lived Intangible Assets [Line Items] | ' |
Amortizable lives | '7 years |
Patents | Maximum | ' |
Finite-Lived Intangible Assets [Line Items] | ' |
Amortizable lives | '15 years |
Completed technology | Minimum | ' |
Finite-Lived Intangible Assets [Line Items] | ' |
Amortizable lives | '2 years |
Completed technology | Maximum | ' |
Finite-Lived Intangible Assets [Line Items] | ' |
Amortizable lives | '10 years |
License agreements | ' |
Finite-Lived Intangible Assets [Line Items] | ' |
Amortizable lives | '5 years |
Trademarks and trade names | Minimum | ' |
Finite-Lived Intangible Assets [Line Items] | ' |
Amortizable lives | '2 years |
Trademarks and trade names | Maximum | ' |
Finite-Lived Intangible Assets [Line Items] | ' |
Amortizable lives | '6 years |
Non-competition agreements | Minimum | ' |
Finite-Lived Intangible Assets [Line Items] | ' |
Amortizable lives | '3 years |
Non-competition agreements | Maximum | ' |
Finite-Lived Intangible Assets [Line Items] | ' |
Amortizable lives | '5 years |
Customer relationships | Minimum | ' |
Finite-Lived Intangible Assets [Line Items] | ' |
Amortizable lives | '4 years |
Customer relationships | Maximum | ' |
Finite-Lived Intangible Assets [Line Items] | ' |
Amortizable lives | '13 years |
Summary_of_Significant_Account6
Summary of Significant Accounting Policies - Compensation Expense (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
Stock-based compensation | $7,757 | $8,647 | $6,752 |
Restricted stock | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
Stock-based compensation | 7,261 | 8,098 | 6,248 |
Employee stock purchase plan | ' | ' | ' |
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] | ' | ' | ' |
Stock-based compensation | $496 | $549 | $504 |
Summary_of_Significant_Account7
Summary of Significant Accounting Policies - Fair Value of Shares Issued under Employee Stock Purchase Plan Estimated using Black-Scholes Option Pricing Model (Detail) | 12 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Risk-free interest rate | 0.10% | 0.10% | 0.20% |
Volatility | 32.00% | 45.00% | 50.00% |
Expected life | '6 months | '6 months | '6 months |
Minimum | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Dividend yield | 3.30% | 2.75% | 0.00% |
Maximum | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' |
Dividend yield | 3.40% | 3.30% | 3.00% |
Acquisitions_and_Divestiture_A
Acquisitions and Divestiture - Additional Information (Detail) (USD $) | 3 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | |||||||||||||||||||||||||
Sep. 30, 2011 | Jun. 30, 2011 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Aug. 01, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Oct. 29, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Mar. 31, 2012 | Dec. 31, 2011 | Sep. 30, 2013 | Dec. 30, 2011 | Dec. 30, 2011 | Sep. 30, 2012 | Jul. 25, 2011 | Jul. 25, 2011 | Jul. 25, 2011 | Sep. 30, 2012 | Apr. 02, 2011 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Jul. 25, 2011 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Jul. 25, 2011 | Sep. 30, 2013 | Jul. 25, 2011 | Jul. 25, 2011 | |
Matrical | Matrical | Matrical | Crossing Automation Inc | Crossing Automation Inc | Crossing Automation Inc | Crossing Automation Inc | Crossing Automation Inc | Crossing Automation Inc | Intevac, Inc. | CeligoCell Cytometer product line | CeligoCell Cytometer product line | CeligoCell Cytometer product line | CeligoCell Cytometer product line | Nexus | Nexus | Nexus | Nexus | RTS | RTS | RTS | RTS | Minimum | Minimum | Minimum | Minimum | Maximum | Maximum | Maximum | Maximum | System General | Consumables | ||||||
Completed technology | Customer relationships | Banker fees | Incentive compensation payments | Completed technology | Customer relationships | Completed technology | Completed technology | Trade Names | Customer relationships | Trademarks and trade names | Completed technology | Customer relationships | Nexus | RTS | Completed technology | Customer relationships | Nexus | RTS | Nexus | Nexus | |||||||||||||||||
Customer relationships | Completed technology | Customer relationships | Completed technology | Customer relationships | Customer relationships | ||||||||||||||||||||||||||||||||
Business Acquisition [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Business acquisition, cash payment | ' | ' | ' | ' | ' | $9,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $8,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cash flow discount rate | ' | ' | ' | ' | ' | 18.00% | ' | ' | ' | ' | ' | ' | 15.00% | ' | ' | ' | ' | ' | 25.00% | ' | ' | 17.00% | ' | ' | ' | ' | ' | ' | ' | 17.00% | ' | ' | ' | 18.00% | ' | ' | ' |
Amortizable lives | ' | ' | ' | ' | ' | ' | '4 years 7 months | '7 years | ' | ' | ' | ' | '7 years 8 months | '8 years | ' | ' | ' | ' | ' | ' | ' | '6 years | '2 years | ' | ' | '7 years | '3 years | '2 years | '4 years | ' | '5 years | '10 years | '13 years | ' | '7 years | '6 years | '13 years |
Transaction costs | ' | ' | ' | ' | ' | 300,000 | ' | ' | 3,600,000 | ' | 1,500,000 | 1,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue of acquiree | ' | ' | ' | ' | ' | ' | ' | ' | 41,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net loss of acquiree | ' | ' | ' | ' | ' | ' | ' | ' | 2,600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Inventory Step Up | ' | ' | ' | ' | ' | ' | ' | ' | 2,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amortization | ' | ' | ' | ' | ' | ' | ' | ' | 3,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total purchase price, net of cash acquired | ' | ' | ' | ' | ' | 9,326,000 | ' | ' | ' | 59,005,000 | ' | ' | ' | ' | 3,000,000 | ' | ' | 9,216,000 | ' | ' | 84,928,000 | ' | ' | ' | 3,381,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Royalty Payment Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Transaction costs related to acquisition | ' | ' | ' | ' | ' | ' | ' | ' | 600,000 | ' | ' | ' | ' | ' | ' | 100,000 | ' | ' | ' | 719,000 | ' | ' | ' | 188,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Business acquisition deferred cash payable | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Impairment loss | 614,958,000 | ' | 614,958,000 | 614,958,000 | 614,958,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,960,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Revenues | ' | ' | 450,952,000 | 519,451,000 | 688,105,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,900,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net Income (Loss) Attributable to Parent | ' | ' | -2,215,000 | 136,789,000 | 130,385,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -3,200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Writeoff Of Fair Value Stepup On Acquired Inventories | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Inventory Write-down | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Proceeds from the sale of the contract manufacturing business | ' | ' | 0 | 0 | 78,249,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Noncash or Part Noncash Divestiture, Amount of Consideration Received | ' | ' | ' | ' | 1,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Additional Proceeds From Sale Of Assets | 2,500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cost Of Disposal Disposal Group Including Discontinued Operations Transaction Costs | ' | ' | ' | ' | 2,300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Gain on sale of contract manufacturing business | ' | 45,000,000 | 0 | 0 | 45,009,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Gain (Loss) on Sale of Properties, Applicable Income Taxes | ' | $2,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Marketable_Securities_Summary_
Marketable Securities - Summary of Marketable Securities Including Accrued Interest Receivable (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||
Schedule of Available-for-sale Securities [Line Items] | ' | ' |
Amortized Cost | $90,404 | $145,391 |
Gross Unrealized Gains | 57 | 221 |
Gross Unrealized Losses | -70 | -20 |
Fair Value | 90,391 | 145,592 |
U.S. Treasury securities and obligations of U.S. government agencies | ' | ' |
Schedule of Available-for-sale Securities [Line Items] | ' | ' |
Amortized Cost | 19,528 | 41,202 |
Gross Unrealized Gains | 6 | 15 |
Gross Unrealized Losses | -13 | -2 |
Fair Value | 19,521 | 41,215 |
Corporate securities | ' | ' |
Schedule of Available-for-sale Securities [Line Items] | ' | ' |
Amortized Cost | 35,045 | 64,102 |
Gross Unrealized Gains | 11 | 138 |
Gross Unrealized Losses | -47 | -16 |
Fair Value | 35,009 | 64,224 |
Mortgage-backed securities | ' | ' |
Schedule of Available-for-sale Securities [Line Items] | ' | ' |
Amortized Cost | 1,093 | 1,310 |
Gross Unrealized Gains | 25 | 42 |
Gross Unrealized Losses | -1 | -1 |
Fair Value | 1,117 | 1,351 |
Other debt securities | ' | ' |
Schedule of Available-for-sale Securities [Line Items] | ' | ' |
Amortized Cost | 88 | 13 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | 88 | 13 |
Municipal securities | ' | ' |
Schedule of Available-for-sale Securities [Line Items] | ' | ' |
Amortized Cost | 25,199 | 34,777 |
Gross Unrealized Gains | 15 | 25 |
Gross Unrealized Losses | -7 | -1 |
Fair Value | 25,207 | 34,801 |
Bank certificate of deposits | ' | ' |
Schedule of Available-for-sale Securities [Line Items] | ' | ' |
Amortized Cost | 9,451 | 3,987 |
Gross Unrealized Gains | 0 | 1 |
Gross Unrealized Losses | -2 | 0 |
Fair Value | $9,449 | $3,988 |
Acquisitions_and_Divestiture_A1
Acquisitions and Divestiture - Amounts of Assets and Liabilities at Fair Value as of Acquisition Date (Detail) (USD $) | Aug. 01, 2013 | Aug. 01, 2013 | Aug. 01, 2013 | Oct. 29, 2012 | Oct. 29, 2012 | Oct. 29, 2012 | Dec. 30, 2011 | Dec. 30, 2011 | Dec. 30, 2011 | Jul. 25, 2011 | Jul. 25, 2011 | Jul. 25, 2011 | Jul. 25, 2011 | Apr. 02, 2011 | Apr. 02, 2011 | Apr. 02, 2011 | Apr. 02, 2011 |
In Thousands, unless otherwise specified | Matrical | Matrical | Matrical | Crossing Automation Inc | Crossing Automation Inc | Crossing Automation Inc | CeligoCell Cytometer product line | CeligoCell Cytometer product line | CeligoCell Cytometer product line | Nexus | Nexus | Nexus | Nexus | RTS | RTS | RTS | RTS |
Completed technology | Customer relationships | Completed technology | Customer relationships | Completed technology | Trademarks and trade names | Completed technology | Customer relationships | Trademarks and trade names | Completed technology | Customer relationships | Trademarks and trade names | ||||||
Business Acquisition [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accounts receivable | $636 | ' | ' | $5,356 | ' | ' | $897 | ' | ' | $5,708 | ' | ' | ' | $3,156 | ' | ' | ' |
Inventory | 2,095 | ' | ' | 8,668 | ' | ' | 1,139 | ' | ' | 7,481 | ' | ' | ' | 1,668 | ' | ' | ' |
Prepaid expenses and other current assets | 103 | ' | ' | 1,968 | ' | ' | ' | ' | ' | 4,522 | ' | ' | ' | 1,008 | ' | ' | ' |
Property, plant and equipment | 534 | ' | ' | 2,270 | ' | ' | 202 | ' | ' | 12,527 | ' | ' | ' | 860 | ' | ' | ' |
Identifiable intangible assets | ' | 500 | 1,500 | ' | 10,530 | 20,010 | ' | 3,540 | 70 | ' | 6,000 | 31,000 | 100 | ' | 1,524 | 577 | 64 |
Goodwill | 7,137 | ' | ' | 26,453 | ' | ' | 3,713 | ' | ' | 33,033 | ' | ' | ' | 3,556 | ' | ' | ' |
Debt | -902 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other long term assets | ' | ' | ' | 885 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accounts payable | -294 | ' | ' | -3,024 | ' | ' | -13 | ' | ' | ' | ' | ' | ' | -1,397 | ' | ' | ' |
Accrued liabilities | ' | ' | ' | -5,172 | ' | ' | ' | ' | ' | -6,563 | ' | ' | ' | ' | ' | ' | ' |
Deferred revenue | -412 | ' | ' | -319 | ' | ' | -326 | ' | ' | -3,692 | ' | ' | ' | -5,232 | ' | ' | ' |
Customer deposits | -1,249 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other current liabilities | -322 | ' | ' | -388 | ' | ' | -6 | ' | ' | -1,534 | ' | ' | ' | -2,403 | ' | ' | ' |
Deferred tax liabilities | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,584 | ' | ' | ' | ' | ' | ' | ' |
Other long-term liabilities | ' | ' | ' | -8,232 | ' | ' | ' | ' | ' | -1,070 | ' | ' | ' | ' | ' | ' | ' |
Total purchase price, net of cash acquired | $9,326 | ' | ' | $59,005 | ' | ' | $9,216 | ' | ' | $84,928 | ' | ' | ' | $3,381 | ' | ' | ' |
Marketable_Securities_Addition
Marketable Securities - Additional Information (Detail) (USD $) | 12 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |
Investments, Debt and Equity Securities [Abstract] | ' | ' | ' |
Gross realized gains on sales of available-for-sale marketable securities | $57,000 | $15,000 | $24,000 |
Gross realized losses on sales of available-for-sale marketable securities | $36,000 | $0 | $0 |
Acquisitions_and_Divestiture_P
Acquisitions and Divestiture - Pro Forma Information (Detail) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 |
Crossing Automation Inc | ' | ' |
Business Acquisition [Line Items] | ' | ' |
Revenue | $453,045 | $570,864 |
Net income (loss) attributable to Brooks Automation, Inc. | -3,216 | 135,245 |
Nexus | ' | ' |
Business Acquisition [Line Items] | ' | ' |
Revenue | ' | 720,989 |
Net income (loss) attributable to Brooks Automation, Inc. | ' | $124,114 |
Marketable_Securities_Fair_Val
Marketable Securities - Fair Value of Marketable Securities by Contractual Maturity (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||
Investments, Debt and Equity Securities [Abstract] | ' | ' |
Due in one year or less | $45,900 | ' |
Due after one year through five years | 41,194 | ' |
Due after ten years | 3,297 | ' |
Fair Value | $90,391 | $145,592 |
Fair_Value_Measurements_Assets
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||
Assets | ' | ' |
Available-for-sale securities | $90,391 | $145,592 |
Fair Value, Measurements, Recurring | ' | ' |
Assets | ' | ' |
Cash equivalents | 7,754 | 17,508 |
Available-for-sale securities | 90,391 | 145,592 |
Foreign exchange contracts | 31 | 10 |
Total Assets | 98,176 | 163,110 |
Liabilities | ' | ' |
Foreign exchange contracts | 5 | 13 |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | ' | ' |
Assets | ' | ' |
Cash equivalents | 6,152 | 17,508 |
Available-for-sale securities | 2,199 | 60,231 |
Foreign exchange contracts | ' | 0 |
Total Assets | 8,351 | 77,739 |
Liabilities | ' | ' |
Foreign exchange contracts | ' | 0 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | ' | ' |
Assets | ' | ' |
Cash equivalents | 1,602 | 0 |
Available-for-sale securities | 88,192 | 85,361 |
Foreign exchange contracts | 31 | 10 |
Total Assets | 89,825 | 85,371 |
Liabilities | ' | ' |
Foreign exchange contracts | $5 | $13 |
Fair_Value_Measurements_Additi
Fair Value Measurements - Additional Information (Details) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Available-for-sale securities | $90,391 | $145,592 |
Fair Value, Measurements, Recurring | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash equivalents | 7,754 | 17,508 |
Available-for-sale securities | 90,391 | 145,592 |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash equivalents | 6,152 | 17,508 |
Available-for-sale securities | 2,199 | 60,231 |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | ' | ' |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ' | ' |
Cash equivalents | 1,602 | 0 |
Available-for-sale securities | $88,192 | $85,361 |
Property_Plant_and_Equipment_S
Property, Plant and Equipment - Schedule (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||
Property, Plant and Equipment [Line Items] | ' | ' |
Property, plant and equipment, gross | $195,759 | $210,344 |
Less accumulated depreciation and amortization | -147,889 | -145,866 |
Property, plant and equipment, net | 47,870 | 64,478 |
Buildings and land | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, plant and equipment, gross | 38,539 | 55,352 |
Computer equipment and software | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, plant and equipment, gross | 72,927 | 70,719 |
Machinery and equipment | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, plant and equipment, gross | 55,375 | 51,813 |
Furniture and fixtures | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, plant and equipment, gross | 10,298 | 10,908 |
Leasehold improvements | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, plant and equipment, gross | 16,522 | 18,938 |
Capital projects in progress | ' | ' |
Property, Plant and Equipment [Line Items] | ' | ' |
Property, plant and equipment, gross | $2,098 | $2,614 |
Property_Plant_and_Equipment_A
Property, Plant and Equipment - Additional Information (Detail) (USD $) | 12 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Property, Plant and Equipment [Abstract] | ' | ' | ' |
Depreciation expense | $14 | $13.40 | $12.60 |
Goodwill_and_Intangible_Assets2
Goodwill and Intangible Assets - Additional Information (Detail) (USD $) | 12 Months Ended | 12 Months Ended | |||||||||||||||||||||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2013 | Dec. 30, 2011 | Dec. 30, 2011 | Oct. 29, 2012 | Oct. 29, 2012 | Aug. 01, 2013 | Aug. 01, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2013 | Oct. 29, 2012 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2013 | Oct. 29, 2012 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2013 | Sep. 30, 2013 | |
CeligoCell Cytometer product line | CeligoCell Cytometer product line | CeligoCell Cytometer product line | Crossing Automation Inc | Crossing Automation Inc | Matrical | Matrical | Brooks Life Science Systems | Brooks Life Science Systems | Brooks Life Science Systems | Brooks Product Solutions | Brooks Product Solutions | Brooks Product Solutions | Brooks Product Solutions | Brooks Global Services | Brooks Global Services | Brooks Global Services | Brooks Global Services | Minimum | Maximum | ||||
Completed technology | Trademarks and trade names | Completed technology | Customer relationships | Completed technology | Customer relationships | ||||||||||||||||||
Goodwill and Intangible Assets Disclosure [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Impairment loss | $1,960,000 | $0 | $0 | $1,960,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of fair value in excess of carrying amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.18 | 1.14 |
Discount rate used in discounted cash flow analysis | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Revenue multiple used in terminal value calculation | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.03 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill, Impaired, Accumulated Impairment Loss | 614,958,000 | 614,958,000 | 614,958,000 | 1,960,000 | ' | ' | ' | ' | ' | ' | 0 | 0 | 0 | 437,706,000 | ' | 437,706,000 | 437,706,000 | 151,238,000 | ' | 151,238,000 | 151,238,000 | ' | ' |
Identifiable intangible assets | ' | ' | ' | ' | 3,540,000 | 70,000 | 10,530,000 | 20,010,000 | 500,000 | 1,500,000 | ' | ' | ' | ' | 24,600,000 | ' | ' | ' | 5,900,000 | ' | ' | ' | ' |
Amortization expense for intangible assets | $10,100,000 | $8,200,000 | $4,600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Goodwill_and_Intangible_Assets3
Goodwill and Intangible Assets - Components of Goodwill by Business Segment (Detail) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 |
Goodwill [Roll Forward] | ' | ' |
Gross goodwill, period start | $703,398 | $699,685 |
Acquisitions and adjustments during fiscal year | 33,590 | 3,713 |
Gross goodwill, period end | 736,988 | 703,398 |
Accumulated goodwill impairments, beginning balance | -614,958 | -614,958 |
Impairments recorded during fiscal year | 0 | 0 |
Accumulated goodwill impairments, ending balance | -614,958 | -614,958 |
Goodwill, less accumulated impairments | 122,030 | 88,440 |
Brooks Product Solutions | ' | ' |
Goodwill [Roll Forward] | ' | ' |
Gross goodwill, period start | 485,844 | 485,844 |
Acquisitions and adjustments during fiscal year | 20,899 | 0 |
Gross goodwill, period end | 506,743 | 485,844 |
Accumulated goodwill impairments, beginning balance | -437,706 | -437,706 |
Impairments recorded during fiscal year | 0 | 0 |
Accumulated goodwill impairments, ending balance | -437,706 | -437,706 |
Goodwill, less accumulated impairments | 69,037 | 48,138 |
Brooks Global Services | ' | ' |
Goodwill [Roll Forward] | ' | ' |
Gross goodwill, period start | 151,238 | 151,238 |
Acquisitions and adjustments during fiscal year | 5,554 | 0 |
Gross goodwill, period end | 156,792 | 151,238 |
Accumulated goodwill impairments, beginning balance | -151,238 | -151,238 |
Impairments recorded during fiscal year | 0 | 0 |
Accumulated goodwill impairments, ending balance | -151,238 | -151,238 |
Goodwill, less accumulated impairments | 5,554 | 0 |
Brooks Life Science Systems | ' | ' |
Goodwill [Roll Forward] | ' | ' |
Gross goodwill, period start | 40,302 | 36,589 |
Acquisitions and adjustments during fiscal year | 7,137 | 3,713 |
Gross goodwill, period end | 47,439 | 40,302 |
Accumulated goodwill impairments, beginning balance | 0 | 0 |
Impairments recorded during fiscal year | 0 | 0 |
Accumulated goodwill impairments, ending balance | 0 | 0 |
Goodwill, less accumulated impairments | 47,439 | 40,302 |
Contract Manufacturing | ' | ' |
Goodwill [Roll Forward] | ' | ' |
Gross goodwill, period start | 18,593 | 18,593 |
Acquisitions and adjustments during fiscal year | 0 | 0 |
Gross goodwill, period end | 18,593 | 18,593 |
Accumulated goodwill impairments, beginning balance | -18,593 | -18,593 |
Impairments recorded during fiscal year | 0 | 0 |
Accumulated goodwill impairments, ending balance | -18,593 | -18,593 |
Goodwill, less accumulated impairments | 0 | 0 |
Other | ' | ' |
Goodwill [Roll Forward] | ' | ' |
Gross goodwill, period start | 7,421 | 7,421 |
Acquisitions and adjustments during fiscal year | 0 | 0 |
Gross goodwill, period end | 7,421 | 7,421 |
Accumulated goodwill impairments, beginning balance | -7,421 | -7,421 |
Impairments recorded during fiscal year | 0 | 0 |
Accumulated goodwill impairments, ending balance | -7,421 | -7,421 |
Goodwill, less accumulated impairments | $0 | $0 |
Goodwill_and_Intangible_Assets4
Goodwill and Intangible Assets - Components of Impaired Intangible Assets (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' |
Impairment loss | $1,960 | $0 | $0 |
CeligoCell Cytometer product line | ' | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' |
Impairment loss | 1,960 | ' | ' |
CeligoCell Cytometer product line | Cost of Revenue | Completed technology | ' | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' |
Impairment loss | 1,910 | ' | ' |
CeligoCell Cytometer product line | Selling, General and Administrative Expenses | Trademarks and trade names | ' | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' |
Impairment loss | $50 | ' | ' |
Goodwill_and_Intangible_Assets5
Goodwill and Intangible Assets - Components of Identifiable Intangible Assets (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Cost | $147,905 | $115,059 |
Accumulated Amortization | 87,817 | 75,659 |
Net Book Value | 60,088 | 39,400 |
Patents | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Cost | 7,808 | 7,808 |
Accumulated Amortization | 7,196 | 7,093 |
Net Book Value | 612 | 715 |
Completed technology | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Cost | 65,594 | 54,583 |
Accumulated Amortization | 48,898 | 42,751 |
Net Book Value | 16,696 | 11,832 |
Trademarks and trade names | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Cost | 4,013 | 4,014 |
Accumulated Amortization | 4,003 | 3,880 |
Net Book Value | 10 | 134 |
Customer relationships | ' | ' |
Finite-Lived Intangible Assets [Line Items] | ' | ' |
Cost | 70,490 | 48,654 |
Accumulated Amortization | 27,720 | 21,935 |
Net Book Value | $42,770 | $26,719 |
Goodwill_and_Intangible_Assets6
Goodwill and Intangible Assets - Estimated Future Amortization Expense for Intangible Assets (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
Goodwill and Intangible Assets Disclosure [Abstract] | ' | ' |
2013 | $10,100,000 | ' |
2014 | 9,400,000 | ' |
2015 | 8,700,000 | ' |
2016 | 8,000,000 | ' |
2017 | 6,100,000 | ' |
Thereafter | 17,800,000 | ' |
Net Book Value | $60,088,000 | $39,400,000 |
Investment_in_Affiliates_Addit
Investment in Affiliates - Additional information (Detail) (USD $) | 12 Months Ended | |||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2010 | |
Schedule of Equity Method Investments [Line Items] | ' | ' | ' | ' |
Equity investment in joint ventures | $25,687,000 | $31,428,000 | ' | ' |
Equity in earnings of joint ventures | 2,442,000 | 2,133,000 | 4,815,000 | ' |
ULVAC Cryogenics, Inc. | ' | ' | ' | ' |
Schedule of Equity Method Investments [Line Items] | ' | ' | ' | ' |
Joint venture interest, percentage | 50.00% | ' | ' | 50.00% |
Equity investment in joint ventures | 22,700,000 | 27,400,000 | ' | ' |
Equity in earnings of joint ventures | 2,600,000 | 2,000,000 | 4,300,000 | ' |
Management fee payments received | 600,000 | 1,000,000 | 1,100,000 | ' |
Charges for products or services | 500,000 | 800,000 | 400,000 | ' |
Accounts payable for unpaid products and services | 26,000 | 73,000 | ' | ' |
Cash dividend received | 5,000,000 | 5,100,000 | ' | ' |
Yaskawa Brooks Automation, Inc. | ' | ' | ' | ' |
Schedule of Equity Method Investments [Line Items] | ' | ' | ' | ' |
Joint venture interest, percentage | 50.00% | ' | ' | 50.00% |
Equity investment in joint ventures | 3,000,000 | 4,000,000 | ' | ' |
Equity in earnings of joint ventures | -200,000 | 100,000 | 500,000 | ' |
Revenues earned from joint ventures | 6,300,000 | 8,000,000 | 9,600,000 | ' |
Due from joint venture | 2,300,000 | 2,000,000 | ' | ' |
Charges for products or services | 500,000 | 500,000 | 300,000 | ' |
Accounts payable for unpaid products and services | $47,000 | $58,000 | ' | ' |
Earnings_per_Share_Reconciliat
Earnings per Share - Reconciliation of Weighted Average Common Shares Outstanding for Purposes of Calculating Basic and Diluted Earnings Per Share (Detail) (USD $) | 12 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Earnings Per Share [Abstract] | ' | ' | ' |
Net income attributable to Brooks Automation, Inc. | ($2,215) | $136,789 | $130,385 |
Weighted average common shares outstanding used in computing basic earnings per share | 65,912 | 65,128 | 64,549 |
Dilutive common stock options and restricted stock awards | 0 | 594 | 454 |
Weighted average common shares outstanding for purposes of computing diluted earnings per share | 65,912 | 65,722 | 65,003 |
Basic net income per share attributable to Brooks Automation, Inc. common stockholders | ($0.03) | $2.10 | $2.02 |
Diluted net income per share attributable to Brooks Automation, Inc. common stockholders | ($0.03) | $2.08 | $2.01 |
Earnings_per_Share_Additional_
Earnings per Share - Additional Information (Detail) | 3 Months Ended | 12 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Stock options | ' | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' | ' |
Anti-dilutive securities excluded from computation of diluted earnings per share | 43 | 238 | 387 |
Restricted stock | ' | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' | ' |
Anti-dilutive securities excluded from computation of diluted earnings per share | 3,006 | 2 | 413 |
Investment_in_Variable_Interes1
Investment in Variable Interest Entity - Additional Information (Detail) (USD $) | 12 Months Ended | 3 Months Ended | ||||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Jun. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | |
Variable Interest Entity | Variable Interest Entity | Variable Interest Entity | ||||
Variable Interest Entity [Line Items] | ' | ' | ' | ' | ' | ' |
Loan provided to borrower | $0 | $3,000,000 | $0 | $3,000,000 | ' | ' |
Loan provided to borrower, interest rate | ' | ' | ' | 9.00% | ' | ' |
Debt, fair value | ' | ' | ' | ' | 2,900,000 | 2,800,000 |
Warrants, fair value | ' | ' | ' | ' | $200,000 | $200,000 |
Derivative_Instruments_Additio
Derivative Instruments - Additional Information (Details) (USD $) | 12 Months Ended | |
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | ' | ' |
Net gains related to foreign currency contracts, not qualified for hedge accounting | $0.10 | ($0.20) |
Derivative_Instruments_Notiona
Derivative Instruments - Notional Amounts Outstanding under Foreign Currency Contracts (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||
Buy Currency, Korean Won; Sell Currency, U.S. Dollar | ' | ' |
Derivative [Line Items] | ' | ' |
Fair Value of Assets | $0 | ' |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | ' | ' |
Derivative [Line Items] | ' | ' |
Fair Value of Assets | 8 | 10 |
Fair Value of Liabilities | 5 | 13 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Buy Currency, U.S. Dollar; Sell Currency, Taiwan Dollar | ' | ' |
Derivative [Line Items] | ' | ' |
Fair Value of Assets | ' | 5 |
Fair Value of Liabilities | ' | 0 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Buy Currency, U.S. Dollar; Sell Currency, Israeli Shekel | ' | ' |
Derivative [Line Items] | ' | ' |
Fair Value of Assets | ' | 0 |
Fair Value of Liabilities | ' | 12 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Buy Currency, U.S. Dollar; Sell Currency, Singapore Dollar | ' | ' |
Derivative [Line Items] | ' | ' |
Fair Value of Assets | ' | 2 |
Fair Value of Liabilities | ' | 0 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Buy Currency, U.S. Dollar; Sell Currency, Korean Won | ' | ' |
Derivative [Line Items] | ' | ' |
Fair Value of Assets | ' | 3 |
Fair Value of Liabilities | ' | 0 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Buy Currency, U.S. Dollar; Sell Currency, Japanese Yen | ' | ' |
Derivative [Line Items] | ' | ' |
Fair Value of Assets | ' | 0 |
Fair Value of Liabilities | ' | 0 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Buy Currency, U.S. Dollar; Sell Currency, British Pound | ' | ' |
Derivative [Line Items] | ' | ' |
Fair Value of Assets | ' | 0 |
Fair Value of Liabilities | ' | 1 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Buy Currency, U.S. Dollar; Sell Currency, Japanese Yen | ' | ' |
Derivative [Line Items] | ' | ' |
Fair Value of Assets | 8 | ' |
Fair Value of Liabilities | 0 | ' |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Buy Currency, Korean Won; Sell Currency, U.S. Dollar | ' | ' |
Derivative [Line Items] | ' | ' |
Fair Value of Liabilities | 2 | ' |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Buy Currency, U.S. Dollar; Sell Currency, Israeli Shekel | ' | ' |
Derivative [Line Items] | ' | ' |
Fair Value of Assets | 0 | ' |
Fair Value of Liabilities | 3 | ' |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Buy Currency, U.S. Dollar; Sell Currency, Singapore Dollar | ' | ' |
Derivative [Line Items] | ' | ' |
Fair Value of Assets | 0 | ' |
Fair Value of Liabilities | 0 | ' |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Long [Member] | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | 3,988 | 7,632 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Long [Member] | Buy Currency, U.S. Dollar; Sell Currency, Taiwan Dollar | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | ' | 2,791 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Long [Member] | Buy Currency, U.S. Dollar; Sell Currency, Israeli Shekel | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | ' | 1,842 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Long [Member] | Buy Currency, U.S. Dollar; Sell Currency, Singapore Dollar | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | ' | 1,058 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Long [Member] | Buy Currency, U.S. Dollar; Sell Currency, Korean Won | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | ' | 806 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Long [Member] | Buy Currency, U.S. Dollar; Sell Currency, Japanese Yen | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | ' | 611 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Long [Member] | Buy Currency, U.S. Dollar; Sell Currency, British Pound | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | ' | 524 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Long [Member] | Buy Currency, U.S. Dollar; Sell Currency, Japanese Yen | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | 2,770 | ' |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Long [Member] | Buy Currency, Korean Won; Sell Currency, U.S. Dollar | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | 686 | ' |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Long [Member] | Buy Currency, U.S. Dollar; Sell Currency, Israeli Shekel | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | 301 | ' |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Long [Member] | Buy Currency, U.S. Dollar; Sell Currency, Singapore Dollar | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | 231 | ' |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Short [Member] | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | 3,985 | 7,635 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Short [Member] | Buy Currency, U.S. Dollar; Sell Currency, Taiwan Dollar | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | ' | 2,786 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Short [Member] | Buy Currency, U.S. Dollar; Sell Currency, Israeli Shekel | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | ' | 1,854 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Short [Member] | Buy Currency, U.S. Dollar; Sell Currency, Singapore Dollar | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | ' | 1,056 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Short [Member] | Buy Currency, U.S. Dollar; Sell Currency, Korean Won | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | ' | 803 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Short [Member] | Buy Currency, U.S. Dollar; Sell Currency, Japanese Yen | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | ' | 611 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Short [Member] | Buy Currency, U.S. Dollar; Sell Currency, British Pound | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | ' | 525 |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Short [Member] | Buy Currency, U.S. Dollar; Sell Currency, Japanese Yen | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | 2,762 | ' |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Short [Member] | Buy Currency, Korean Won; Sell Currency, U.S. Dollar | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | 688 | ' |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Short [Member] | Buy Currency, U.S. Dollar; Sell Currency, Israeli Shekel | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | 304 | ' |
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Short [Member] | Buy Currency, U.S. Dollar; Sell Currency, Singapore Dollar | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | 231 | ' |
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Buy Currency, U.S. Dollar; Sell Currency, Japanese Yen | ' | ' |
Derivative [Line Items] | ' | ' |
Fair Value of Assets | 23 | ' |
Fair Value of Liabilities | 0 | ' |
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Long [Member] | Buy Currency, U.S. Dollar; Sell Currency, Japanese Yen | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | 2,037 | ' |
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Short [Member] | Buy Currency, U.S. Dollar; Sell Currency, Japanese Yen | ' | ' |
Derivative [Line Items] | ' | ' |
Notional Amount | $2,014 | ' |
Income_Taxes_Components_of_Inc
Income Taxes - Components of Income Tax Provision (Benefit) (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Current income tax provision (benefit): | ' | ' | ' |
Federal | $15 | $15 | $16 |
State | 70 | 213 | 1,356 |
Foreign | 681 | -1,374 | 858 |
Total current income tax provision (benefit) | 766 | -1,146 | 2,230 |
Deferred income tax (benefit): | ' | ' | ' |
Federal | -2,523 | -118,432 | 0 |
State | -90 | -291 | 0 |
Foreign | -323 | -3,413 | -276 |
Total deferred income tax (benefit) | -2,936 | -122,136 | -276 |
Income tax provision (benefit) | ($2,170) | ($123,282) | $1,954 |
Income_Taxes_Components_of_Inc1
Income Taxes - Components of Income Before Income Taxes and Equity in Earnings of Joint Ventures (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Income Tax Disclosure [Abstract] | ' | ' | ' |
Domestic | ($6,968) | $2,204 | $111,053 |
Foreign | 206 | 9,216 | 16,523 |
Income (loss) before income taxes and equity in earnings of joint ventures | ($6,762) | $11,420 | $127,576 |
Income_Taxes_Differences_Betwe
Income Taxes - Differences Between Income Tax Provision (Benefit) and Income Taxes Computed using Applicable U.S. Statutory Federal Tax Rate (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Income Tax Disclosure [Abstract] | ' | ' | ' |
Income tax provision computed at federal statutory rate | ($1,535) | $4,728 | $45,736 |
State income taxes, net of federal benefit | -8 | 260 | 1,848 |
Foreign income taxed at different rates | 493 | -832 | -1,546 |
Dividends | 115 | 956 | -219 |
Change in deferred tax asset valuation allowance | 523 | -125,479 | -42,608 |
Reduction in uncertain tax positions | -1,022 | -3,732 | -3,719 |
Nondeductible compensation | 474 | 1,339 | 295 |
Tax credits generated | -2,002 | -1,195 | -1,179 |
Travel and entertainment | 124 | 139 | 119 |
Merger costs | 251 | 0 | 315 |
Other | 417 | 534 | 2,912 |
Income tax provision (benefit) | ($2,170) | ($123,282) | $1,954 |
Income_Taxes_Additional_Inform
Income Taxes - Additional Information (Detail) (USD $) | 12 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |
Income Taxes [Line Items] | ' | ' | ' |
Undistributed earnings of foreign subsidiaries | $17,500,000 | ' | ' |
Deferred income tax benefit | ' | -121,800,000 | ' |
Federal and state research and development tax credit carryforwards | 24,000,000 | ' | ' |
Federal and state research and development tax credit carryforwards, expiration year | '2033 | ' | ' |
Net operating losses, expiration year | '2030 | ' | ' |
Interest related to unrecognized benefits | 200,000 | 200,000 | 400,000 |
Reductions from lapses in statutes of limitations | -1,022,000 | -3,732,000 | -961,000 |
Anticipated unrecognized tax benefit reduction during next twelve months | 1,300,000 | ' | ' |
Federal | ' | ' | ' |
Income Taxes [Line Items] | ' | ' | ' |
Net operating loss carryforwards | 242,000,000 | ' | ' |
State | ' | ' | ' |
Income Taxes [Line Items] | ' | ' | ' |
Net operating loss carryforwards | 122,200,000 | ' | ' |
Foreign | ' | ' | ' |
Income Taxes [Line Items] | ' | ' | ' |
Net operating loss carryforwards | 37,300,000 | ' | ' |
Reductions from lapses in statutes of limitations | -1,000,000 | ' | ' |
Stock Compensation Plan | ' | ' | ' |
Income Taxes [Line Items] | ' | ' | ' |
Net operating loss carryforwards | $11,700,000 | ' | ' |
Income_Taxes_Significant_Compo
Income Taxes - Significant Components of Net Deferred Tax Assets and Liabilities (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||
Income Tax Disclosure [Abstract] | ' | ' |
Accruals and reserves not currently deductible | $11,050 | $10,489 |
Federal, state and foreign tax credits | 20,084 | 18,963 |
Other assets | 1,859 | 1,655 |
Net operating loss carryforwards | 101,717 | 101,713 |
Inventory reserves and valuation | 9,052 | 8,790 |
Deferred tax assets | 143,762 | 141,610 |
Depreciation and intangible amortization | 12,208 | 5,418 |
Deferred tax liabilities | 12,208 | 5,418 |
Valuation allowance | -16,509 | -16,035 |
Net deferred tax asset (liability) | $115,045 | $120,157 |
Income_Taxes_Reconciliation_of
Income Taxes - Reconciliation of Beginning and Ending Amount of Consolidated Liability for Unrecognized Income Tax Benefits (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | ' | ' | ' |
Beginning Balance | $7,605 | $11,000 | $14,968 |
Additions for tax positions of prior years | 228 | 489 | 631 |
Additions for tax positions related to current year | ' | ' | 242 |
Additions for tax positions related to acquired entities | 116 | ' | ' |
Reductions from lapses in statutes of limitations | -1,022 | -3,732 | -961 |
Reductions from settlements with taxing authorities | ' | ' | -4,002 |
Foreign exchange rate adjustment | 14 | -152 | 122 |
Ending Balance | 6,941 | 7,605 | 11,000 |
Unrecognized Tax Benefits | ' | ' | ' |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | ' | ' | ' |
Beginning Balance | 5,961 | 9,011 | 12,816 |
Additions for tax positions of prior years | 0 | 242 | 184 |
Additions for tax positions related to current year | ' | ' | 242 |
Additions for tax positions related to acquired entities | 116 | ' | ' |
Reductions from lapses in statutes of limitations | -944 | -3,125 | -961 |
Reductions from settlements with taxing authorities | ' | ' | -3,392 |
Foreign exchange rate adjustment | 14 | -167 | 122 |
Ending Balance | 5,147 | 5,961 | 9,011 |
Interest and Penalties | ' | ' | ' |
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] | ' | ' | ' |
Beginning Balance | 1,644 | 1,989 | 2,152 |
Additions for tax positions of prior years | 228 | 247 | 447 |
Additions for tax positions related to current year | ' | ' | 0 |
Additions for tax positions related to acquired entities | 0 | ' | ' |
Reductions from lapses in statutes of limitations | -78 | -607 | 0 |
Reductions from settlements with taxing authorities | ' | ' | -610 |
Foreign exchange rate adjustment | 0 | 15 | 0 |
Ending Balance | $1,794 | $1,644 | $1,989 |
Postretirement_Benefits_Additi
Postretirement Benefits - Additional Information (Detail) (USD $) | 12 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 12 Months Ended | ||||||||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2010 | |
Nexus Plan | Nexus Plan | Helix Plan | Helix Plan | Helix Plan | Taiwan Plan Assets | Market Related Valuation of Assets | Other actuarial losses | Worldwide Defined Contribution Plans | Worldwide Defined Contribution Plans | Worldwide Defined Contribution Plans | ||||
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Accelerated amortization of prior pension losses | ' | ' | ' | $100,000 | $100,000 | ' | $8,900,000 | ' | ' | ' | ' | ' | ' | ' |
Settlements paid | 1,383,000 | 18,928,000 | ' | ' | ' | ' | 6,400,000 | ' | ' | ' | ' | ' | ' | ' |
Investment gains or losses recognition period | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | ' | ' | ' | ' |
Unrecognized net actuarial gains (losses) | 500,000 | -1,100,000 | ' | ' | ' | ' | ' | ' | ' | 100,000 | 400,000 | ' | ' | ' |
Fair value of plan assets | 5,996,000 | 8,015,000 | 20,173,000 | ' | 5,500,000 | ' | ' | ' | 500,000 | ' | ' | ' | ' | ' |
Voluntary contribution | ' | ' | ' | ' | ' | 100,000 | ' | ' | ' | ' | ' | ' | ' | ' |
Required minimum contributions | 300,000 | ' | ' | ' | ' | ' | ' | 200,000 | ' | ' | ' | ' | ' | ' |
Expected contribution to the Plan to meet minimum funding targets | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Employer contributions | $292,000 | $7,684,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | $3,200,000 | $3,100,000 | $2,900,000 |
Postretirement_Benefits_Funded
Postretirement Benefits - Funded Status and Amounts Recognized in Consolidated Balance Sheet (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] | ' | ' | ' |
Benefit obligation at beginning of year | $10,181 | $28,068 | ' |
Service cost | 604 | 787 | 216 |
Interest cost | 148 | 984 | 796 |
Actuarial loss | -670 | 1,235 | ' |
Benefits paid | -1,421 | -2,203 | ' |
Settlement loss | 0 | 1,040 | ' |
Settlements paid | -1,383 | -18,928 | ' |
Defined Benefit Plan, Curtailments | -500 | 0 | ' |
Foreign currency translation | 148 | -802 | ' |
Benefit obligation at end of year | 7,107 | 10,181 | 28,068 |
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] | ' | ' | ' |
Fair value of assets at beginning of year | 8,015 | 20,173 | ' |
Actual return on plan assets | 304 | 1,446 | ' |
Disbursements | -1,573 | -2,463 | ' |
Employer contributions | 292 | 7,684 | ' |
Employee contributions | 194 | 334 | ' |
Settlements paid | -1,383 | -18,928 | ' |
Foreign currency translation | 147 | -231 | ' |
Fair value of assets at end of year | 5,996 | 8,015 | 20,173 |
Funded status/accrued benefit liability | ($1,111) | ($2,166) | ' |
Postretirement_Benefits_Pensio
Postretirement Benefits - Pension Amounts Recorded Within Account Line Items of Balance Sheet (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||
Compensation and Retirement Disclosure [Abstract] | ' | ' |
Accrued compensation and benefits | $296 | $478 |
Long-term pension liability | $815 | $1,688 |
Postretirement_Benefits_Net_Pe
Postretirement Benefits - Net Periodic Pension Cost (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Compensation and Retirement Disclosure [Abstract] | ' | ' | ' |
Service cost | $604 | $787 | $216 |
Interest cost | 148 | 984 | 796 |
Expected return on assets | -247 | -1,072 | -764 |
Amortization of losses | 4 | 620 | 458 |
Other | 160 | 0 | 0 |
Net periodic pension cost | 669 | 1,319 | 706 |
Settlement loss | 87 | 8,937 | 0 |
Total pension cost | $756 | $10,256 | $706 |
Postretirement_Benefits_Other_
Postretirement Benefits - Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Loss (Detail) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 |
Compensation and Retirement Disclosure [Abstract] | ' | ' |
Net (gain) loss | ($791) | $1,226 |
Amortization of net loss | -3 | -620 |
Curtailment loss | -675 | 0 |
Settlement loss | -87 | -8,937 |
Total recognized in other comprehensive income (loss) | -1,556 | -8,331 |
Total recognized in net periodic pension cost and other comprehensive income (loss) | ($887) | ($7,012) |
Postretirement_Benefits_Certai
Postretirement Benefits - Certain Information for Plans with Respect to Accumulated Benefit Obligation (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
In Thousands, unless otherwise specified | |||
Compensation and Retirement Disclosure [Abstract] | ' | ' | ' |
Projected benefit obligation | $7,107 | $10,181 | $28,068 |
Accumulated benefit obligation | 6,272 | 8,906 | ' |
Fair value of plan assets | $5,996 | $8,015 | $20,173 |
Postretirement_Benefits_Weight
Postretirement Benefits - Weighted-Average Assumption Used to Determine Net Cost (Detail) | 12 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |
Compensation and Retirement Disclosure [Abstract] | ' | ' | ' |
Discount rate | 2.15% | 3.51% | 3.99% |
Expected return on plan assets | 2.17% | 2.18% | 4.68% |
Rate of compensation increase | 1.89% | 1.84% | 1.79% |
Postretirement_Benefits_Weight1
Postretirement Benefits - Weighted Average Assumption Used to Determine Pension Obligation (Detail) | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Compensation and Retirement Disclosure [Abstract] | ' | ' | ' |
Discount rate | 2.15% | 1.89% | 3.76% |
Rate of compensation increase | 1.89% | 1.84% | 1.79% |
Postretirement_Benefits_Asset_
Postretirement Benefits - Asset Allocation of Plan Assets of Non-U.S. Plans (Detail) (Non-U.S. Plans) | Sep. 30, 2013 |
Defined Benefit Plan Disclosure [Line Items] | ' |
Percentage of Plan Assets | 100.00% |
Debt Securities | ' |
Defined Benefit Plan Disclosure [Line Items] | ' |
Percentage of Plan Assets | 75.00% |
Equity securities | ' |
Defined Benefit Plan Disclosure [Line Items] | ' |
Percentage of Plan Assets | 5.00% |
Cash | ' |
Defined Benefit Plan Disclosure [Line Items] | ' |
Percentage of Plan Assets | 2.00% |
Other Investments | ' |
Defined Benefit Plan Disclosure [Line Items] | ' |
Percentage of Plan Assets | 18.00% |
Postretirement_Benefits_Fair_V
Postretirement Benefits - Fair Value of Pension Assets by Asset Category and by Level (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
In Thousands, unless otherwise specified | |||
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Fair value of plan assets | $5,996 | $8,015 | $20,173 |
Other Investments | Swiss Life collective foundation | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Fair value of plan assets | 5,474 | ' | ' |
Other Investments | Taiwan collective trust | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Fair value of plan assets | 522 | ' | ' |
Level 2 | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Fair value of plan assets | 5,996 | ' | ' |
Level 2 | Other Investments | Swiss Life collective foundation | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Fair value of plan assets | 5,474 | ' | ' |
Level 2 | Other Investments | Taiwan collective trust | ' | ' | ' |
Defined Benefit Plan Disclosure [Line Items] | ' | ' | ' |
Fair value of plan assets | $522 | ' | ' |
Postretirement_Benefits_Expect
Postretirement Benefits - Expected Benefit Payment Over Next Ten Years are Anticipated to be Paid (Detail) (USD $) | Sep. 30, 2013 |
In Thousands, unless otherwise specified | |
Compensation and Retirement Disclosure [Abstract] | ' |
2014 | $232 |
2015 | 56 |
2016 | 57 |
2017 | 58 |
2018 | 59 |
2019-2023 | $583 |
Stockholders_Equity_Additional
Stockholders' Equity - Additional Information (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
Equity [Abstract] | ' | ' |
Preferred stock, shares authorized | 1,000,000 | 1,000,000 |
Preferred stock, par value (USD per share) | $0.01 | $0.01 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Stockholders_Equity_Accumulate
Stockholders' Equity - Accumulated Other Comprehensive Income (Details) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward] | ' | ' | ' |
Accumulated other comprehensive income (loss), net of tax, beginning of period | $23,642 | $17,324 | $17,866 |
Other comprehensive income before reclassifications | -1,104 | -2,604 | -518 |
Amounts reclassified from accumulated other comprehensive income | 66 | 8,922 | -24 |
Accumulated other comprehensive income (loss), net of tax, end of period | 22,604 | 23,642 | 17,324 |
Currency Translation Adjustments | ' | ' | ' |
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward] | ' | ' | ' |
Accumulated other comprehensive income (loss), net of tax, beginning of period | 24,511 | 26,917 | 25,970 |
Other comprehensive income before reclassifications | -2,113 | -2,406 | 947 |
Amounts reclassified from accumulated other comprehensive income | 0 | 0 | 0 |
Accumulated other comprehensive income (loss), net of tax, end of period | 22,398 | 24,511 | 26,917 |
Unrealized Gains (Losses) on Available-for-Sale Securities | ' | ' | ' |
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward] | ' | ' | ' |
Accumulated other comprehensive income (loss), net of tax, beginning of period | 201 | -192 | 253 |
Other comprehensive income before reclassifications | -114 | 408 | -421 |
Amounts reclassified from accumulated other comprehensive income | -21 | -15 | -24 |
Accumulated other comprehensive income (loss), net of tax, end of period | 66 | 201 | -192 |
Unrealized Gains on Cash Flow Hedges | ' | ' | ' |
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward] | ' | ' | ' |
Accumulated other comprehensive income (loss), net of tax, beginning of period | 0 | 0 | 0 |
Other comprehensive income before reclassifications | 14 | 0 | 0 |
Amounts reclassified from accumulated other comprehensive income | 0 | 0 | 0 |
Accumulated other comprehensive income (loss), net of tax, end of period | 14 | 0 | 0 |
Pension Liability Adjustments | ' | ' | ' |
Increase (Decrease) in Accumulated Other Comprehensive Income [Roll Forward] | ' | ' | ' |
Accumulated other comprehensive income (loss), net of tax, beginning of period | -1,070 | -9,401 | -8,357 |
Other comprehensive income before reclassifications | 1,109 | -606 | -1,044 |
Amounts reclassified from accumulated other comprehensive income | 87 | 8,937 | 0 |
Accumulated other comprehensive income (loss), net of tax, end of period | $126 | ($1,070) | ($9,401) |
Stock_Plans_Additional_Informa
Stock Plans - Additional Information (Detail) (USD $) | 12 Months Ended | 0 Months Ended | 1 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | 0 Months Ended | ||||||||||||||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Feb. 08, 2012 | Feb. 29, 1996 | Sep. 30, 2013 | Feb. 12, 1996 | Feb. 08, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 | Oct. 26, 2005 | Sep. 30, 2013 | |
Restricted stock | Restricted stock | Restricted stock | Restricted stock | Restricted stock | Restricted stock | Employee Stock Purchase Plan, 1995 Plan | Employee Stock Purchase Plan, 1995 Plan | Employee Stock Purchase Plan, 1995 Plan | Employee Stock Purchase Plan, 1995 Plan | Employee Stock Purchase Plan, 1995 Plan | 1998 Employee Equity Incentive Plan | Equity Incentive Plan 2000 | Equity Incentive Plan 2000 | Equity Incentive Plan 2000 | Equity Incentive Plan 2000 | Helix Stock Options | Helix Stock Options | ||||
Maximum | Senior Management | Senior Management | Before Amendment | After Amendment | Stock options | Restricted stock | Restricted stock | Restricted stock | |||||||||||||
Maximum | Senior Management | Share Vesting Over Three Year Period | |||||||||||||||||||
Equity Incentive Plan [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Equity incentive plan, vesting period | ' | ' | ' | ' | ' | ' | '4 years | ' | ' | ' | ' | ' | ' | ' | '4 years | ' | '3 years | ' | ' | ' | ' |
Equity incentive plan, expiration Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '7 years | ' | ' | ' | ' | ' | ' |
Shares of common stock reserved for issuance | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,000,000 | ' | ' | ' | ' | ' |
Options outstanding | 15,540 | 193,182 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | ' | 689,622 | 15,540 |
Shares available for grant | 3,259,558 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,792,393 | ' | ' | ' | ' | 467,165 |
Restricted stock or units issued net of cancellations | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 392,931 | ' | ' | ' | ' |
Awards granted | ' | ' | ' | 1,471,977 | ' | ' | ' | 1,394,000 | 1,527,000 | ' | ' | ' | ' | ' | ' | ' | ' | 562,125 | ' | ' | ' |
Restricted stock or units vesting description | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 'These restricted stock awards generally have the following vesting schedules: immediate; three year vesting in which one-third vest at the end of Year 1, one-third vest at the end of Year 2 and one-third vest at the end of Year 3 | ' | ' | ' | ' |
Equity incentive plan vesting in year one, percentage | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 33.33% | ' | ' | ' | ' |
Equity incentive plan vesting in year two, percentage | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 33.33% | ' | 50.00% | ' | ' |
Equity incentive plan vesting in year three, percentage | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 33.34% | ' | 50.00% | ' | ' |
Options to purchase Helix common stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 765,480 | ' |
Closing stock price | $9.31 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Total intrinsic value of options exercised | $19,000 | $56,000 | $15,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cash received from employee stock option exercises | 67,000 | 103,000 | 6,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Weighted average grant date fair value, Awards granted | ' | ' | ' | $9.33 | $11.80 | $11.27 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair value of restricted stock awards vested | ' | ' | ' | 7,300,000 | 5,600,000 | 7,400,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unrecognized compensation cost | ' | ' | ' | $5,600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unrecognized compensation cost, estimated weighted average amortization period | ' | ' | ' | '1 year 6 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Additional shares of common stock available for purchase | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares of common stock available for purchase | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 865,926 | 3,000,000 | 4,000,000 | ' | ' | ' | ' | ' | ' | ' |
Employee stock purchase plan, offering period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '6 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Employee stock purchase plan, price per share percentage | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 85.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Maximum percentage of base pay withheld and applied toward the purchase of shares | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock purchase under employee stock purchase plan | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,134,074 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock_Plans_Stock_Option_Activ
Stock Plans - Stock Option Activity (Detail) (USD $) | 12 Months Ended |
In Thousands, except Share data, unless otherwise specified | Sep. 30, 2013 |
Number of Stock Options | ' |
Options outstanding at beginning of period (shares) | 193,182 |
Exercised | -8,600 |
Forfeited/expired | -169,042 |
Options outstanding at end of period (shares) | 15,540 |
Vested at end of year | 15,540 |
Options exercisable at end of period (shares) | 15,540 |
Options available for future grant | 3,259,558 |
Weighted-Average Remaining Contractual Term | ' |
Options outstanding at end of period | '9 months |
Vested at end of period | '9 months |
Options exercisable at end of period | '9 months |
Weighted Average Exercise Price | ' |
Options outstanding at beginning of period (USD per share) | $13.11 |
Exercised (USD per share) | $7.75 |
Forfeited/expired (USD per share) | $13.13 |
Options outstanding at end of year (USD per share) | $15.86 |
Vested at end of period (USD per share) | $15.86 |
Options exercisable at end of period (USD per share) | $15.86 |
Aggregate Intrinsic Value | ' |
Options outstanding at end of period | $0 |
Vested at end of period | 0 |
Options exercisable at end of period | $0 |
Stock_Plans_Restricted_Stock_A
Stock Plans - Restricted Stock Activity (Detail) (Restricted stock, USD $) | 12 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |
Restricted stock | ' | ' | ' |
Shares | ' | ' | ' |
Outstanding at beginning of year | 2,732,448 | ' | ' |
Awards granted | 1,471,977 | ' | ' |
Awards vested (shares) | -755,187 | ' | ' |
Awards canceled | -533,825 | ' | ' |
Outstanding at end of year | 2,915,413 | 2,732,448 | ' |
Weighted Average Grant-Date Fair Value | ' | ' | ' |
Outstanding at beginning of period (USD per share) | $10.47 | ' | ' |
Awards granted (USD per share) | $9.33 | $11.80 | $11.27 |
Awards vested (USD per share) | $9.67 | ' | ' |
Awards canceled (USD per share) | $11.41 | ' | ' |
Outstanding at end of period (USD per share) | $11.25 | $10.47 | ' |
Restructuring_and_Other_Charge2
Restructuring and Other Charges - Additional Information (Detail) (USD $) | 12 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||||||||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Dec. 31, 2012 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2011 | Sep. 30, 2011 | |
Nexus Plan | Nexus Plan | Workforce-related | Workforce-related | Workforce-related | Workforce-related | Workforce-related | Workforce-related | Workforce-related | Workforce-related | Workforce-related | Workforce-related | Workforce-related | Workforce-related | Workforce-related | Workforce-related | Facilities and other | Facilities and other | Corporate management | ||||
Employee | Brooks Product Solutions | Brooks Product Solutions | Brooks Global Services | Brooks Global Services | Brooks Global Services | Brooks Life Science Systems | Brooks Life Science Systems | Corporate Support functions | Corporate Support functions | Corporate Support functions | Polycold Manufacturing Operation | Employee | ||||||||||
Employee | ||||||||||||||||||||||
Restructuring Cost and Reserve [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring and other charges | $6,465,000 | $3,275,000 | $1,036,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring charges | 6,378,000 | ' | 1,036,000 | ' | ' | 5,560,000 | 3,275,000 | 726,000 | 2,600,000 | 1,300,000 | 1,100,000 | 1,000,000 | 1,000,000 | 400,000 | 300,000 | 1,500,000 | 700,000 | 700,000 | 1,300,000 | 818,000 | 310,000 | ' |
Number of employees impacted by workforce reductions | ' | ' | ' | ' | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | ' | ' | ' | 0 | ' |
Partial settlement of defined pension plan | ' | ' | ' | 100,000 | 100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Severance cost | 600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 400,000 |
Unpaid severance expected to be paid in 2014 | ' | ' | ' | ' | ' | 800,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Unpaid severance expected to be paid in 2015 | ' | ' | ' | ' | ' | $500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Restructuring_and_Other_Charge3
Restructuring and Other Charges - Activity Related to Restructuring Accruals (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Restructuring Reserve [Roll Forward] | ' | ' | ' |
Beginning Balance | $2,098 | ' | $3,509 |
Expense | 6,378 | ' | 1,036 |
Utilization | -7,064 | ' | -4,252 |
Ending Balance | 1,412 | ' | 293 |
Facilities and other | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' |
Beginning Balance | 0 | ' | 3,509 |
Expense | 818 | ' | 310 |
Utilization | -663 | ' | -3,819 |
Ending Balance | 155 | ' | 0 |
Workforce-related | ' | ' | ' |
Restructuring Reserve [Roll Forward] | ' | ' | ' |
Beginning Balance | 2,098 | 293 | 0 |
Expense | 5,560 | 3,275 | 726 |
Utilization | -6,401 | -1,470 | -433 |
Ending Balance | $1,257 | $2,098 | $293 |
Segment_and_Geographic_Informa2
Segment and Geographic Information - Additional Information (Detail) (USD $) | 12 Months Ended | ||||
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Sep. 30, 2011 | Sep. 30, 2013 |
Segment | Entity | Brooks Product Solutions | Contract Manufacturing | Securities Litigation | |
Segment Reporting [Abstract] | ' | ' | ' | ' | ' |
Number of reportable segments | 4 | ' | ' | ' | ' |
Number of companies acquired | ' | 2 | ' | ' | ' |
Segment Reporting Information [Line Items] | ' | ' | ' | ' | ' |
Intercompany sales | ' | ' | $49.20 | $10.70 | ' |
Insurance Recoveries | ' | ' | ' | ' | $3.30 |
Segment_and_Geographic_Informa3
Segment and Geographic Information - Financial Information for Business Segments (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Revenue | ' | ' | ' |
Product | $362,404 | $431,961 | $611,117 |
Services | 88,548 | 87,490 | 76,988 |
Total revenues | 450,952 | 519,451 | 688,105 |
Gross profit | 145,982 | 173,486 | 223,021 |
Segment operating income (loss) | -9,019 | 9,561 | 79,597 |
Depreciation | 14,000 | 13,400 | 12,600 |
Assets | 736,763 | 741,960 | ' |
Brooks Product Solutions | ' | ' | ' |
Revenue | ' | ' | ' |
Product | 317,916 | 380,888 | 451,287 |
Services | 0 | 0 | 0 |
Total revenues | 317,916 | 380,888 | 451,287 |
Gross profit | 104,350 | 127,472 | 171,801 |
Segment operating income (loss) | 8,509 | 21,319 | 64,921 |
Depreciation | 9,022 | 8,952 | 8,597 |
Assets | 254,424 | 218,799 | 235,322 |
Brooks Global Services | ' | ' | ' |
Revenue | ' | ' | ' |
Product | 13,152 | 11,324 | 14,786 |
Services | 76,596 | 74,628 | 74,058 |
Total revenues | 89,748 | 85,952 | 88,844 |
Gross profit | 27,492 | 25,599 | 31,750 |
Segment operating income (loss) | 10,172 | 9,404 | 13,293 |
Depreciation | 2,746 | 2,344 | 2,481 |
Assets | 59,875 | 56,120 | 52,354 |
Brooks Life Science Systems | ' | ' | ' |
Revenue | ' | ' | ' |
Product | 31,336 | 39,749 | 7,715 |
Services | 11,952 | 12,862 | 2,930 |
Total revenues | 43,288 | 52,611 | 10,645 |
Gross profit | 14,140 | 20,415 | 2,260 |
Segment operating income (loss) | -12,380 | -3,139 | -4,684 |
Depreciation | 2,256 | 2,111 | 543 |
Assets | 105,221 | 107,530 | 101,331 |
Contract Manufacturing | ' | ' | ' |
Revenue | ' | ' | ' |
Product | 0 | 0 | 137,329 |
Services | 0 | 0 | 0 |
Total revenues | 0 | 0 | 137,329 |
Gross profit | 0 | 0 | 17,210 |
Segment operating income (loss) | 0 | 0 | 10,649 |
Depreciation | 0 | 0 | 1,000 |
Assets | 0 | 0 | 0 |
Operating Segments, Total | ' | ' | ' |
Revenue | ' | ' | ' |
Product | 362,404 | 431,961 | 611,117 |
Services | 88,548 | 87,490 | 76,988 |
Total revenues | 450,952 | 519,451 | 688,105 |
Gross profit | 145,982 | 173,486 | 223,021 |
Segment operating income (loss) | 6,301 | 27,584 | 84,179 |
Depreciation | 14,024 | 13,407 | 12,621 |
Assets | $419,520 | $382,449 | $389,007 |
Segment_and_Geographic_Informa4
Segment and Geographic Information - Reconciliation of Reportable Segment Operating Income and Segment Assets to Corresponding Consolidated Amounts (Detail) (USD $) | 12 Months Ended | |||||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |||
Segment Reporting, Other Significant Reconciling Item [Line Items] | ' | ' | ' | |||
Other unallocated corporate expenses | $3,002 | [1] | ($1,833) | [1] | $1,135 | [1] |
Amortization of acquired intangible assets | 5,853 | 4,618 | 2,411 | |||
Restructuring and other charges | 6,465 | 3,275 | 1,036 | |||
Pension settlement | 0 | 8,937 | 0 | |||
In-process research and development | 0 | 3,026 | 0 | |||
Operating income (loss) | -9,019 | 9,561 | 79,597 | |||
Investments in cash, cash equivalents, restricted cash and marketable securities | 173,539 | 200,994 | ' | |||
Deferred Tax Assets, Net of Valuation Allowance | 115,985 | 120,157 | ' | |||
Investments in joint ventures | 25,687 | 31,428 | ' | |||
Other unallocated corporate net assets | 2,032 | 6,932 | ' | |||
Total assets | 736,763 | 741,960 | ' | |||
Operating Segments, Total | ' | ' | ' | |||
Segment Reporting, Other Significant Reconciling Item [Line Items] | ' | ' | ' | |||
Operating income (loss) | 6,301 | 27,584 | 84,179 | |||
Total assets | $419,520 | $382,449 | $389,007 | |||
[1] | Other unallocated corporate expenses for the year ended September 30, 2012 includes a credit of $3.3 million related to insurance proceeds received as reimbursement of litigation costs previously incurred. |
Segment_and_Geographic_Informa5
Segment and Geographic Information - Net Revenues based upon Source of Order by Geographic Area (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Net Revenues | $450,952 | $519,451 | $688,105 |
North America | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Net Revenues | 193,222 | 230,735 | 349,456 |
Asia/Pacific | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Net Revenues | 165,452 | 194,711 | 244,524 |
Europe | ' | ' | ' |
Revenues from External Customers and Long-Lived Assets [Line Items] | ' | ' | ' |
Net Revenues | $92,278 | $94,005 | $94,125 |
Segment_and_Geographic_Informa6
Segment and Geographic Information - Long-Lived Assets, Consisting of Property, Plant and Equipment by Geographic Area (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||
Long-Lived Assets by Geographical Areas [Line Items] | ' | ' |
Property, plant and equipment, net | $47,870 | $64,478 |
North America | ' | ' |
Long-Lived Assets by Geographical Areas [Line Items] | ' | ' |
Property, plant and equipment, net | 38,869 | 51,546 |
Asia/Pacific | ' | ' |
Long-Lived Assets by Geographical Areas [Line Items] | ' | ' |
Property, plant and equipment, net | 1,646 | 2,123 |
Europe | ' | ' |
Long-Lived Assets by Geographical Areas [Line Items] | ' | ' |
Property, plant and equipment, net | $7,355 | $10,809 |
Significant_Customers_Addition
Significant Customers - Additional Information (Detail) | 12 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |
customer | customer | customer | |
Revenue, Major Customer [Line Items] | ' | ' | ' |
Number of major customer by revenue | 1 | 1 | 2 |
Percentage of revenues by customer | 11.00% | 13.00% | ' |
Customer 1 | ' | ' | ' |
Revenue, Major Customer [Line Items] | ' | ' | ' |
Percentage of revenues by customer | 11.00% | ' | 15.00% |
Customer 2 | ' | ' | ' |
Revenue, Major Customer [Line Items] | ' | ' | ' |
Percentage of revenues by customer | ' | ' | 13.00% |
Other_Balance_Sheet_Informatio2
Other Balance Sheet Information - Additional Information (Detail) (USD $) | 12 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | |
Valuation and Qualifying Accounts Disclosure [Line Items] | ' | ' | ' |
Inventory Valuation Reserves | $24,300,000 | $23,200,000 | ' |
Inventory Valuation Reserve | ' | ' | ' |
Valuation and Qualifying Accounts Disclosure [Line Items] | ' | ' | ' |
Charges/credits to reserves for excess and obsolete inventory | 5,400,000 | 4,300,000 | 2,200,000 |
Reduction in reserves for excess and obsolete inventory | $4,300,000 | $5,800,000 | $3,500,000 |
Other_Balance_Sheet_Informatio3
Other Balance Sheet Information - Summary of Accounts Receivable (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||
Accounts Receivable, Net [Abstract] | ' | ' |
Accounts receivable | $78,460 | $79,706 |
Accounts receivable, net | 77,483 | 78,855 |
Allowance for doubtful accounts | ' | ' |
Accounts Receivable, Net [Abstract] | ' | ' |
Less allowances | -863 | -851 |
Allowance for sales returns | ' | ' |
Accounts Receivable, Net [Abstract] | ' | ' |
Less allowances | ($114) | $0 |
Other_Balance_Sheet_Informatio4
Other Balance Sheet Information - Allowance for Doubtful Accounts Activity (Detail) (Allowance for doubtful accounts, USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Allowance for doubtful accounts | ' | ' | ' |
Valuation and Qualifying Accounts Disclosure [Line Items] | ' | ' | ' |
Balance at Beginning of Period | $851 | $617 | $491 |
Provisions | 48 | 367 | 0 |
Reversals of Bad Debt Expense | -143 | -130 | 0 |
Write-offs and Adjustments | 107 | -3 | 126 |
Balance at End of Period | $863 | $851 | $617 |
Other_Balance_Sheet_Informatio5
Other Balance Sheet Information - Allowance for Sales Returns (Details) (Allowance for sales returns, USD $) | 12 Months Ended |
In Thousands, unless otherwise specified | Sep. 30, 2013 |
Allowance for sales returns | ' |
Financing Receivable, Allowance for Credit Losses [Line Items] | ' |
Balance at Beginning of Period | $0 |
Provisions | 72 |
Write-offs and Adjustments | 42 |
Balance at End of Period | $114 |
Other_Balance_Sheet_Informatio6
Other Balance Sheet Information - Summary of Inventories (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
In Thousands, unless otherwise specified | ||
Inventories | ' | ' |
Raw materials and purchased parts | $60,106 | $64,732 |
Work-in-process | 20,256 | 20,800 |
Finished goods | 17,357 | 17,453 |
Inventory, net | $97,719 | $102,985 |
Other_Balance_Sheet_Informatio7
Other Balance Sheet Information - Product Warranty and Retrofit Activity on Gross Basis (Detail) (USD $) | 12 Months Ended | ||
In Thousands, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' | ' | ' |
Balance at beginning of year | $7,329 | $7,438 | $8,195 |
Adjustments for acquisitions and divestitures | 1,187 | 7 | 698 |
Accruals for warranties during the year | 10,111 | 13,751 | 11,299 |
Costs incurred | -11,278 | -13,867 | -12,754 |
Balance at end of year | $7,349 | $7,329 | $7,438 |
Sale_of_Building_and_Land_Addi
Sale of Building and Land - Additional Information (Detail) (USD $) | 0 Months Ended | 9 Months Ended | 12 Months Ended |
In Thousands, unless otherwise specified | Sep. 27, 2013 | Sep. 27, 2013 | Sep. 30, 2013 |
Chelmsford, Massachusetts Campus | Chelmsford, Massachusetts Campus | Oberdiessbach, Switzerland | |
Real Estate Properties [Line Items] | ' | ' | ' |
Proceeds from sale of buildings | $11,275 | ' | $3,200 |
Unamortized deferred leasing costs | ' | 3,718 | ' |
Gain on sale of assets | $1,025 | ' | $200 |
Sale_of_Building_and_Land_Sche
Sale of Building and Land - Schedule of realized gain on sale of building and land (Detail) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 27, 2013 | Sep. 27, 2013 | Sep. 27, 2013 |
In Thousands, unless otherwise specified | Chelmsford, Massachusetts Campus | Chelmsford, Massachusetts Campus | Chelmsford, Massachusetts Campus | ||
Buildings and land | |||||
Real Estate Properties [Line Items] | ' | ' | ' | ' | ' |
Sale proceeds | ' | ' | $11,275 | ' | ' |
Net book value of building and land | -47,870 | -64,478 | ' | ' | -6,095 |
Amortization of Deferred Leasing Fees | ' | ' | ' | -3,718 | ' |
Direct transaction costs | ' | ' | -437 | ' | ' |
Gain on the sale of building and land | ' | ' | $1,025 | ' | ' |
Commitments_and_Contingencies_1
Commitments and Contingencies - Additional Information (Detail) (USD $) | 12 Months Ended | ||
In Millions, unless otherwise specified | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 |
Commitments and Contingencies Disclosure [Abstract] | ' | ' | ' |
Rental expense under operating leases | $8.40 | $4.80 | $4.90 |
Outstanding letters of credit | 5.7 | ' | ' |
Non-cancelable contracts and purchase orders for inventory | 68.6 | ' | ' |
Mexico | ' | ' | ' |
Guarantor Obligations [Line Items] | ' | ' | ' |
Remaining payments under lease guarantee | $0.50 | ' | ' |
Commitments_and_Contingencies_2
Commitments and Contingencies - Future Minimum Lease Commitments on Non-Cancelable Operating Leases, Lease Income and Sublease Income (Detail) (USD $) | Sep. 30, 2013 |
In Thousands, unless otherwise specified | |
Operating Lease | ' |
Year ended September 30, 2014 | $7,199 |
2015 | 5,084 |
2016 | 2,728 |
2017 | 1,557 |
2018 | 1,359 |
Thereafter | 1,625 |
Future minimum lease commitments, total | $19,552 |
Subsequent_Events_Additional_I
Subsequent Events - Additional Information (Detail) (USD $) | 12 Months Ended | 0 Months Ended | ||
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2011 | Nov. 12, 2013 | |
Subsequent Event | ||||
Subsequent Event [Line Items] | ' | ' | ' | ' |
Dividend declared per share | $0.32 | $0.32 | $0.08 | $0.08 |